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ABSTRACT 
Saliva contains a variety of biochemical components, some of which may be used for the diagnosis 
of metabolic disorders, as cancer and heart disease markers, and the drug monitoring purposes. 
Saliva collection is particularly attractive as a non-invasive sampling method for infants and elderly 
patients. However, the use of saliva to evaluate metabolic status has not been widely studied; in 
particular, nucleotide metabolites in saliva have received little attention.  
Nucleotides are divided mainly into purines and pyrimidines, and they play an essential role in 
many cellular processes involving biosynthesis, energy supply, DNA/RNA synthesis, essential 
coenzymes, and regulatory mechanisms. Nucleotides are synthesised in mammalian cells by de 
novo pathways, which are energy-consuming; alternatively they are recycled by energy-saving 
pathways from nucleosides and bases that act as nucleotide salvage metabolites. 
This project was initiated by the discovery of a wide variation in salivary concentrations of 
nucleosides and bases between individuals, raising questions about their biological function. A 
method was developed and validated for the collection of small volumes of saliva as well as the 
extraction of purines and pyrimidines from oral swabs. These were then analysed by HPLC with 
tandem mass spectrometry.  
A survey of salivary nucleotide metabolites in 77 adults was performed, followed by a study of 60 
neonates. Concentrations of the major salivary nucleobases and nucleosides were significantly 
higher in neonatal compared to adult saliva. The median concentrations (µM) in neonates\adults 
respectively were: Uracil 7.3\<1.5, Uridine 12\0.4, Hypoxanthine 27\2.1, Xanthine 19\1.7, 
Adenosine 12\0.1, Inosine 11\0.2, Guanosine 6.8\0.1. These nucleotide metabolites were not simply 
in equilibrium with plasma, but appeared to be actively secreted into saliva. The high levels of 
xanthine and hypoxanthine in neonates were particularly interesting, because these are substrates 
for xanthine oxidase (XO), which occurs with high activity in breast milk. 
These observations led to a general hypothesis that the role of these nucleotide metabolites in 
neonatal saliva is concerned with regulation of the oral microbiota of infants. XO is involved in the 
final stage of degradation of purine nucleotides, and it has been proposed to have a role in the innate 
immunity of babies arising from its ability to generate antibacterial ‘reactive oxygen species’. The 
hypothesis proposed that high concentrations of nucleotide metabolites in neonatal saliva, together 
with stimulation of antibacterial breast milk XO activity, may play significant roles in early innate 
immunity in neonates. As part of the project, it was decided to also screen saliva from a selection of 
domestic mammals, which were found to have large differences in metabolite concentrations. 
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Investigation of the generation of hydrogen peroxide (H2O2) by breast milk XO was conducted in 
three stages: (1) fresh breast milk samples were collected and the endogenous H2O2 concentration 
was determined to be 27.3±12.2 µM; (2) XO activity was then assayed in the same samples using a 
horseradish peroxidase-Ampliflu™ Red based reaction; the activity of breast milk XO was found to 
be 8.0±5.3 Units/L; (3) The ability of breast milk to generate H2O2 (40 µM) when mixed with 
neonatal saliva was successfully demonstrated. XO was confirmed to be inactive in milk formula 
and pasteurized bovine milk and human breast milk. 
Investigation of the effect of exogenous H2O2 on the in vitro growth of 4 bacterial species was 
undertaken. The peroxide mechanism had a strong inhibitory effect on Staphylococcus aureus at 
low, physiologically relevant concentrations (>25 µM H2O2). Lactobacillus plantarum and 
Escherichia coli required significantly higher concentrations of peroxide (~200 µM) to inhibit 
growth, while the effect of peroxide on the growth of Salmonella species was intermediate. As a 
proof-of-principle experiment, the effects of a saliva and breast milk mixture on bacterial growth in 
vitro were then tested. The reaction between salivary xanthine/hypoxanthine and breast milk XO 
was shown to be bactericidal against S. aureus and Salmonella spp., (p=0.001, p=0.007 
respectively) whereas the effects on L. plantarum and E. coli were not statistically significant. A 
dose-dependent bactericidal effect of hypoxanthine/xanthine with milk on the 4 bacterial species 
was also demonstrated. 
Finally, to test whether breast-feeding (i.e. active XO mechanism), compared with formula-feeding 
(inactive XO mechanism), produces an in vivo effect on the oral microbiota, a survey of oral 
microbiota in infants was undertaken. Oral swabs were collected from both groups and the           
16S rRNA bacterial gene was ‘deep sequenced’ using Roche 454 platform. Bioinformatic analysis 
software was used to determine bacterial phyla and families (and is continuing to species level). 
Significant variation between the oral microbiota of breast-fed and formula-fed infants was found. 
Although other components of breast milk such as antibodies are presumed to have an effect on the 
infant’s microbiota, it was considered essential to show that an effect existed, and that it could be 
measured in the mouth – this has not previously been demonstrated. Teasing apart the ‘innate’ 
(peroxidative mechanism) immune system from the specific (antibody mechanism) system is a task 
for future studies. 
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1.1 THESIS STRUCTURE 
This thesis is divided into five chapters, followed by References and Appendices. The introductory 
chapter presents general information and a literature review of the research project. Overall research 
Hypothesis and Aim, Funding sources and Ethical approvals are summarised at the end of this 
chapter. Chapters 2 to 4 present the three distinct but inter-related research studies that were 
undertaken. Each has an additional short Introduction to introduce the study and to cover the variety 
of topics in this project. Specific Hypotheses and Aims of each study are also presented, followed 
by Materials and Methods used, then Results, and finally a Discussion has been included in each 
chapter separately. Chapter 5 presents general Conclusions summarising the important findings of 
this project as well as a focus on the future directions for this research. 
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1.2 GENERAL LITERATURE REVIEW 
1.2.1 PURINE AND PYRIMIDINE BASES AND NUCLEOSIDES 
Purines and pyrimidines are nitrogenous bases that are an essential part of nucleotide structures. 
The major purine and pyrimidine bases are shown in (Fig. 1.1). Purine bases have a double 
heterocyclic ring structure including 4 nitrogens. Adenine and guanine are the major purine bases in 
nucleic acids (DNA, RNA), while hypoxanthine, xanthine and uric acid are components of the 
catabolic pathway. On the other hand, pyrimidine bases have a single heterocyclic ring containing 2 
nitrogen atoms, with the major pyrimidine bases being uracil, cytosine and thymine [1, 2]. 
 
 
 
Figure ‎1.1 Purine bases (left) and pyrimidine bases (right). 
 
Purine and pyrimidine bases attached to either ribose or 2-deoxyribose are called nucleosides or 
deoxynucleosides respectively. Purines link to the sugar moiety by β-N-glycosidic bonding at 
position N-9, while pyrimidines have a glycosidic bond at position N-1 (Fig. 1.2). Adenosine, 
guanosine and deoxyadenosine are examples of purine nucleosides, while uridine, cytidine, and 
deoxythymidine are example of pyrimidine nucleosides [3].  
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Figure  1.2 Examples of nucleosides. Purine nucleosides: (1) adenosine; (2) guanosine; (3) 
deoxyadenosine. Pyrimidine nucleosides: (4) cytidine; (5) uridine; (6) (deoxy-) thymidine. 
 
1.2.2 PURINE AND PYRIMIDINE NUCLEOTIDES 
Nucleotides are nucleosides with one or more phosphate groups attached to the sugar moiety at the 
5’-position (Fig.1.3). In normal cells, triphosphate and diphosphate nucleotides exist in higher 
concentrations than monophosphate nucleotides, nucleosides, and free bases [2]. Similarly, the 
concentration of nucleoside triphosphate (NTP) is higher than deoxynucleoside triphosphate 
(dNTP) in non-dividing cells, as the latter is needed only for the synthesis of DNA [4]. Nucleic 
acids (RNA or DNA) are polymers of nucleoside or deoxy-nucleoside monophosphates, 
respectively. 
In addition to the role of purine nucleotides in the synthesis of genetic material these compounds 
have central roles in many metabolic processes, e.g. adenosine 5-triphosphate (ATP) functions as a 
carrier of cellular and mitochondrial chemical energy [5]. Guanosine triphosphate (GTP) is 
important for cellular synthetic reactions, as well as regulating with G-proteins to drive transmission 
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of stimuli across cell membranes; many hormones, neurotransmitters, local mediators exert their 
function by coupling to G-proteins [6]. Cyclic nucleotides such as cAMP and cGMP are other forms 
of nucleotides which function as second messengers in numerous cellular metabolism [7].  
Besides their function in nucleic acids, pyrimidine nucleotides play an important role in synthetic 
cellular metabolism. For example, UDP-sugars are required for protein glycosylation and glycogen 
synthesis, while CDP conjugates with various lipids, e.g. CDP-choline and CDP diacylglycerol 
phosphoglyceride, for synthesis of cell membranes [8, 9]. 
 
Figure  1.3 Examples of nucleotides. 
1.2.3 COENZYME NUCLEOTIDES 
The coenzymes nicotinamide adenine dinucleotide (NAD), nicotinamide adenine dinucleotide 
phosphate (NADP), flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD) are 
specialised electron-transfer nucleotides, all derived from ATP (Fig. 1.4) [10, 11]. 
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Figure  1.4 Examples of coenzyme nucleotides. Nicotinamide adenine dinucleotide (NAD); Flavin 
adenine dinucleotide (FAD). 
 
1.2.4 NUCLEOTIDE CELLULAR FUNCTIONS 
Purine and pyrimidine nucleotides are formed by either de novo synthesis pathways, or by salvage 
of catabolised bases and nucleosides. Because nucleotides are so central to cellular function, defects 
in the metabolic pathways of nucleotides can lead to severe metabolic diseases, resulting in 
immunodeficiency, anaemia, neuropathologies, and renal disease [12, 13]. 
The concentrations of nucleotides in tissues vary widely reflecting specialised cellular function. The 
nucleotides in red blood cells rely on the salvage paths and are primarily concerned with 
synthesising ATP, NAD and NADP [14]. In contrast, ADP occurs in high concentrations in 
platelets, being part of the crucial mechanism mediating platelet aggregation [15]. In liver, a variety 
of nucleotides and their sugar and lipid derivatives are present for use in biosynthetic processes. In 
non-dividing cells the concentration of nucleotides in the form of ribonucleotides is higher than for 
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deoxyribonucleotides, but when DNA replicates before cell division the concentrations of deoxy-
ribonucleotides are highly elevated to supply the cell with the required substrates for DNA synthesis 
[16]. 
Dietary DNA and RNA are fully hydrolysed to mono-nucleotides in the small gut, then converted to 
nucleosides by the action of phosphatases in the enterocyte. Dietary purines and pyrimidines are 
then handled differently by the gut (Fig. 1.5). Purines are mainly degraded via mucosal xanthine 
oxidase to uric acid before entry into the circulation, although the gut mucosal cells may use some 
dietary purines for their own metabolism [17]. In contrast, dietary pyrimidines are directly absorbed 
by the gut and passed into the circulation; pyrimidine salvage – or further catabolism – occurs 
mainly in liver [12]. Purine and pyrimidine nucleotides are also metabolised by the intestinal 
bacteria either for incorporation into their own nucleotides and nucleic acids, or for energy- 
releasing catabolism (see Section 1.2.7). 
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Figure  1.5 Dietary metabolism of purines and pyrimidines. Abbreviations: XO, xanthine oxidase; 
DPD, dihydropyrimidine dehydrogenase; DHP, dihydropyrimidinase; UP, Ureidopropionase. 
Diagram from Loffler et al. [12] with modification. 
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1.2.5 METABOLISM OF PURINE NUCLEOTIDES 
1.2.5.1   De novo synthesis  
De novo synthesis of purine nucleotides is initiated when 5-phosphoribosyl-1-pyrophosphate 
(PRPP) is synthesised from ribose 5-phosphate, by the enzyme PRPP synthetase (PRPS1: OMIM 
*603762). PRPP is also important for biosynthesis of pyrimidine nucleotides as well as 
nicotinamide coenzymes and the amino acids histidine and tryptophan [18].  
The committed step in purine synthesis is the conversion of PRPP to 5-phosphoribosylamine in the 
presence of glutamine, catalysed by glutamine PRPP amidotransferase (PPAT: OMIM *172450) 
[19]. A 10-step pathway then leads to formation of the nucleotide inosine monophosphate (IMP), 
which is then converted either to AMP or GMP and subsequently to ATP and GTP by kinases [2]. 
Note that the de novo synthesis of purine is expensive in term of energy utilization, since 6 moles of 
ATP is consumed per mole of purine formed [20]. See Figure 1.6 for full purine de novo synthesis 
steps including enzyme nomenclature. 
1.2.5.2 Synthesis of deoxyribonucleotides  
An important property of purines and pyrimidines is their ability to form hydrogen-bonded pairs 
composed of one purine and one pyrimidine, such as guanine-cytosine and adenine-thymine, which 
is essential for double-stranded DNA. The substrates for both purine and pyrimidine 
deoxyribonucleotides are ribonucleoside 5-diphosphates (NDP). Reduction at the 2-position of the 
ribose ring in NDPs leads to 2-deoxyribonucleotide formation, catalysed by ribonucleotide 
reductase (RRM2B: OMIM *604712). Deoxy-NDPs are then converted to the triphosphates by 
kinases, for use as substrates for DNA [16]. 
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Figure  1.6 De novo synthesis of purine nucleotides. Enzymes: (1) Phosphoribosylpyrophosphate 
synthetase; (2) Glu:PRPP amidotransferase; (3) GAR synthetase; (4) GAR transformylase; (5) 
FGAM synthetase; (6) AIR synthetase; (7) AIR carboxylase; (8) SAICAR synthetase; (9) 
adenylosuccinate lyase; (10) AICAR transformylase; (11) IMP synthase; (12) adenylosuccinate 
synthase/ lyase; (13) IMP dehydrogenase/GMP synthetase; (14) nucleoside monophosphate kinase; 
(15) nucleoside diphosphate kinase; (16) ribonucleotides reductase; (17) AMP deaminase. 
Abbreviations: PRPP, 5-phosphoribosyl-1-pyrophosphate; PRA, phosphoribosyl-amine; GAR, 
glycinamide ribonucleotide; FGAR, formylglycinamide ribonucleotides; FGAM, formyl-
glycinamidine ribonucleotides; AIR, 5-aminoimidazole ribonucleotides ; CAIR, carboxy-
aminoimidazole ribonucleotides; SAICAR, N-succinylo-5-aminoimidazole carboxamide 
ribonucleotide; AICAR, 5-aminoimidazole-4-carboxamide ribonucleotide; FAICAR, N-formyl-
AICAR; IMP, inosine monophosphate; (-) inhibition. Diagram from Camici et al. [19] with 
modification. 
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1.2.5.3 Salvage of purines 
The salvage of purine nucleotides is important to minimise energy consumption, as the salvage 
pathway consumes only 1 mole of ATP [21]. The salvage of purine nucleotides occurs principally 
from the bases via phosphoribosyltransferases (Fig.1.7). Hypoxanthine-guanine 
phosphoribosyltransferase (HPRT1: OMIM *308000) converts guanine and hypoxanthine to GMP 
and IMP, and adenine phosphoribosyltransferase (APRT:OMIM +102600) salvages adenine to 
AMP [22]. These salvage reactions are highly regulated by their nucleotide end-products which act 
as competitive inhibitors. AMP is also produced by phosphorylation of adenosine by adenosine 
kinase (ADK: OMIM *102750) [19]. Significantly, dietary purines are not used in the body; apart 
from purine bases salvaged by gut cells, all other purines in the diet are degraded to uric acid by the 
small intestine. 
Purine salvage has a significant role in controlling the de novo synthesis pathway as the recycling of 
AMP and GMP inhibits the de novo PRPP amidotransferase step. Furthermore, consumption of 
PRPP, an activator for purine de novo synthesis, by the salvage pathway, reduces the activity of the 
synthetic pathway [19].  
 
1.2.5.4 Catabolism of purines 
The turnover of cells includes the breakdown of nucleotides and nucleic acids. ATP and GTP are 
degraded to their mononucleotides, AMP and GMP. DNA and RNA are degraded by nucleases to 
monophosphates. Purine nucleotidases convert nucleotides into nucleosides, then purine nucleoside 
phosphorylase (PNP: OMIM *164050) converts these to purine bases (hypoxanthine and guanine) 
(Fig. 1.7). Importantly, adenosine is not a substrate for PNP; it is first converted to inosine by 
adenosine deaminase (ADA: OMIM *608958) [23]. Guanine is converted to xanthine by guanine 
deaminase (GDA: OMIM *139260), while hypoxanthine and xanthine are converted to uric acid by 
xanthine oxidase [19].  
The last step of purine degradation by xanthine oxidase is characterized by uric acid production 
associated with hydrogen peroxide (H2O2) generation [24]. In humans and higher apes, uric acid is 
the final product of purine catabolism. 
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Figure ‎1.7 Catabolism and salvage pathway of purines. 
Abbreviations: IMP: inosine-5′-monophosphate; PRPP: phosphoribosylpyrophosphate; PPi: 
inorganic phosphate; APRT: adenine phosphoribosyltransferase; HGPRT: hypoxanthine-guanine 
phosphoribosyltransferase; AMPD: adenosine monophosphate deaminase; ADA: adenosine 
deaminase; 5’-NT: 5'-nucleotidase; PNP: Purine nucleoside phosphorylase; GMP: guanosine 
monophosphate; GDA: guanine deaminase; XO: xanthine oxidase. Note conversion of adenosine to 
AMP is catalysed by adenosine kinase. Diagram was adapted from 
http://themedicalbiochemistrypage.org/nucleotide-metabolism.html (accessed 14/3/2010) with 
modification. 
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1.2.6 METABOLISM OF PYRIMIDINE NUCLEOTIDES 
1.2.6.1 De novo synthesis  
The de novo synthesis of pyrimidine nucleotides begins with 6 metabolic steps, shown in Figure 
1.8. Initially, carbamoyl phosphate is synthesised by carbamoyl phosphate synthetase (CPS1: 
OMIM *114010) via glutamine, bicarbonate and 2 ATP molecules [12, 25]. Carbamoyl phosphate 
may then enter either the urea cycle or the pyrimidine pathway, however some studies suggest that 
this enzyme works independently in both pyrimidine synthesis and urea cycle [26, 27]. The 
conversion of carbamoyl phosphate to orotate is catalysed by a tri-functional enzyme (CAD: OMIM 
*114010): carbamylphosphate synthase-aspartate transcarbamoylase-dihydroorotase. Note that the 
next step, dihydroorotate dehydrogenase (DHODH: OMIM*126064) is the only mitochondrial 
enzyme in the de novo synthesis of pyrimidines; all other enzymes are located in the cytosol [9, 12]. 
Uridine 5-monophosphate (UMP) is the central pyrimidine nucleotide synthesised from orotate by a 
bi-functional enzyme orotate phosphoribosyltransferase – orotidine-5-monophosphate (OMP) 
decarboxylase, defined as UMP synthase (UMPS: OMIM +258900) [25]. In the first step, the base 
orotate is converted to the nucleotide OMP using PRPP as the ribose phosphate donor, then OMP is 
decarboxylated to uridine 5-monophosphate (UMP). Nucleotide kinases convert UMP to UTP. The 
latter can be converted to CTP by the action of CTP synthetase (CTPS: OMIM *123860) [9, 12, 28-
30]. The thymidine deoxy-nucleotides are synthesised via thymidylate synthase (TYMS: 
OMIM*188350) from UMP via a folate-dependent path. This latter reaction has become a target for 
the inhibitory drugs of DNA synthesis such as fluorouracil, methotrexate, and trimethoprim [31]. 
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Figure ‎1.8 Pyrimidine de novo synthesis.  
(1) carbamyl-phosphate synthetase; (2) aspartate transcarbamylase; (3) dihydroorotase; (4) di-
hydroorotate dehydrogenase; (5) orotate phosphoribosyltransferase; (6) orotidine 5'-monophosphate 
decarboxylase; (7) UMP kinase; (8) UDP kinase; (9) CTP synthetase. Diagram from 
biochem4.okstate.edu/.../nucleotides.htm (accessed 25/4/2013). 
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1.2.6.2 Salvage of pyrimidines 
The cellular requirement for pyrimidine nucleotides is also met by the recycling (‘salvage’) of 
pyrimidine nucleosides [32]. Mitochondrial and cytosolic nucleoside kinases catalyse the 
phosphorylation of uridine, deoxycytidine and deoxythymidine to their corresponding nucleotides 
[12] (Fig. 1.9). Uridine is central to the salvage of normal nucleotides, while deoxy-nucleotide 
salvage is reserved for few specialised functions. 
 
1.2.6.3 Catabolism of pyrimidines 
Similar to purines, pyrimidine nucleotides and nucleic acids are initially broken down to 
mononucleotides which are then dephosphorylated to nucleosides by pyrimidine nucleotidases. 
Cytidine is converted to uridine by the action of cytidine deaminase (CDA: OMIM *123320). The 
degradation of uridine by uridine phosphorylase (UPP1: OMIM *191730) to uracil and the 
degradation of thymidine by thymidine phosphorylase (TYMP: OMIM *131222) to thymine are the 
first committed steps of the catabolism of pyrimidines in humans [12]. Dihydropyrimidine 
dehydrogenase (DPYD: OMIM*612779) then catalyses the reduction of thymine and uracil to 
dihydrothymine and dihydrouracil respectively. Dihydropyrimidinase (DPYS: OMIM *613326) 
catalyses the hydrolysis of these dihydropyrimidines to ureidoisobutryic and ureidopropionic acid, 
respectively. Finally, these are broken down by ureidopropionase (UPB1: OMIM *606673) to form 
β-aminoisobutyrate and β-alanine, releasing ammonia and CO2 [29]. As the end-product of thymine 
degradation, β-aminoisobutyric acid has been measured in urine to estimate DNA turnover [33, 34]. 
The catabolism of pyrimidines mainly occurs in liver; however Van Kuilenburg and co-workers 
(2006) [29] suggested that it may also involve other organs such as kidney and spleen. Pyrimidine 
metabolic pathways are illustrated in Figure 1.9. 
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Figure  1.9 Overview of pyrimidine metabolism. Abbreviations: UMP: Uridine monophosphate; 
UDP: Uridine diphosphate; UTP: Uridine triphosphate; CMP: Cytidine monophosphate; CDP: 
Cytidine diphosphate; CTP: Cytidine triphosphate; dTMP: Deoxy- thymidine monophosphate; 
dTDP: Deoxy- thymidine diphosphate; dTTP: Deoxy- thymidine triphosphate. RNR: 
Ribonucleotide reductase; CDA: Cytidine deaminase; UMPH: uridine 5’ phosphate hydrolase; UK: 
uridine kinase; dCK: deoxycytidine kinase; URH: Uridine nucleosidase; TP: Thymidine 
phosphorylase; TK: Thymidine kinase; DPD: dihydropyrimidine dehydrogenase; DPA: di-
hydropyrimidinase; UP: Ureidopropionase. Diagram from Loffler et al. [12], Nyhan [13], and 
Zrenner et al. [35] with modification. 
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1.2.7 BACTERIAL UPTAKE AND METABOLISM OF PURINES AND PYRIMIDINES  
While most bacteria can synthesise nucleotides de novo, some, including lactic acid bacteria (e.g. 
Lactococcus lactis), require external sources of purines or pyrimidines to enhance their growth in 
synthetic media [18, 36]. These auxotrophic bacteria utilise salvage pathways to convert exogenous 
bases or nucleosides to their corresponding nucleotides (Fig. 1.10). In addition, exogenous 
nucleotides can be used by some types of bacteria as a source for purines or pyrimidines, with these 
nucleotides being dephosphorylated by extracellular nucleotidases prior to entering the cell [18]. 
However, prototrophic bacteria can also salvage nucleobases and nucleotides; the de novo pathways 
in these bacteria are usually silenced in the presence of excess external purine or pyrimidine sources 
[18]. For example, exogenous uracil, uridine, deoxyuridine, cytosine, cytidine, and deoxycytidine, 
thymine and thymidine are taken up by Escherichia coli and Salmonella typhimurium from their 
host.  
Uptake mechanisms show great diversity. L. lactis has a high affinity uptake system for uracil but 
not cytosine and thymine [18, 37-39], as with Neisseria meningitidis which utilises only uracil but 
not uridine, deoxyuridine, cytosine, cytidine, or deoxycytidine suggesting this bacterium lacks the 
appropriate nucleotide salvage pathways [40].  
Many other bacteria such as Lactobacillus species have additional requirements for 
deoxynucleotides, as they lack the ability to reduce ribonucleotides to deoxyribonucleotides, which 
is crucial for DNA synthesis. Rather, they use a salvage enzyme, trans-N-deoxyribosylase [18], 
which catalyses the exchange reaction of the base moiety of 2′-deoxyribonucleoside [41]. 
Importantly, some strains of Lactobacillus bulgaricus and Lactobacillus jugurti were found to be 
stimulated by bovine milk which contains high concentrations of orotic acid that is an important 
intermediate in pyrimidine synthesis. Growth of these same bacteria was inhibited in orotate-free 
milk suggesting that orotic acid is used for pyrimidine nucleotide synthesis [42]. It has been found 
that pyrimidine de novo synthesis was inhibited as a result of long habitation of these bacteria in 
milk containing orotic acid, while this does not support other auxotrophic bacteria such as L. lactis 
and Streptococcus thermophilus, which were characterised by inability to grow in milk [18].  
In addition to purine and pyrimidine salvage by bacteria, some bacteria such as E. coli use 
nucleotides very efficiently as carbon and energy sources, for example degradation of the ribose 
sugar of the nucleosides. Bacteria may also utilise the amino group in cytidine and adenosine as a 
nitrogen source without degradation of the purine and pyrimidine rings [18]. 
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Figure  1.10 The salvage pathways of external nucleosides and nucleobases in microorganisms with 
nucleoside phosphorylases (e.g. L. lactis). Diagram from Kilstrup, M et al. [18] with modification.  
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1.2.8 XANTHINE OXIDASE 
1.2.8.1 General characteristics 
Xanthine oxidase (XO; OMIM-607633) is widely distributed in many species of mammals and 
bacteria [43, 44], but in humans XO distribution is restricted. The enzyme shows highest activity in 
intestine and liver [45], with low levels of XO RNA transcription reported in the human heart, 
brain, lung and kidney [46]. Surprisingly, XO is present in high activity in the milk of mammals 
where it is associated with the milk fat globule membrane (MFGM) [24, 47, 48].  
1.2.8.2 Structure and reaction mechanism 
Xanthine oxidoreductase (XOR) exists in two protein forms of the same gene product. After 
proteolysis by trypsin digestion, the protein has been shown to comprise a complex of three linked 
structural domains [43] (Fig. 1.11). 
 
Figure  1.11 The three structural domains of xanthine oxidoreductase protein [49]. Domains of 20, 
40, and 85 kDa, associated with an FeS domain containing two Fe2S2 groups, a flavin domain 
containing the FAD cofactor, and a molybdenum binding domain with the active site respectively. 
Abbreviations: Mo, molybdenum; FAD, flavin adenine dinucleotide; Fe-S, iron sulfate.  
 
The two forms of the enzyme are referred to as XO and xanthine dehydrogenase (XDH). 
Degradation of xanthine and hypoxanthine to uric acid is accompanied by reduction of oxygen to 
H2O2 for XO, while XDH reduces NAD
+
 to NADH [50]. A summary of the reaction is illustrated in 
Figure 1.12. The XO gene is located in human chromosome 2p22 and is large at 60kb in length 
containing 36 exons and 35 introns [51] corresponding to 1330-1335 amino acids. 
The oxidation reaction occurs at the molybdenum (Mo) centre where electrons are donated from the 
substrate accompanied by the reduction of Mo (VI) to Mo (IV) [52, 53]. Electrons are then passed 
through the Fe2S2 cluster to either NAD
+
 (for XDH), or to oxygen at the FAD site (for XO) [24]. 
Unlike cytochrome P450 oxidation reactions, the oxygen that accepts electrons from xanthine and 
hypoxanthine substrates comes from a water ligand and not from molecular oxygen [53, 54].  
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It has been shown that the XDH form exists predominant intracellularly, but it is converted to XO 
by extracellular oxidation of the free sulfhydryls to disulfides, with the process being reversible by 
sulfhydryl-reactive reagents suggesting that the disulfide bond in cysteine is associated with this 
phenomenon. Cysteine oxidation leads to modification of the flavin site and loss of NAD binding 
[43, 55]. Nishino and co-workers reported that rat liver XDH is converted to XO by modification of 
Cys
535
 and Cys
992
 residues [56]. XDH can also be converted irreversibly to XO by proteolysis [44, 
57]. 
The enzyme present in milk appears to exist exclusively in the XO form, presumably following 
proteolysis of XDH before secretion. It has been shown that XO from human breast milk has 
activity of only about 5% that of purified bovine milk XO, due to low molybdenum (Mo) content of 
the human form. Purified human milk XO was reported to comprise at least 95% demolybdo-
enzyme, compared with 30–40% for the bovine milk enzyme [58].  
 
 
 Figure  1.12 Reactions catalysed by XDH and XO forms of xanthine oxidoreductase. 
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1.2.8.3 Antibacterial properties of xanthine oxidase 
Xanthine oxidase (XO) generates reactive oxygen species (ROS) and reactive nitrogen species 
(RNS) [59], which are known to act as destructive agents in many situations, especially in ischemia-
reperfusion injury [60-63]. However, ROS also have been long recognised as antiseptic agents, with 
peroxide being used also for sterilising and bleaching. XO is highly expressed in the upper small 
intestine, especially in basal and apical layers [64, 65], as evidenced by assays of the intestinal villi 
and positive immunohistochemistry staining using monoclonal anti-human milk XO antibodies 
(Fig. 1.13). The presence of XO in the upper small intestine particularly in the surface epithelial 
cells suggests an antimicrobial role by the production of peroxide. This hypothesis was supported 
from a study by Van Den Munckhof who found bacteria were killed by XO in the rat digestive tract 
[66]. Furthermore, XO has been shown to be present at the luminal surface of bile duct and in 
biliary secretions where it may also act as an antibacterial agent to protect the biliary system [24, 
47]. Gut XO also appears to function as a barrier against dietary purines, which are converted to 
uric acid when crossing the small intestine.  
 
Figure  1.13 Positive reaction for mouse monoclonal anti-human XO antibodies in small intestine. 
Arrows show that XO is localised predominantly from mid-villi to the tip [67].  
 
In mammalian milk XO is a major protein component of milk fat globule membrane (MFGM). 
MFGM is synthesised from fat droplets, which originate in the endoplasmic reticulum of secretory 
mammary gland cells. The fat droplets are then enveloped by the apical cell membrane before 
release [68, 69]. Interestingly, mammary glands in mice showed an increase in XO mRNA 
transcription during pregnancy and lactation [70].  
There are also anecdotal but widespread “mid-wives’ tales” alluding to the antiseptic properties of 
breast milk, for example in treating eye infections in babies or for sores on the breast (from: 
http://thetruthaboutbreastfeeding.com/2009/10/11/can-breast-milk-cure-an-eye-infection/, accessed 
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1/8/2013). Purified bovine milk XO has been shown to inhibit the growth of several bacteria 
species, including the clinically important and ubiquitous Staphylococcus aureus [67]. Stevens and 
co-workers found that breast milk inhibited the growth of E.coli and Salmonella enteritidis, 
particularly following the addition of hypoxanthine (a substrate for xanthine oxidase) to milk-
supplemented media [71].  
 
Under anaerobic conditions, XO can also reduce nitrite (NO2
-
) at the molybdenum site [72, 73]. The 
product, nitric oxide (NO), in low concentration has important physiological roles of vasodilation, 
neurotransmission and platelet aggregation [74]. But in high concentration NO is toxic and 
inactivates many enzymes [75]. Superoxide generated in the presence of molecular oxygen can 
react rapidly with NO to yield peroxynitrite ONOO
-
, which also is a powerful antibacterial agent 
[24]. Even though superoxide and H2O2 generation is markedly stimulated above pH 7 in the 
presence of oxygen, Stevens and co-workers [71] found that neonatal gastric conditions (pH 4 to pH 
6, with an oxygen tension less than 5%) are sufficient for XO to generate NO and consequently 
peroxynitrite (Fig. 1.14). 
 
Figure  1.14 Xanthine oxidase catalyses production of NO and peroxynitrite. Diagram was adapted 
from [24]. Abbreviations: Mo, molybdenum; Fe2S2, iron sulfate; FAD, flavin adenine dinucleotide; 
NAD, nicotinamide adenine dinucleotide; NO2-, nitrite; NO, nitric oxide; ONOO-, peroxynitrite. 
 
Furthermore, peroxide-free radicals can combine with thiocyanate (SCN
-
), catalysed by the enzyme 
lactoperoxidase (LPO), which is also present in milk and saliva, to produce a more potent anti-
bacterial free radical hypothiocyanite (OSCN
-
); this is known as the 'lactoperoxidase system' [76-
78]. In addition, the role of XO in milk secretion is considered to be primarily to produce ROS, 
which then act as an antibacterial agent in both the milk glands to prevent mastitis, and in the milk 
itself to inhibit microbial growth [79]. 
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1.2.9 PHYSIOLOGY OF REACTIVE OXYGEN SPECIES 
ROS are mediated metabolically in the human body by enzymes (e.g. NADPH oxidases, XO, nitric 
oxide synthetase, glutathione oxidase, cytochrome P450) as well as non-enzymatically by redox 
reactive compounds such as the semi-ubiquinones of mitochondria produced as a consequence of 
oxidative phosphorylation processes, and by peroxisomes as metabolic by-products [80]. 
Mitochondria are the major source of cellular ROS, especially during pathological conditions, when 
electrons leak.  
In cells the initial reaction of ROS is an electron transfer to oxygen to form superoxide (O2
.-
). 
Superoxide dismutase (SOD) then converts superoxide to long-lasting and membrane-diffusible 
H2O2 [81]. In the presences of reduced metals such as ferrous ions, H2O2 may split into two 
molecules of a highly reactive hydroxyl radical (
.
OH); otherwise H2O2 is converted to water by 
catalase or glutathione peroxidase (Fig 1.15) [82]. Free radicals have been described as destructive 
agents for tissues and organs causing pathological conditions [83, 84]. At high concentrations, ROS 
can react with cellular proteins, lipids, and nucleic acids thereby inducing functional alterations, or 
complete destruction. 
 However, it is important to note that ROS have an essential role in human normal physiology. At 
moderate (micromolar) concentrations, ROS are critical for cellular proliferation, differentiation, 
growth regulation, apoptosis, and other second messenger signalling pathways [82, 85, 86] (Fig 
1.16). In addition, they have vital roles in the innate immune system where they directly fight 
pathogens [59]. When exposed to pathogens, activated phagocytic white blood cells present in 
localised inflammation within tissues produce an oxidative burst of excess ROS as a part of the first 
line defence against microbial invasion [85]. Recently, it was suggested that cryptotanshinone, (a 
compound isolated from some medicinal plants) exhibits its antimicrobial activity against S. aureus 
strains by generating ROS [87]. Importantly, this molecule targets S. aureus isolates of which more 
than 60% are resistant to methicillin. Research in this area of utilising ROS activity is promising 
and aims to discover novel oxidative molecules that target antibiotic resistant bacterial strains, a 
serious clinical problem that is increasingly encountered. 
Therefore, the term “oxidative regulation” might prove to be more precise than “oxidative stress” to 
describe the role of ROS in the body. An example of a revised role for ROS is illustrated by the 
interesting question, “Can antioxidants promote diseases?” addressed by Perera and Bardeesy in 
their 2011 Nature paper: “Cancer: when antioxidants are bad?” [88]. This is an area of research 
finding increasing applications in cancer and other disease-related studies. 
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Figure  1.15 Metabolism of ROS in normal state. Abbreviations: XO, xanthine oxidase; SOD, 
superoxide dismutase; GSH, glutathione; GSSG, glutathione disulfide; NADPH, nicotinamide 
adenine dinucleotide phosphate. Diagram from Droge [82] with modification. 
 
 
 
 
Figure  1.16 ROS generation and health. At micromolar concentrations, ROS have crucial roles in 
cells through mechanisms including signalling, biosynthetic processes, and host defence. When 
ROS levels are too low, the condition may result in decreased antimicrobial and anticancer defence 
and inappropriate signalling. When levels are too high there is increased non-specific tissue 
damage, resulting in a higher risk of cardiovascular disease, neurological damage, and chronic 
inflammation. Diagram from Brieger et al. [80]. 
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1.2.10   PHYSIOLOGY OF SALIVA 
1.2.10.1 Functions of saliva 
Saliva is a complex fluid secreted by 3 pairs of salivary glands (parotid, submandibular, sublingual) 
which are located under and to the side of the oral cavity, and which secrete saliva into the mouth 
via a series of short ducts (Fig. 1.17) [89]. Saliva has a variety of functions; see Figure 1.18 for a 
summary of salivary components and functions. Saliva lubricates and partially digests food before 
swallowing and plays an important role in buffering the pH of the oral cavity [90]. 
The pH of saliva can range from 5.3 during low flow to 7.8 during peak salivary flow. Bicarbonate 
and phosphate are major buffering ions that neutralise acids formed by bacterial fermentation of 
sugar, which causes dental caries. Urea also plays a significant role in saliva buffering, as some oral 
bacteria can hydrolyse urea to ammonia and carbon dioxide, which consequently increases the pH, 
although elevation of ammonia in saliva can initiate gingivitis [91].  
 
Figure  1.17 The human salivary glands – from http://www.oral-cancer.info/ (accessed 30/3/2013). 
 
1.2.10.2 Protein components of saliva 
Saliva contains a variety of specialised proteins and enzymes. The immunologic proteins of saliva 
are IgA, IgM, and IgG, with secretory IgA having the highest concentration [92]. These 
immunoglobulins bind the bacteria and inhibit their adhesion to oral tissues. Lactoferrin and 
cystatines also play a role in inhibiting microbial activity. Non-immunologic antibacterial 
components of saliva include several enzymes, in particular peroxidase (which has a significant role 
in ROS generation), lysozyme and lactoferrin. Salivary enzymes also include amylase, lipase, 
protease, DNAse and RNAse [90, 91].  
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Proline-rich proteins (PRPs) comprise approximately 70% of the total protein content of human 
parotid saliva [90]. PRPs inhibit spontaneous precipitation of calcium phosphate salts on the tooth 
surface, preventing the formation of dental caries. These proteins also improve oral lubrication and 
selectively enhance bacterial adhesion to teeth surfaces [91]. Histatins, a class of protein rich in 
histidine and found in both parotid and submandibular secretions, reportedly show antimicrobial 
properties against the yeast Candida albicans [93]. These anti-Candidal properties of histatins were 
demonstrated when a recombinant adenovirus vector containing histatin-3 DNA was transferred 
into the rat parotid gland, histatin was secreted into rat saliva and demonstrated increased inhibitory 
activity against Candida compared to control animals [94].  
Proteins of submandibular and sublingual saliva also include the mucins, which are large viscous 
glycoproteins comprising 2 groups: highly-glycosylated MG1 and single-glycosylated MG2 [90]. 
Mucins are characterised by low solubility, high viscosity, high elasticity, and strong adhesiveness 
[95]. They have a lubricating function when food is swallowed as well as protecting oral surfaces 
against friction, and similar to the role within the gut, they form a barrier between bacteria and 
epithelial cells in the mouth [91].  
 
Figure  1.18 Saliva composition. Diagram from [96]. 
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1.2.10.3 Electrolyte components of saliva 
The major component of saliva is water (99% w/w), with dissolved inorganic salts containing 
sodium, potassium, calcium, magnesium, bicarbonate, phosphate, and chloride. Table 1.1 contains 
summary data for electrolytes and total protein concentrations in whole human saliva compared 
with plasma. Note that while plasma ultrafiltrates are isotonic in the acinar cells of salivary glands, 
the energy-dependent reabsorption of Na
+
 and Cl
-
 from the salivary ductal system results in saliva 
being a hypotonic secretion. This hypotonic state facilitates the function of taste and also allows 
hydration and expansion of mucin glycoproteins [91, 95, 97]. The thiocyanate ion (SCN
-
) is 
secreted in high concentrations in saliva - it is negligible in plasma (Table 1.1). Thiocyanate plays a 
role in combination with H2O2 and lactoperoxidase to produce the bacteriostatic nitrogen species, 
hypothiocyanate.  
Table  1.1 Electrolyte and total protein concentrations in whole human saliva and plasma. From Aps 
and Martens, 2005 [97]. (NH2)2CO2, urea; SCN
-
, thiocyanate; HCO3
-
, bicarbonate; NH3, ammonia. 
 
 Plasma 
 
Whole human resting 
saliva 
Whole human stimulated 
saliva 
Na+ (mM) 145 5 20–80 
K+ (mM) 4 22 20 
Ca2+ (mM) 2.2 1–4 1–4 
Cl− (mM) 120 15 30–100 
HCO3− (mM) 25 5 15–80 
Phosphate (mM) 1.2 6 4 
Mg2+ (mM) 1.2 0.2 0.2 
SCN− (mM) <0.2 2.5 2 
NH3 (mM) 0.05 6 3 
(NH2)2CO (mM) 2–7 3.3 2–4 
Protein (g/l) 70 3 3 
 
1.2.10.4 Oral microbiota 
The human body is host to many commensal microorganisms, with distinct communities at 
different anatomical sites [98, 99]. Recent studies have highlighted the importance of the gut 
microbiota to the host. These microorganisms contribute to the metabolism and supply of essential 
nutrients, they stimulate the immune system assisting in its development and the immune response, 
and these colonizers protect the host from invasive pathogens (see Section 4.1.1). The healthy oral 
cavity is constantly moist with a temperature range of 34
o
C to 36
o
C and an approximately neutral 
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pH [100]. These conditions provide an ideal environment for the growth of many microorganisms. 
Early studies reported that the oral cavity contained at least 300 cultivable bacterial species 
including mutans streptococci (Streptococcus mutans, S. sobrinus, S. cricetus, and S. rattus); S. 
sanguis, which are found in larger numbers on teeth than on soft tissues; and S. salivarius, which is 
located chiefly on the surface of the tongue [101, 102]. However, the use of culture-independent 
methods for determining the composition of the oral microbiota, allied with next generation DNA 
sequencing methods is providing a far deeper analysis, as a majority of bacteria have yet to be 
cultivated [103]. Recent studies using DNA-based methods have demonstrated the presence of non-
cultivable bacterial strains, which indicates that the oral microbiome is far more diverse than 
originally thought. Most of these molecular studies are based on sequencing of the small subunit 
(16S) ribosomal RNA (rRNA) gene because of its universal presence in bacterial organisms, the 
presence of conserved regions and its reliability for phylogenetic analysis [104, 105]. Using 16S 
rRNA gene-based techniques, it is estimated that the bacterial communities found in the human 
mouth are highly complex with around 1000 species present [106]. The oral microbiome has also 
been shown to be the second most complex in the body, after the colon [98].  
 
Recent molecular genetic studies of bacterial communities in the mouth have shown that the phyla 
Firmicutes, Bacteroidetes, Proteobacteria, Actinobacteria, Spirochaetes and Fusobacteria [106] are 
the most predominant; and the most predominant bacterial genera in the human adult oral cavity 
include Streptococcus, Gemella, Abiotrophia, Granulicatella, Rothia, Neisseria, Prevotella, 
Haemophilus and Lautropia. However, large differences within the community composition were 
reported between individuals [107]. Most oral diseases are caused by multiple bacteria, e.g. dental 
caries are caused by acid-tolerant bacteria: streptococcal species, lactobacilli, and the actinomyces 
[103]. Lesions of oral tissues thus may contain hundreds of bacterial species [108]. The oral cavity 
also accommodates other non-bacterial microbiome including yeasts, e.g. Candida albicans, and 
protozoans, such as Entamoeba gingivalis and Trichomonas tenax [103]. 
 
The gut microbiome has been intensively studied in infants (Section 4.1.1), however, there are few 
studies examining microbial communities in the mouths of neonates and the differences in the 
community structure between breast-fed and formula-fed infants. Bacteria from the mother’s 
vagina, gut, and skin may be transmitted to neonates during delivery. Importantly, breast milk 
affects the establishment of the microbiota in the mouth as well as in the gastrointestinal tract (GIT) 
by providing nutrition and bacteria, predominantly lactobacilli, bifidobacteria, and streptococci 
[109]. Interestingly, recent publications report that the oral microbiota in infants also differ 
depending on the mode of delivery. Significantly higher numbers of bacterial taxa were also 
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detected in the mouths of vaginally-delivered infants compared with infants delivered by Caesarean 
section [110]. The mode of delivery therefore influences the types of bacteria acquired by the 
neonate and the communities established [111].  
1.2.10.5 Salivary production 
Healthy adults produce approximately 500-1500 mL of saliva per day. However, daytime salivary 
flow rates vary greatly between individuals [92]. The normal flow rate of stimulated saliva is 1-3 
mL/min and up to 6 mL/min. The low range is considered to be 0.7-1.0 mL/min, with 
hyposalivation usually defined as flow rates less than 0.7 mL/min. By contrast, normal unstimulated 
saliva secretion ranges from 0.25-0.35 mL/min, with low values ranging from 0.1-0.25 mL/min, and 
hyposalivation defined as less than 0.1 mL/min [91]. Circadian rhythms greatly influence the 
salivary flow rate, with the salivary flow reaching its highest peak at the end of the afternoon then 
declining to almost zero during sleep [95].  
However, several factors which vary greatly among individuals influence salivary flow. The degree 
of hydration is the most potent factor. Irritation of salivary glands by tobacco components 
stimulates salivary secretion, thus smokers have higher salivary flow than non-smokers [112], while 
alcohol intake significantly reduces the salivary flow [113]. Other factors such as various 
medications, thinking about food, and mechanical stimulation, can influence salivary flow [91, 95]. 
Saliva is stimulated by smells and tastes, and mild food acids such as citric acid are considered to be 
the most potent stimulators [114].  
The contribution by the various salivary glands to secretion during unstimulated flow is 20% by 
parotid glands, 65-70% by the submandibular gland, 7-8% by the sublingual glands, and less than 
10% by the minor salivary glands (Fig. 1.19). However, during stimulation, the parotids contribute 
on average more than half of total salivary secretion [91, 95]. 
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Figure  1.19 Glandular contribution to unstimulated salivary flow [91]. 
 
1.2.10.6 Diagnostic and metabolic roles of saliva 
Analysis of saliva for investigation of diseases is potentially valuable for children and for older 
adults, as sample collection is less invasive than blood collection. In addition, analysis of saliva may 
provide a cost effective approach for screening for some types of diseases [115]. It is used to assess 
the diagnosis of dental conditions such as caries, periodontal disease, salivary gland disease, and 
Candida infections, as well as for the diagnosis of viral diseases, tuberculosis, lymphoma, gastric 
ulcer and cancers, heart disease, and Sjogren’s syndrome [95, 116]. However, the use of saliva to 
diagnose metabolic status has not been widely studied. In particular, purines and pyrimidines have 
only been analysed in one short report about adult saliva [117]. Saliva has also been advocated for 
some forms of therapeutic drug monitoring [118-120]. 
31 
 
1.2.11 HUMAN MILK PHYSIOLOGY AND COMPOSITION 
One aim of the present study was to investigate the interaction between neonatal saliva and breast 
milk. As discussed above, xanthine oxidase (XO) is found in an active form in mammalian milk 
[67], and it has been suggested that this plays an important role in establishing immunity in the 
newborn through its ability to generate ROS and RNS which have antibacterial properties [71]. 
Xanthine is excreted in the mammary glands coincident with milk, and this generates peroxide in 
the mammary milk sinuses, although this peroxidative power is considered to be depleted by the 
time the milk is exuded [24, 47, 73].  
1.2.11.1 Physiology of human milk secretion 
There are 2 essential hormones controlling breast milk secretion, prolactin and oxytocin. Prolactin 
is produced by the anterior pituitary gland and functions as a stimulator for secretory cells in the 
mammary alveoli to produce milk. This hormone is inhibited during pregnancy by the high level of 
oestrogen and progesterone, which consequently inhibits lactation during pregnancy. Oxytocin is 
produced by the posterior pituitary and enhances the alveoli to contract and push milk from the 
secretory cells to the milk sinuses in the mammary alveolar area. Sucking plays an important part in 
the secretion of milk, as prolactin and oxytocin are both stimulated by this neonatal reflex [121]. 
The volume and contents of human milk are influenced by various factors such as genetic profile, 
maternal nutrition, and lactation [122]. The initial form of milk produced at the beginning of 
lactation is called “colostrum” and has differences in protein content including high concentrations 
of XO [123]. 
1.2.11.2 Human milk proteins 
Human milk contains the lowest total protein concentration of all mammalian milk, with 
approximately 0.8-0.9 g/dL, perhaps due to the slow growth of the child [122, 124]. Human milk 
proteins are classified as three types: casein, mucins and whey proteins, containing an adequate 
amount of amino acids except phenylalanine and tyrosine which are present in low levels [124]. 
Casein has highly glycosylated subunits [125] which bind to form micelles [126]. Casein also binds 
calcium and phosphorus to facilitate their absorption, [124] and forms curds in the stomach [121] 
which reduce gastric emptying time in infants [124]. Furthermore, the casein κ-subunit shows some 
antibacterial activity, as casein can inhibit the adherence of Helicobacter pylori to gastric mucosa, 
and Streptococcus pneumoniae and Haemophilus influenzae to respiratory-tract epithelial cells in 
infants [125]. 
 
Mucins comprise the lowest fraction of human milk proteins and function mainly to surround the fat 
globules with membranes. Interestingly, the mucin protein fraction remains constant as a result of 
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stable milk fat secretion during the period of lactation [127]. Milk whey proteins comprise all other 
proteins including enzymes. These have functions in digestion, metabolism, immunity, proteolysis 
inhibition, and transportation. Examples of whey proteins include lactoferrin, albumin, 
immunoglobulins, lysozyme, lactoperoxidase, protease inhibitors and XO [126].  
 
Human milk especially colostrum, is rich in immunoglobulins. Secretory IgA represents the highest 
immunoglobulin levels, while IgG and IgM occur in lower concentrations. These immunoglobulins 
may protect the mammary gland and infants from infection. Secretory IgA is resistant to 
proteolysis, a feature that may allow it to exert its function in the gastrointestinal tract of breast-fed 
infants [126].  
1.2.11.3 Human milk lipids 
Fat is present in breast milk as triglycerides, phospholipids and cholesterol, and represents the main 
energy source for infants (35%-50% of total needs). Most human milk fats are present as globules 
[124]. Triglycerides, the main components of milk fats, [121] are digested by lipase into glycerol 
and free fatty acids, especially long-chain polyunsaturated fatty acids (docosahexaenoic acid and 
arachidonic acid) which are important for growth and brain development [124]. 
1.2.11.4 Human milk carbohydrates  
Most carbohydrate in human milk is in the form of the disaccharide lactose. Lactose is degraded to 
monosaccharaides galactose and glucose, the former having an essential role in the development of 
brain white matter in infants [124]. Moreover, lactose facilitates the absorption of calcium and iron 
and enhances the growth of lactobacilli in the intestinal lumen, which acts to minimise the 
proliferation of pathogenic bacteria. On the other hand, glucose derived from lactose is an important 
energy source for the infant brain [121]. Other complex carbohydrates in human milk have 
antibacterial properties such as glycoproteins, glycolipids, and oligosaccharides [124] 
1.2.11.5 White blood cells in human milk 
Leukocytes (white cells) occur in human milk and comprise macrophages (40%-50%), neutrophils 
(40%-50%) and lymphocytes (5%-10%). These occur in high numbers at the beginning of lactation 
in colostrum, but then decrease in the mature milk [124, 126]. Leukocytes in human milk 
predominantly exert their function by phagocytosis of foreign microorganisms, and this is enhanced 
when complement proteins C3b first coat the surface of microorganisms [124]. 
1.2.11.6 Human milk minerals 
Sodium, potassium, chloride, calcium, magnesium, and phosphorus are the major mineral elements 
in human milk [124]. Interestingly, there is a weak correlation between calcium, magnesium, and 
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phosphorus in human milk and maternal serum. The infant serum concentrations of calcium and 
magnesium increase with lactation which is associated with a decline in phosphorus concentration 
as this element is absorbed with bone growth [122]  
The trace minerals zinc, iron, copper, selenium and manganese are also found in human milk. 
Breast-fed infants have adequate amounts of zinc compared to formula-fed. Copper and iron 
decrease rapidly in early lactation and are stable in mature milk, while zinc undergoes a continuous 
decline overtime even in mature milk [122]. Infants absorb iron from human milk at a five-times 
higher rate than from bovine milk [128]. The absorption of iron from human milk is enhanced by 
the presence of vitamin C and lactose [124]. 
1.2.11.7 Human milk vitamins 
The vitamin content of human milk is markedly affected by the maternal nutritional status. All 
water soluble vitamins are found in breast milk, with vitamin C concentrations in maternal milk 
being 8 to 10 times higher than in plasma. Furthermore, fat-soluble vitamins are also present in 
human milk; vitamin D supplementation is essential especially in vegetarian mothers as 
concentrations of this vitamin critically decrease in maternal milk [124, 129]. 
1.2.11.8 Human milk nucleotides 
Human milk has high amounts of nucleotides compared to bovine milk. Human milk is reported to 
contain the mononucleotides CMP, UMP, AMP, GMP and IMP, and the dinucleotides CDP, UDP, 
ADP and GDP, with the pyrimidine nucleotides (of cytidine and uridine) representing the highest 
fractions [130, 131]. Interestingly, no trinucleotides have been detected in these studies. It has been 
suggested that human nucleotides may have roles in intestinal development, iron absorption, 
regulation of intestinal flora, lipid metabolism, and immune function [132, 133]. More recently, 
some studies have shown a reduction in the incidence of diarrhoea in infants who are fed 
nucleotide-supplemented infant formula compared to those fed non-supplemented formula [134]. 
There appears to be no published analyses of the nucleoside and base composition of human milk, 
although bovine milk has been shown to have high levels of the pyrimidine base orotic acid [135] 
which appears to be absent in human milk. 
1.2.11.9 Mastitis 
Mastitis is an inflammation of breast tissues brought about by infection with several species of 
microorganisms. The usual symptoms of mastitis are breast pain, redness, tenderness, and fever. 
The inflammation can develop into abscesses and septicaemia [136]. Many factors have been 
reported to predispose to mastitis such as stress, malnutrition [137], trauma, immunity, hygiene and 
genetic factors [138]. 
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 Mastitis can occur at any stage of lactation but the infection rate is highest in the first few weeks 
postpartum at an incidence of 2%-33% [136, 139]. Some mastitis infections are asymptomatic 
(subclinical mastitis) but may be identified by low milk production and increased sodium 
concentration and bacterial counts [138]. 
The most common bacteria causing mastitis is S. aureus (especially hospital-acquired mastitis) and 
other Staphylococcal species as well as E. coli. Mastitis is caused rarely by some Mycobacterium 
species, and the yeast, Candida and Cryptococcus species [137-140]. As discussed above, an 
important role attributed to XO in milk, has been protection against mastitis by the production of 
H2O2 within the mammary alveolar spaces and storage ducts. 
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1.3 OVERALL PROJECT HYPOTHESIS  
It is hypothesised that the substrates for xanthine oxidase (XO), xanthine and hypoxanthine, as well 
as other nucleotide metabolites are present in higher concentrations in neonatal saliva, have 
important roles in generating H2O2 and in oral biology by regulating the microbiota of the mouth 
and the gut. 
 
1.4 OVERALL PROJECT AIM 
To study and establish a new research direction for the role of nucleotide metabolites in saliva, and 
to compare patterns of concentrations of these metabolites in mammals specially humans. In 
particular, neonatal salivary nucleotide metabolite concentrations and their possible interaction with 
breast milk will be studied. These metabolites are poorly described and their functions and level of 
excretion by salivary glands are still unknown. 
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Chapter 2 
Determination of nucleotide metabolites in human and mammalian 
saliva by high performance liquid chromatography with tandem mass 
spectrometry: changes during early human infancy and a survey of 
ranges in adult humans and other mammals 
 
 
The methodology component and relevant results of this chapter have been published in Journal of 
Chromatography B (see Appendix 9) 
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2.1 INTRODUCTION 
2.1.1 ROLES OF PURINES AND PYRIMIDINES 
Purine and pyrimidine nucleotides are critical molecules in cells, being essential in many 
biochemical functions including biosynthesis, energy supply, units of DNA and RNA, essential 
coenzymes, and regulatory mechanisms. They are synthesised in mammalian cells by either de novo 
pathways that are energy consuming, or by salvage pathways that conserve energy [28, 141]. Purine 
nucleotides are usually salvaged from their nucleobases, whereas pyrimidines are recovered from 
their nucleosides. Non-salvaged purines are catabolised to uric acid by the enzyme xanthine oxidase 
(XO), while pyrimidines are catabolised to amino acids, ammonia and carbon dioxide [12, 19]. 
 
Dietary and endogenous nucleosides and bases are rapidly absorbed for salvage or catabolism, and 
their plasma concentrations are very low. With the exception of uridine and uric acid, nucleoside 
and base concentrations are less than 1 µM in plasma [4, 142-145]. Nucleotides are usually located 
intracellularly and are therefore regarded as indicators of cellular damage when they appear in the 
extracellular fluid. Nucleosides and bases (which are metabolites of nucleotides) occur 
extracellularly, and raised concentrations in plasma and urine are used as markers of nucleotide 
metabolic disorders [142, 146].  
 
2.1.2 SALIVARY PURINES AND PYRIMIDINES 
Research interest in saliva has been heightened with the discovery that saliva contains a number of 
biochemical components, which may be useful for the monitoring of drugs and for early diagnosis 
of diseases such as cancer and heart disease [97, 116, 147, 148]. Moreover, for young children and 
the elderly the collection of saliva is much less invasive than blood sampling [115]. However, the 
use of saliva to evaluate metabolic status has not been widely studied; in particular, purine and 
pyrimidine metabolites in saliva have been examined only by one group, with this report not being 
followed up elsewhere [117].  
 
In this chapter a method is described that was developed specifically for the collection of saliva in 
neonates and adults. This was validated and then applied for the determination of purine and 
pyrimidine metabolites in small volumes of saliva using high performance liquid chromatography 
(HPLC), initially with detection by photodiode-array (PDA) and then tandem mass spectrometry 
(MS/MS). Pilot data concerning the salivary concentrations of nucleotide metabolites were 
collected from a small sample of adults and neonates. It was discovered that the concentrations of 
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these metabolites were significantly raised in neonates compared with adults. Salivary analyses of 
77 adults, and 60 neonates were conducted. A longitudinal study of infants over 12 months was 
then undertaken. In addition, a selection of domestic animals was chosen for analysis and the 
patterns of salivary purines and pyrimidines were found to vary greatly. The proposed function of 
these metabolites in saliva, especially from neonates, was subsequently discussed.  
 
Initially, a pilot study on infants of ages ranging from newborn to 2 weeks to 3 years led to the 
finding that neonatal saliva had higher concentrations of nucleosides and bases compared to adults, 
and that the transition between infant and adult saliva patterns of purines and pyrimidines 
apparently occurs during the first year of life. These observations led to the formulation of the 
hypotheses listed below. 
39 
 
2.2 SPECIFIC HYPOTHESES AND RATIONALE 
Hypothesis 1: That purine and pyrimidine bases and nucleosides are present in adult and neonatal 
saliva and that these nucleotide metabolites are present in higher concentrations in neonatal saliva 
compared to adults. 
 
Hypothesis 2: That the presence of raised concentrations of purine and pyrimidine bases and their 
nucleosides in neonatal saliva return to adult levels in the first year of life. 
 
Hypothesis 3: That purine and pyrimidine bases and their nucleosides are present in saliva of some 
other mammals.  
 
Rationale: Low concentrations of some purine bases, nucleosides and nucleotides have been 
reported in adult saliva; but these have not been studied in infants or children. If they are different 
then they may relate to early regulation of the micro-environment of the infant mouth, and must 
change to the adult pattern at some stage. For ethical and organisational reasons at the Mater 
Hospital where this study was to be undertaken, this initial investigation was most easily performed 
over the first year of life. Similarly, the pattern of nucleotide metabolites in mammals other than 
humans has not been reported previously. This will provide species comparative data on salivary 
purines and pyrimidines. It may also provide clues to the roles of salivary nucleotide metabolites by 
relating them to known oral microbial compositions and dietary habits (i.e. grass-eating, 
omnivorous, carnivorous). Any such study will be dependent upon initial careful standardisation of 
methods for saliva collection and the development of sufficiently sensitive analytical methods. 
 
 
2.3 SPECIFIC AIMS 
1. To develop and validate a method for sampling saliva from adults and infants and extraction 
of purines and pyrimidines metabolites, including a method for collection of small volumes of 
saliva from neonates  
2. To develop and validate an analytical method for the determination of purine and pyrimidine 
metabolites in small volumes of saliva using high performance liquid chromatography 
(HPLC) with tandem mass spectrometry (LC-MS/MS) 
3. To conduct a survey of concentration ranges of nucleotide metabolites in adult saliva 
4. To conduct a survey of concentration ranges of metabolites in neonatal saliva 
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5.  To conduct a 12-month longitudinal study of the nucleobases and nucleosides metabolome of 
saliva of newborn babies through to weaning and early infancy 
6. To conduct a survey of saliva from other mammalian species to investigate and compare the 
salivary nucleotide metabolite patterns between mammals and humans 
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2.4 MATERIALS AND METHODS 
2.4.1 SUBJECTS AND SAMPLE COLLECTION 
 Study protocols received prior written approval from Mater Health Services and The University of 
Queensland Human Research Ethics Committees (see Appendices 1-4). 
2.4.1.1 Adults for saliva survey 
Unstimulated whole saliva samples were collected from 77 adult volunteers, 30 males and 47 
females, aged 19-70 years, at the Mater Adult Hospital, Brisbane, Australia. The inclusion criteria 
for the study were healthy adults (>18 years old), males and females. Adults of ethnicity other than 
Caucasian and adults with metabolic disorders or oral pathology were excluded from the study. The 
reason for excluding non-Caucasian was to minimising genetic variance. Sampling was performed 
between 0800 and 0900, with subjects having no food or drink for at least 2 h before sampling. The 
participants were asked to rinse their mouth with water and wait for approximately 10 min before 
salivating ('passive drool') into sterile 50 mL polypropylene universal containers (Sarstedt Ply Ltd, 
Mawson Lakes, SA, Australia). Samples were immediately placed on ice, transferred to the 
laboratory, divided into small portions and stored at -80
o
C until analysed.  
2.4.1.2 Neonates for saliva survey 
Neonatal saliva was collected using cotton oral swabs (Swisspers Baby Tips, McPherson’s 
Consumer Products, Kingsgrove, NSW, Australia) with plastic stick and double-ended cotton buds. 
Because of chromatographic interference, it was necessary to remove UV-absorbing compounds 
which were present in the cotton swabs. Therefore, before saliva collection all cotton swabs were 
washed sequentially with deionised water, ethanol, diethyl ether, then left to dry for at least 24 h at 
room temperature.  
 
One cotton tip of each oral swab was removed to avoid confusion between “used” and “unused” 
ends. Two swabs were then placed in a 5 mL screw-cap plastic test tube and weighed to the nearest 
milligram to obtain the (pre-collection) dry weight. Unstimulated whole saliva samples were 
collected by a research nurse from 60 healthy neonates who had not been fed for at least 30 min, 
aged 1-4 days, at the Mater Mothers’ Hospital, South Brisbane, QLD, Australia. The inclusion 
criteria for the study were healthy full-term vaginally-delivered Caucasian neonates, males and 
females. Neonates of ethnicity other than Caucasian and those with complications, pathologies or 
infections and metabolic disorders that may affect the baby’s saliva production or quality were 
excluded. Two cotton swabs were placed at the same time under the tongue and moved gently 
around the buccal cavity for approximately 5 min; no infant experienced any obvious discomfort. 
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The swabs were immediately put back into the capped test tube to prevent evaporation then placed 
on ice. The test tube was re-weighed on the same balance used for the pre-collection weighing to 
calculate the volume of saliva on the swabs assuming a salivary specific gravity of 1.0 (i.e. 
assuming saliva density is similar to the density of water [149]. The samples were then processed as 
described below, or stored at -80°C at which temperature standard solutions of nucleosides and 
bases were found to be stable for at least 12 months. The subjects’ characteristics are shown in 
Table 2.1 below. 
 
Table ‎2.1 Physical information about the participated neonates.  
 
 Male Female p value Total 
N 22 38 n.s. 60 
Gestational age (weeks) 
 
 
    
   Mean±SD                                   40±1.4 40±1.3 0.5 (n.s.) 40±1.3 
   Range 
 
 
38-42 37-42  37-42 
 
Birth weight (g) 
 
 
    
   Mean±SD 3751±467 3665±435 0.5 (n.s.) 3697±445 
   Range 2630-4685 2768-4446  2630-4685 
Age (hours)     
   Mean±SD 34±14 34±16 0.9 (n.s.) 34±14 
   Range 8-62 8-80  8-80 
n.s.= not significant at p=0.05 
2.4.1.3 Subjects for infant longitudinal study 
Of the 60 neonates studied, the parents of 20 of them agreed for their infants to participate in a 
longitudinal study involving follow-up sampling at 6 weeks (n= 20), 6 months (n= 19), and 12 
months (n= 14) after the initial collection. Unstimulated samples were collected as described above 
using polystyrene plastic pipettes (Sigma-Aldrich Pty Ltd, Castle Hill, NSW, Australia) from 
infants who had not been fed for at least 30 min. Samples were immediately placed on ice, then 
transferred without delay to the laboratory for storage at -80
o
C. 
2.4.1.4 Survey of other mammalian species 
Domesticated animals were chosen for saliva sampling. Selection was based essentially on a dietary 
rationale (which may be reflected by the oral microbiota) and the digestive tract characteristics: cat: 
obligatory carnivore; dog: omnivore; horse, cow, sheep, goat and camel: herbivores; cows, sheep 
and goats are ruminants; horses have pre-ruminant sacculation; camels are pseudo-ruminants. Saliva 
was collected from 8 cattle (5 of the 8 samples using cotton swabs, 3 collected from oral drool), 5 
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sheep (cotton swabs), 7 dogs (cotton swabs), 5 cats (cotton swabs), 5 horses (samples collected 
using polystyrene plastic pipettes), 4 goats (cotton swabs), and 1 camel (cotton swab). Sampling the 
herbivorous mammals was initially problematic because of contamination by vegetation, 
presumably by chlorophyll, which resulted in a strong green appearance of the saliva. For horses, 
this was overcome by placing them in a sand yard for one hour prior to sampling. Cows were 
sampled as they waited in bales before milking, during which time they do not tend to regurgitate 
their cud. Sheep, goats and the camel were penned before sampling, which discourages cud-
chewing. Dogs and cats were sampled before feeding. 
 
2.4.2 NEONATAL SALIVA EXTRACTION AND VALIDATION 
2.4.2.1 Investigation for presence of interfering compounds 
Two types of swabs, cotton and Sorbette
®
 sponge swabs (Stratech Scientific, Sydney, NSW, 
Australia) were initially investigated for the presence of interfering compounds. One hundred 
microliters of deionised water was added to each swab which was kept at 4°C for 30 min in a 5 mL 
capped plastic test tube, then sonicated in a bath (Unisonics Pty. Ltd, Brookvale, NSW, Australia) 
for 3 min. The tip of each swab was removed and transferred to a Salivette
® 
(Sarstedt Pty Ltd, 
Mawson Lakes, SA, Australia) and the water was collected by centrifugation at 4500 g, for 5 min, 
then analysed by HPLC with photodiode array (PDA) UV detection at 268 nm which is the mean 
peak wavelength for most purines and pyrimidines. Two recovery methods were evaluated for the 
extraction of nucleotide metabolites from the cotton swabs as detailed below. 
2.4.2.2 Validation of recovery of extraction  
Method #1 (Aqueous extraction): The aqueous extraction of nucleotide metabolites from cotton 
swabs was evaluated by spiking washed cotton swabs with 25, 50, 75, and 100 µL of a mixture of 
uracil, hypoxanthine, xanthine, adenosine, inosine, guanosine, and uridine (59, 55, 75, 47, 47, 41, 
66 µM respectively) prepared in deionised water in 5 replicates. Each cotton swab was then 
maintained at 4°C for 30 min in a 5 mL capped Pyrex test tube (Sarstedt Pty Ltd, Mawson Lakes, 
SA, Australia), then transferred into another 5 mL test tube containing 100 µL of deionised water 
and sonicated in an ultrasonic bath for 3 min. The cotton tip was removed and transferred to a 
Salivette tube and the aqueous component (containing the analytes) was obtained via centrifugation 
at 4500 g, for 5 min at 20
o
C. Extracts were then stored at -80°C pending HPLC-MS/MS analysis. 
 Method #2 (Organic solvent extraction): Organic solvent extraction of nucleotide metabolites 
from cotton swabs was also evaluated as a potential means of improving recovery. Each cotton 
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swab was spiked in 5 replicates with 25, 50, 75, 100 µL of the standard mixture as detailed above. 
The mixture was kept at 4°C for 30 min in a capped test tube, then placed into Pyrex 5 mL test 
tubes, 400 µL of deionised water were added, then the vial was sonicated in the ultrasonic bath for 3 
min. The aqueous extract was transferred to a clean Pyrex glass evaporating tube, and the extraction 
of the swab was repeated twice with 600 µL of acetonitrile, which were then combined with the 
aqueous extract in the evaporating tube. The cotton tip was removed and the swab was transferred 
to a Salivette tube, which was centrifuged at 4500 g for 5 min at 20
o
C to recover the remaining 
acetonitrile in each tip, which was also added to the combined extracts. The total extract was then 
evaporated to dryness in a heating block (Pierce Reacti-Therm III Model 18823, Thermo Fisher 
Scientific Australia Pty Ltd, Scoresby, VIC, Australia) at 40
o
C under a gentle stream of nitrogen. 
The residue was dissolved with vortex mixing in 100 µL of deionised water then stored at -80°C 
pending LC-MS/MS analysis.  
2.4.2.3 Validation of linearity of extraction 
The linearity of the extraction method was evaluated using pooled standard solutions prepared in 
deionised water. Cotton swabs in 5 replicates were spiked with a range of concentrations of bases 
and nucleosides (5, 10, 20, 40, 80 µM) using the standard mixture described above. The bases and 
nucleosides were extracted as described for extraction method #2, then subjected to LC-MS/MS 
analysis. The data were subjected to linear regression analysis (unweighed). 
 
2.4.3 ANALYSIS OF PURINES AND PYRIMIDINES 
2.4.3.1 Sample preparation 
Prior to HPLC analysis, adult and neonatal saliva samples as well as extracted standards were ultra-
filtered by microfuging in 0.5 mL, 50 kDa Amicon ultrafilters (Merck Pty. Ltd., Kilsyth, VIC 
Australia) at 9500 g, for 10 min at 20°C to remove proteins, bacteria and fibres. For HPLC-MS/MS 
analysis each salivary filtrate and the extracted standards were mixed with an isotope-labelled 
internal standard solution as described below (2.4.3.3). 
2.4.3.2 Initial analysis using HPLC  
Initially, the presence of purines and pyrimidines in saliva was investigated using an Agilent 1100 
HPLC system (Agilent Technologies Pty Ltd, Mulgrave, VIC, Australia) with auto-injector, column 
heater and PDA detection, scanning absorbance over a range from 230-350 nm. The initial analyses 
were conducted on a C18 column (Phenomenex Synergy Hydro RP-80A, 4 µm, 250 x 3 mm, Lane 
Cove West, NSW, Australia). Chromatography was performed at 25°C at a flow rate of 0.4 mL/min 
using a linear gradient elution profile of 100% v/v aqueous 40 mM ammonium acetate pH 5.0 
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(mobile phase A) (Sigma-Aldrich Pty. Ltd, Castle Hill, NSW, Australia) to 15% v/v acetonitrile 
(mobile phase B) (Sigma-Aldrich Pty. Ltd , Castle Hill, NSW, Australia) over 25 min; the 
composition was returned to 100% v/v A for 10 min equilibration before the next injection, as 
described previously [146]. Nucleosides and bases were identified by their retention times and UV 
spectra scanning from 230 nm to 350 nm. Subsequently, all HPLC analyses were conducted using 
HPLC with tandem mass spectrometry (LC-MS/MS), as detailed below. 
2.4.3.3 LC-MS/MS conditions 
The LC-MS/MS method for measuring nucleotide metabolites in biological fluids was developed at 
the Pathology Department, and was a modification of that reported previously for purine and 
pyrimidine determination in urine [150], using a Shimadzu Prominence UFLC system (Shimadzu, 
Japan). Briefly, 10 µL of processed saliva sample was mixed with 35 µL of 0.1% (w/w) formic acid 
and 5 µL of a solution of deuterated standards comprising 2,3,7,8-[D4]-hypoxanthine, 5,6-[D2]-
uridine-, 5,6-[D2]-2-deoxyuridine, 6-[D3]-methyl-thymine, 1,3-[15N2]-uric acid, [D3]-methyl-
creatinine, and 1,3-[15N2]-orotic acid (Cambridge Isotope Laboratories Inc. Andover, MA, USA), 
(CDN, Canada), and (Sigma-Aldrich Pty Ltd, Castle Hill, NSW, Australia). Low and high 
concentration quality control standards were prepared similarly to the biological samples.  
 
Samples were injected onto a 4 µm C18 column (Phenomenex Synergy Hydro RP-80A, 4 µm, 150 
x 3.0 mm, Lane Cove West, NSW, Australia). Chromatography was performed at 30°C at a total 
flow rate of 0.3 mL/min, using a linear gradient elution from 98% v/v mobile phase A (aqueous 5 
mM ammonium acetate, 0.05% w/v formic acid) to 15% v/v mobile phase B (0.05% w/v formic 
acid in methanol) over 11 min, then 60% v/v mobile phase B for 1 min, before returning to 2% v/v 
B for a further 6 min for equilibration. The gradient profile is shown in Figure 2.1. This method 
varied slightly from the HPLC-PDA method above, in that a shorter column and a slightly reduced 
flow rate were used. The addition of formic acid to the ammonium acetate buffer and methanol 
provided earlier elution of peaks and faster run time. There was some loss of peak resolution 
compared with the HPLC-PDA method, but this was compensated by the higher specificity and 
positive identification provided by tandem mass spectrometry. 
 
Tandem mass spectrometric (MS/MS) detection was performed using an Applied Biosystems API 
4000 QTRAP mass spectrometer (Applied Biosystems, Forster City, CA, USA), equipped with a 
Turbo V-Spray source with the gas temperature set at 500°C. The source operated an electrospray 
interface (ESI) with switching ionisation polarity (between +5000V and -4000V) during the run (18 
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min). The eluent was monitored by specific ion transitions (MRMs) for each compound and an 
internal standard. All data were quantified using Applied Biosystems Analyst version 1.5 software.
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Figure ‎2.1 Gradient profile of mobile phase B that was used for reversed phase HPLC elution of 
purine and pyrimidine nucleosides and bases followed by MS/MS analysis. Chromatography was 
performed at a total flow rate of 0.3 mL/min, using a linear gradient elution from 98% v/v mobile 
phase A to 15% v/v mobile phase B over 11 min, then 60% v/v mobile phase B for 1 min, before 
returning to 2% v/v B for a further 6 min for equilibration. 
 
 
2.4.3.4 Within run imprecision 
Within-run precision was assessed by spiking 2 adult salivary samples with low (30, 25, 32, 9, 14, 
5, 14 µM) and high (127, 136, 131, 71, 90, 57, 115 µM) concentrations of uracil, hypoxanthine, 
xanthine, adenosine, inosine, guanosine, and uridine respectively. Samples were then ultra-filtered 
and run on LC-MS/MS; 8 replicates were run for each QC. 
2.4.3.5 Limit of detection 
Limit of quantitation (LOQ) and limit of detection (LOD) were determined by injection of 10 µL of 
aqueous standards with varying low metabolite concentrations. The LOD was defined as the lowest 
concentration that gave a signal-to-noise (SN) ratio of 3, while the LOQ was defined by a SN ratio 
of 10. 
 
2.4.4 STATISTICAL ANALYSIS 
Because the raw data were not normally distributed according to D’Agostino and Pearson omnibus 
normality test, non-parametric statistical approaches were used for the data analyses. Median values 
were compared between 2 different groups using the Mann-Whitney test and between more than 2 
groups using the Kruskal-Wallis test. A p-value of 0.05 was the cut-off for statistical significance. 
All analyses were performed using GraphPad Prism 5. 
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2.5 RESULTS 
2.5.1 NEONATAL SALIVA EXTRACTION AND VALIDATION 
Aim1: To develop and validate a method for sampling saliva from infants and extraction of purines 
and pyrimidines metabolites, including a method for collection of small volumes of saliva from 
neonates  
2.5.1.1 Investigation of the presence of interfering compounds 
In this study, the neonatal saliva collection methodology was validated using 2 different types of 
swabs: Sorbette
®
 sponges and cotton swabs. Before sampling, the presence of interfering 
compounds was first checked by spiking the swabs with 100 µL of distilled water, followed by 
extraction and centrifugation and subsequent HPLC-PDA using Method #1 (see section 2.4.2.2) as 
outlined for purine and pyrimidine extraction. Interestingly, the cotton swabs produced large UV-
absorbing peaks in the chromatogram (Fig. 2.2 A). Sorbette sponge swabs have been used 
previously to collect saliva from infants for cortisol determination [151], but in this study the 
Sorbette sponge also produced UV-absorbing peaks (Fig. 2.2 B). However, these swabs could not 
be washed with solvents prior to saliva collection without destroying the sponge. The commercial 
cotton swabs were more robust and were not affected by the washing method.  
 
Removal of UV-absorbing peaks was best achieved by washing the cotton swabs with excess 
volumes of water, ethanol, then diethyl ether followed by air-drying. This removed all but one of 
the UV-absorbing compounds (Fig. 2.2 C); this method was subsequently used for all neonatal and 
animal saliva collections. The remaining UV-absorbing compound was not one of the original peaks 
from the unwashed swabs but may have arisen from the diethyl-ether treatment, but it did not co-
elute with any of the peaks of interest. 
 
The mean±SD volume of neonatal saliva collected on cotton swabs was (135± 79 µL); these small 
volumes were sufﬁcient since only 10 µL of ultrafiltered sample was needed for HPLC-MS/MS 
analysis. Any remaining sample was used for further studies (see Chapter 3 for more details). 
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Figure  2.2 Chromatograms show UV-absorbing peaks at 268 nm present in 100 µL distilled water 
extracted from: (a) a commercial cotton tip, (b) a Sorbette sponge, and (c) a commercial cotton tip 
following washing with water, ethanol and diethyl ether. The water was then extracted from the tips 
by centrifugation and run on HPLC-PDA. A wavelength of 268 nm was used for monitoring as this 
is an average value for purine and pyrimidine peak absorption. 
 
 
 
 
 
 
 
 
 
A 
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2.5.1.2 Validation of recovery of extraction 
Experiments to determine the recovery of nucleotide metabolites from cotton swabs were conducted 
using 5 replicates for each analysis of the aqueous standard mixture of purine and pyrimidine 
metabolites. Extraction of the analytes from cotton tips using water only (Method #1) showed 
marked variability in the recoveries at low volumes (25 µL) of the standard mix (Table 2.2). For 
example, hypoxanthine, xanthine, adenosine, and guanosine recoveries were 66.3% ± 7.8 (mean ± 
SD), 56.9% ± 8.5%, 71.2% ± 10.3, and 75.0% ± 6.9 respectively. This was improved by increasing 
the standard mix volume to at least 100 µL (a volume greater than some neonatal saliva samples) 
(Fig. 2.3). Nonetheless, low overall recoveries persisted for some compounds; e.g. recoveries of 
hypoxanthine (77.8% ± 8.2), xanthine (68.6% ± 8.8) and adenosine (81.0% ± 7.3) were low 
compared to those for uracil (90.6% ± 7.0), inosine (97.3% ± 9.7), guanosine (92.0%±12.0), and 
uridine (109.2% ± 6.6). This may be explained by the use of water only for the extraction 
procedure, as xanthine and hypoxanthine are relatively non-polar compared to the other bases and 
nucleosides and hence are more likely to be adsorbed onto cotton fibres. 
 
In comparison, the recoveries using the water/acetonitrile extraction (Method #2, section 2.4.2.2) 
for all purine and pyrimidine metabolites were consistently high (Table 2.3), even for low standard 
mix volumes, with uracil, adenosine, inosine, and guanosine having the highest overall mean 
recoveries which exceeded 95%. Acceptable mean recoveries (>90%) also were obtained for 
hypoxanthine, xanthine, and uridine. Method #2 thus showed consistently satisfactory recoveries of 
the analytes from cotton swabs, even with low volumes of the standard mixture (Fig. 2.4). This was 
important because neonatal saliva was frequently recovered in small sample volumes. 
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Table ‎2.2 Percent recovery of nucleosides and bases from cotton swabs using centrifugation 
(Method #1). The concentration of the analyte standards are shown in parentheses. The results are 
shown as the mean±SD (n=5) 
 
Volume (µL) 
Uracil 
(59 µM) 
Hypoxanthine 
(55 µM) 
Xanthine 
(75 µM) 
Adenosine 
(47 µM) 
Inosine 
(47 µM) 
Guanosine 
(41 µM) 
Uridine 
(66 µM) 
25 83.6±15.1 66.3±7.8 56.9±8.5 71.2±10 85.2±10 75.0±6.9 100±4.9 
50 89.2±16 80.4±7.1 67.4±7.1 81.9±5.6 95.2±5.5 92.6±7.8 109±7.6 
75 89.4±6.0 78.8±2.2 73.2±5.4 82.1±5.5 100±3.4 98.1±5.1 112±2.9 
100 100±3.9 85.5±5.4 77.0±3.8 88.9±4.6 108±4.5 102±2.7 115±4.1 
Mean±SD 90.6±7.0 77.8±8.2 68.6±8.8 81.0±7.3 97.3±9.7 92.0±12 109±6.6 
 
 
 
 
 
Table ‎2.3 Percent recovery of nucleosides and bases from cotton swabs using the solvent and 
evaporation (Method #2). The concentration of the analyte standards are shown in parentheses. The 
results are shown as the mean±SD (n=5) 
Volume (µL) 
Uracil 
(59 µM) 
Hypoxanthine 
(55 µM) 
Xanthine 
(75 µM) 
Adenosine 
(47 µM) 
Inosine 
(47 µM) 
Guanosine 
(41 µM) 
Uridine 
(66 µM) 
25 101±5.5 90.9±5.0 92.7±3.7 103±6.5 109±4.7 99.3±3.9 90.4±2.4 
50 98.6±3.0 88.0±3.9 88.9±4.8 101±4.3 113±2.7 99.3±3.7 91.4±1.9 
75 108±3.5 98.4±4.0 97.6±3.4 112±6.3 111±5.5 106±4.8 95.9±1.2 
100 108±2.4 93.9±2.8 91.7±3.3 112±2.4 109±3.8 107±4.3 98.2±3.8 
Mean±SD 104±4.2 92.8±3.8 92.7±3.2 106.9±4.8 111±1.5 103±3.7 94.0±3.2 
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Figure  2.3 The “best-fit” curve for the percent recovery of major nucleotide metabolites using 
extraction with water followed by centrifugation (Method #1). The graphs show the gradual 
increase of recovery with increasing volumes of standard mix loaded onto the cotton tips. The error 
bars represent mean±SD (n=5). 
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Figure ‎2.4 Percent recovery of major nucleotide metabolites using extraction with solvent and 
evaporation followed by centrifugation (Method #2). The graph shows consistent recovery with all 
volumes of standard mix loaded onto the cotton tips. The error bars represent mean±SD (n=5).
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2.5.1.3 Validation of linearity of extraction 
Calibration plots for the standard bases and nucleosides recovered from cotton swabs by the solvent 
and evaporation method demonstrated excellent linear relationships between area ratio and 
concentration (Fig. 2.5) for each compound. Results obtained from the linear regression data 
analysis are shown in Table 2.4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
Figure ‎2.5 The results of linear regression analysis of the calibration data in the measurement of 
nucleosides and bases extracted from cotton swabs using the solvent and evaporation method 
(Method #2). The error bars represent mean±SD (n=5). 
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Table ‎2.4 The results of linear regression analysis of the calibration data (Fig. 2.5) in the 
measurement of nucleosides and bases extracted from cotton swabs using the solvent and 
evaporation method (Method #2). The experiment was conducted in 5 replicates. 
Compound Regression equation x-Intercept2 r
2 
Uracil y1=0.001x+0.001 -0.876 0.998 
Hypoxanthine y=0.018x+0.006 -0.351 0.999 
Xanthine y=0.002x+0.004 -1.812 0.998 
Adenosine y=0.016x+0.015 -0.956 0.999 
Inosine y=0.016x+0.005 -0.283 0.999 
Guanosine y=0.011x-0.020 2.052 0.998 
Uridine y=0.009x+0.004 -0.466 0.998 
1
y: Peak area ratio 
2
x: standard concentrations 
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2.5.2 HPLC-MS/MS DETERMINATION OF NUCLEOTIDE METABOLITES  
Aim 2: To develop and validate an analytical method for the determination of purine and 
pyrimidine metabolites in small volumes of saliva using high performance liquid chromatography 
(HPLC) with tandem mass spectrometry (LC-MS/MS) 
2.5.2.1 Within run imprecision 
Adult saliva was spiked with a “high-level” and a “low-level” purine and pyrimidine mix, then 
analysed for precision determination. Within-run precision data were calculated from saliva QC 
samples on a single occasion (8 replicates at each QC level). The data are shown in Table 2.5. 
Precision was expressed as coefficients of variation (CV %), which was less than 10 %. 
 
Table ‎2.5 Within-run precision data. Eight replicates of 2 levels (low and high) of spiked saliva 
with bases and nucleosides were measured for each compound within one run. The high 
concentrations were first prepared in saliva, then diluted 2.25 fold before the injection. 
 
2.5.2.2 Limit of detection and condition parameters  
The detection limits for each metabolite measured in this study and its corresponding internal 
standard are presented in Table 2.6. The limit of detection was based on a 10 µL injection and 
showed good sensitivity with a limit of detection (LOD) and limit of quantitation (LOQ) ranging 
from 0.01 to 1.5 µM and 0.02 to 5 µM, respectively. An example of a chromatogram of a saliva 
sample is shown in Figure 2.6. The HPLC-MS/MS conditions and parameters for optimal 
separation of nucleosides and bases in saliva are shown in Table 2.7. 
Compound 
Low Level (µM) High Level (µM) 
Mean SD %CV Mean SD %CV 
Uracil 31.2 2.2 6.9 131 12 8.9 
Hypoxanthine 24.3 0.6 2.6 135 6.0 4.5 
Xanthine 30.6 2.0 6.4 128 7.2 5.6 
Adenosine 8.40 0.4 4.4 68.8 4.8 7.0 
Inosine 12.9 0.8 6.1 88.1 4.0 4.5 
Guanosine 5.40 0.3 5.8 55.9 2.2 3.9 
Uridine 13.0 0.8 5.9 113 3.8 3.4 
57 
 
 
 
Table ‎2.6 Limit of Quantitation (LOQ) and Limit of Detection (LOD) 
 
Compound LOQ (µM) LOD (µM) 
Creatinine 5.0 1.5 
Pseudouridine 0.20 0.06 
Uracil 1.50 0.50 
Hypoxanthine 0.20 0.07 
Xanthine 0.70 0.24 
Adenine 0.10 0.04 
Adenosine 0.03 0.01 
Inosine 0.06 0.02 
Guanosine  0.03 0.01 
Dihydrothymine 1.5 0.50 
Dihydrouracil 3.00 1.0 
Uridine 0.02 0.01 
Thymine 1.5 0.50 
Orotic acid 0.50 0.15 
Uric acid 0.30 0.10 
Deoxyadenosine 0.02 0.01 
Deoxyuridine 0.50 0.15 
Deoxyinosine 0.40 0.10 
Deoxyguanosine 0.05 0.01 
Thymidine 0.32 0.10 
58 
 
 
 
Figure ‎2.6 An example of LC-MS/MS chromatograms for purine and pyrimidine metabolites and 
creatinine in neonatal saliva. The abundant peak eluting behind the inosine may result from the 
cross-talk from the more abundant adenosine as they have similar MS transitions. The mass 
spectrometry data of the identified bases and nucleosides are shown in Table 2.7. Shading indicates 
peak areas. 
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Table ‎2.7 HPLC-MS/MS conditions and parameters for optimal separation of nucleosides and bases in saliva. Q1: molecular ion; Q3: daughter ion; 
Da, Dalton; DP: declustering potential (volts); CE: collision energy (volts). 
 
Nucleosides/Bases Retention time 
(min) 
Mode Molecular 
weight 
Transition(Da) 
Q1/Q3 
Time (ms) DP (V) CE (V) 
Creatinine 
 
2.64 Positive 113.12 114.1/44.1 30 60 33 
Pseudouridine 4.53 Positive 244.20 245.0/209.2 30 46 15 
Uracil 4.70 Positive 112.10 113.1/70.1 30 50 25 
Hypoxanthine 7.36 Positive 136.11 137.0/119.0 30 86 29 
Xanthine 8.37 Positive 152.11 153.1/110.1 30 70 30 
Adenine 6.59 Positive 135.13 136.1/119.1 30 71 33 
Adenosine 12.7 Positive 267.20 268.1/136.1 30 50 15 
Inosine 11.3 Positive 268.23 269.1/137.1 30 36 23 
Guanosine 11.7 Positive 283.24 284.1/152.1 30 41 23 
Dihydrothymine 8.92 Positive 128.13 129.1/112.1 30 66 13 
Dihydrouracil 4.00 Positive 114.10 115.1/73.1 30 60 17 
Succinyladenosine 14.3 Positive 383.31 384.1/252.1 30 66 29 
Uridine 8.05 Positive 244.20 247.1/115.1 30 36 15 
Thymine 9.70 Negative 126.11 125/42 30 -55 -26 
Orotic acid 3.42 Negative 156.10 154.9/111.1 30 -40 -14 
Uric acid 6.59 Negative 168.11 167.1/124.1 30 -70 -27 
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2.5.3 SURVEY OF ADULT SALIVARY NUCLEOTIDE METABOLITES 
Aim 3: To conduct a survey of concentration ranges of nucleotide metabolites in adult saliva 
The distributions of these metabolites in both adult and neonatal salivary samples are shown in 
Figure 2.7, while the significant differences between both groups are shown in Table 2.8 (see 
Appendix 16 for full data set). The HPLC-MS/MS method also identified creatinine in saliva, albeit 
at very low concentrations compared to plasma levels.  
 
In adult saliva, the concentrations of nucleosides and bases were less than the LOQ, except for 
hypoxanthine (median=2.1 µM) and xanthine (median=1.7 µM). Uric acid was lower than typical 
adult plasma values (median=173 µM), but much higher than for the other metabolites. Adult saliva 
also contained low concentrations of creatinine (median=6.6 µM), which is far below normal 
plasma ranges for males (60-110 µM), and females (45-90 µM). Interestingly, uracil, hypoxanthine, 
xanthine and inosine concentrations exceeded 10 µM in a few adults; these values are the outliers 
presented in Figure 2.7.  
 
 
2.5.4 SURVEY OF NEONATAL SALIVARY NUCLEOTIDE METABOLITES 
Aim 4: To conduct a survey of concentration ranges of metabolites in neonatal saliva 
The chromatograms in Figure 2.6 correspond to the major purine and pyrimidine nucleosides and 
bases identified in neonatal saliva using this HPLC-MS/MS method. The median concentrations of 
most purine and pyrimidine metabolites in neonatal saliva were much higher than for adults (Fig. 
2.7). Some neonates showed low concentrations but in contrast to adults they were never below the 
LOQ except for thymine and orotate (Table 2.8) (see Appendix 17 for full data set). Adenine 
(p=0.15) and uric acid (p=0.07) were respectively similar in each of the two groups. Median 
thymine concentrations in adult and neonatal saliva were both below the LOQ, which was 
supported by commensurate low levels of its metabolite, dihydrothymine. 
Creatinine concentrations in neonatal saliva (median=22 µM) were low compared to the typical 
ranges in plasma, but significantly higher than in adult saliva (median=6.6 µM, p=0.001), which 
could be a result of high plasma creatinine in newborns especially in the first 5 days of life [152] 
and where the smaller the birth weight, the higher the plasma creatinine level [153]. In contrast, uric 
acid concentrations in adults saliva were high, but not significantly different to those in neonatal 
saliva (p=0.9). The level of the deoxy- forms of nucleosides, orotidine, succinyladenosine, AICAR 
were negligible (<1 µM) in both neonatal and adult saliva (not shown). 
61 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure ‎2.7 Distribution and median values of nucleotide metabolites in adults and neonatal whole 
saliva. (A) adults, n= 77 and (B) full-term neonates, n=60. Straight lines show median values (µM). 
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Table ‎2.8 Salivary levels (median with range, µM) of nucleotide metabolites in neonates compared 
to adults 
Nucleotide metabolites 
Neonates  adults 
 p value (n=60) (n=77) 
Median Range Median Range 
Creatinine 22 *<5.0-58 6.6 <5-12 <0.0001 
Pseudouridine 2.1 0.5-11 0.3 <0.2-1.0 <0.0001 
Uracil 7.3 <1.5-95 <1.5 <1.5-21 n.a 
Hypoxanthine 27 4.1-113 2.1 0.2-22 <0.0001 
Xanthine 19 1.2-92 1.7 0.8-33 <0.0001 
Adenine 1.3 <0.1-14 0.7 <0.1-3.7 0.15(n.s.) 
Adenosine 12 0.6-76 0.1 <0.03-1.2 <0.0001 
Inosine 11 0.8-99 0.2 <0.06-51 <0.0001 
Guanosine 6.8 0.9-35 0.1 <0.03-0.7 <0.0001 
Dihydrothymine 2.0 <1.5-3.9 <1.5 <1.5-1.8 n.a 
Dihydrouracil 5.2 <3.0-25 <3.0 <3.0-3.4 n.a 
Uridine 12 2.9-54 0.4 <0.02-8.4 <0.0001 
Thymine <1.5 <1.5 <1.5 <1.5-4.4 <0.0001 
Orotic acid <0.5 <0.5-26 <1.5 <1.5 n.a 
Uric acid 133 26-509 173 39-611 0.07(n.s.) 
*
<: less than LOQ  
n.s.: not significant 
n.a: not applicable 
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2.5.5 INFANT LONGITUDINAL STUDY 
Aim 5: To conduct a 12-month longitudinal study of the nucleobases and nucleosides metabolome 
of saliva of newborn babies through to weaning and early infancy 
 
In this longitudinal study, saliva samples were collected from infants aged 1-4 days, 6 weeks, 6 
months and 12 months. Figure 2.8 shows the pattern of salivary concentrations of purine and 
pyrimidine metabolites decreasing from birth until they attained adult values by 12 months of age. 
The median and range concentrations of each metabolite are shown in Table 2.9. In particular, the 
purine metabolites hypoxanthine, xanthine, inosine and guanosine gradually decreased from 6 
weeks to adult levels at 6-12 months of age. In contrast, the pyrimidine metabolites uracil and 
uridine decreased sharply to adult levels by 6 weeks of age. The primary pyrimidine precursor 
orotic acid was unusual because while the median concentrations were less than 1 µM for all time 
periods (p=0.2), some neonatal saliva samples greatly exceeded 10 µM and which remained stable 
for all 4 time points examined. Uric acid levels were also exceptional, with median values of 133 
µM at birth, decreasing to 81.55 µM at 6 weeks of age, then gradually increasing to 199 µM at 6 
months and 379 µM at 12 months. The major nucleotide metabolites of 10 individual neonates out 
of 14 who participated in every time point of the longitudinal study are shown in Figure 2.9. 
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Figure ‎2.8 Median concentrations of nucleotide metabolites in whole saliva of full-term infants 1-4 
days (n=60), 6 weeks (n=20), 6 months (n=19), 12 months (n=14).  
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Figure  2.9 Median concentrations of the major nucleotide metabolites in whole saliva of 10 
followed up full-term infants at 1-4 days, 6 weeks, 6 months, 12 months. 
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Table ‎2.9 Salivary levels (median with range, µM) of nucleotide metabolites in a longitudinal study of infants’ saliva  
Nucleotide 
metabolites 
1-4 days  6 weeks 6 months 12 months 
p values (n=60) (n=20) (n=19) (n=14) 
Median Range Median Range Median Range Median Range 
Pseudouridine 2.1 0.5-11 0.9 0.3-1.1 0.3 *<0.2-6.0 <0.2 <0.2 <0.0001 
Uracil 5.3 <1.5-95 <1.5 <1.5 1.6 <1.5-2.7 <1.5 <1.5-5.0 <0.0001 
Hypoxanthine 27 4.1-113 6.9 0.3-31 1.1 0.4-2 0.8 <0.2-12 <0.001 
Xanthine 19 1.2-92 7.0 0.7-25 1.7 <0.7-4.8 1.7 <0.7-12 <0.001 
Adenine 0.9 <0.1-14 0.8 0.1-7.3 0.2 <0.1-0.8 0.7 0.3-3.9 0.001 
Adenosine 12 0.6-76 7.0 1.2-29 0.9 <0.03-2.2 0.8 0.03-1.2 <0.0001 
Inosine 11 0.8-99 4.9 0.3-41 0.3 0.1-1.3 0.4 0.1-1.5 <0.0001 
Guanosine 6.8 0.9-35 5.6 0.2-21 0.5 0.1-1.5 0.4 0.1-1.0 <0.0001 
Dihydrothymine 1.6 <1.5-3.9 <1.5 <1.5 <1.5 <1.5 <1.5 <1.5 n.a 
Dihydrouracil 5.2 <3.0-25 <3.0 <3.0-10 <3.0 <3.0-4.5 <3.0 <3.0-5.6 n.a 
Uridine 12 2.9-54 0.8 0.1-3.3 0.3 0.1-0.9 0.9 0.5-7.5 <0.0001 
Thymine <1.5 <1.5 <1.5 <1.5 <1.5 <1.5-11 <1.5 <1.5-2.0 <0.0001 
Orotic acid <0.5 <0.5-26 <0.5 <0.5-48 <0.5 <0.5-14 <0.5 <0.5-12 n.a 
Uric acid 133 26-509 81.55 18-232 199 81-352 379 185-978 <0.0001 
                                       *
<
:
 less than LOQ;                         
                          n.s.: not significant,  
                          n.a: not applicable
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2.5.6 ANIMAL SALIVARY NUCLEOTIDE METABOLITES 
Aim 6: To conduct a survey of saliva from other mammalian species to investigate and compare the 
salivary nucleotide metabolite patterns between mammals and humans  
 
Nucleotide metabolite patterns in mammalian saliva samples are summarised in Figure 2.10 and the 
descriptive statistics of the data are shown in Table 2.10 (see Appendices 18-24 for full data set). 
Substantial variability was observed among species. Similar to humans, salivary deoxy-nucleosides 
were generally negligible in most species, but horse saliva contained high levels of deoxyuridine, 
deoxyinosine, (deoxy) thymidine and deoxyguanosine. The pyrimidine base uracil was elevated in 
the non-human mammalian saliva (similar to neonate humans) compared to adult humans, with 
horse saliva showing the highest level (median=81 µM) followed by goats (45 µM), cats (33 µM), 
and then the camel (24 µM). A similar species distribution was found for the pyrimidine nucleoside 
uridine, and for the purine bases xanthine and hypoxanthine.  
Overall, the lowest levels of nucleosides and bases were detected in bovine and ovine saliva, with 
the ovine results proving to be markedly different from the goat results, even though these animals 
are considered to be evolutionarily close. Curiously, canine saliva differed from all other animals 
with respect to adenine metabolites; it had high concentrations of adenosine (median=19 µM) and 
adenine (5.7 µM), which were very low in the other species. As expected, uric acid median 
concentrations were generally low (30-60 µM) compared to humans, because non-human mammals 
have uricase which metabolises uric acid to allantoin, however, in the horses the median 
concentration was 193 µM.  
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Figure ‎2.10 Mammalian salivary nucleotide metabolite concentrations. Metabolites were divided 
into functional groups; Group 1: Pyrimidines (Pseudouridine to Orotate); Group 2: Purine bases 
(Hypoxanthine/Xanthine); Group 3: Purine nucleosides (Inosine/Guanosine), Group 4: ATP 
metabolites (Adenine/Adenosine); Group 5: DNA metabolites (Deoxyadenosine to Deoxyuridine). 
The values are shown as median concentrations, µM. 
 
 
 Group1 Group2 Group3 Group4 Group5 
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Table ‎2.10 Salivary levels (median with range, µM) of nucleotide metabolites in a selection of mammals 
Nucleotide 
metabolites 
Cow Sheep Goat Horse Camel Dog Cat 
(n=8) (n=5) (n=4) (n=5) (n=1) (n=7) (n=5) 
Median Range Median Range Median Range Median Range Median Median Range Median Range 
Pseudouridine 0.2 *<0.2-0.5 0.2 0.2-0.4 1.6 1.5-1.7 2.3 1.2-5.0 1.3 0.4 <0.2-1.1 1.2 0.4-2.2 
Uracil 3.8 1.6-5.8 8.3 3.4-9.7 45 30-61 81 28-130 24 12 <1.5-37 33 25-190 
Hypoxanthine 0.2 <0.2-0.4 1.1 0.7-1.3 22 13-32 6.9 0.6-19 15 0.2 <0.2-0.5 12 0.5-68 
Xanthine <0.7 <0.7 1.7 0.9-7.8 27 14-31 34 2.4-51 9.3 1.3 <0.7-4.2 11 2.1-115 
Adenine 0.1 <0.1-0.6 1.2 0.1-1.6 3.3 1.1-4.2 0.2 0.1-2.5 2.5 5.7 0.1-19.3 1.8 0.2-38 
Adenosine 0.2 <0.03-1.2 8 2.1-11 2.7 1.4-4.0 0.1 0.1-0.2 1.4 19 0.8-36 2 0.7-10 
Deoxyadenosine 0.1 <0.02-0.3 0.2 0.1-2 0.2 0.1-0.6 0.04 0.02-0.1 0.5 3.6 0.04-18 2.5 0.4-2.7 
Deoxyuridine <0.5 <0.5 <0.5 <0.5 <0.5 <0.5 13 6.2-25 4.8 1.1 <0.5-3.7 4.5 1.6-25 
Inosine 0.7 <0.2-3 1.1 1.0-2.0 5.7 4.8-27 9.4 5.4-27 10 3.4 0.4-11 10 1.8-31 
Guanosine 0.3 0.03-3.9 2.8 1.9-6.5 5.2 2.7-30 10 6.2-40 10 3.3 0.5-6.0 12 2.6-33 
Deoxyinosine <0.4 <0.4-1.9 <0.4 <0.4 0.7 0.6-0.9 10 5.7-19 2.9 1.0 <0.4-4.8 5.2 2.1-27 
Deoxyguanosine 0.4 0.1-2.0 0.2 0.2-0.3 0.4 0.3-0.8 7.4 3.0-15 2.6 2.3 0.1-6.0 3.6 1.5-21 
Thymidine 0.6 <0.3-1.7 0.4 <0.3-0.6 2.4 1.8-5.1 18 7.6-25 5.5 2.6 <0.3-14 13 4.6-48 
Dihydrouracil <3.0 <3.0-6.5 6.3 <3.0-10 7.6 <3.0-16 <3.0 <3.0 <3.0 5.0 <3.0-6.3 <3.0 <3.0 
Uridine 0.4 0.1-3.9 2.2 1.5-3.7 10 5.6-48 30 20-94 18 3.9 0.4-9.3 13 3.3-40 
Orotate <0.5 <0.5 <0.5 <0.5 <0.5 <0.5-1.0 1.2 0.5-1.4 <0.5 <0.5 <0.5 1.3 <0.5-3 
Urate 35 26 -40 42 40-44 59 48-103 193 71-394 47 45 34-62 47 31-68 
Thymine <1.5 <1.5 <1.5 <1.5 4.1 2.2-10 26 12-48 9 2.1 <1.5-8.4 16 12-75 
*
<: less than LOQ 
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2.6 DISCUSSION 
This project was inspired initially from the use of reverse phase HPLC with UV-photodiode array 
(PDA), which has traditionally been used to screen purine and pyrimidine metabolites [146], to 
examine a small number of saliva samples as a pilot study. Subsequently, a pilot study of several 
infants ranging in age from newborn to 3 years led to the serendipitous finding that neonatal saliva 
had higher concentrations of nucleosides and bases compared to adults, and that the transition 
between infant and adult saliva patterns of purines and pyrimidines appeared to occur during the 
first year of life. This led to the formation of the first two Specific Hypotheses (Section 2.2). 
 
Amino acids, proteins, anions, vitamins, hormones and other small molecules have been intensively 
studied in saliva and found to include important biomarkers for several diseases [91, 93, 154-156]. 
But only one study of nucleotide metabolites in human saliva has been published [117]. For this 
part of the project, it was hypothesised that the presence of nucleotide metabolites in saliva may 
have an important role in oral biology, especially in neonates. Characterisation of these metabolites 
in saliva also may facilitate investigation of inborn errors of metabolism of purines and pyrimidines, 
as it was found that the salivary patterns were unique compared to plasma or urine. 
 
2.6.1 COLLECTION OF SALIVA SAMPLES 
Adult saliva collection by passive drool was found to be simple, non-invasive and easier to 
standardise than stimulated saliva. It was not, however, completely without ethical restrictions; 
some adults felt 'embarrassed' by having to salivate into a container and declined to participate. In 
some cases it may be simpler to use cotton buds for collection of adult saliva, to avoid this 
restriction. 
However, neonates and early infants often produce only small amounts of saliva compared to adults 
[157], and this presented a particular challenge to this project. In addition, there were ethical 
concerns about stimulating saliva in neonates and early infants. It was found that obtaining adequate 
volumes of saliva directly from neonates (e.g. using plastic pipettes) proved difficult when 
compared to non-invasive oral swabbing. Saliva collections from neonates and infants by cotton 
swabs previously have been used to investigate various biochemical markers and proteins such as 
cortisol [158], melatonin [159, 160] and immunoglobulins [161]. The oral swab collection method 
needed to overcome problems of; (1) contaminants in the cotton; (2) absorbance of the metabolites 
onto the cotton, which then acted like a reversed-phase medium and required a 2-step solvent 
elution to fully remove the various nucleosides and bases; (3) careful sample handling and weighing 
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of swabs before and after sampling, was essential to obtain accurate values for the volumes of saliva 
collected so that concentrations could be accurately calculated.  
 
2.6.2 HPLC-MS/MS DETERMINATION OF NUCLEOTIDE METABOLITES  
HPLC-PDA analysis was used to develop methods for the extraction of the nucleosides and bases 
from cotton swabs used to collect saliva from the young infants. However, LC-MS/MS was 
subsequently adopted as the preferred method for analysis of large numbers of saliva samples from 
screening adults and infants, and a selection of domestic animals. There were at least 4 reasons why 
MS/MS analysis was selected for saliva analyses; (1) Greater sensitivity, as the adult saliva in the 
pilot studies had metabolite values as low as 1 µM, similar to that reported by Kochanska et. al. 
[117] and this sensitivity was not achievable by UV/PDA; (2) Greater specificity, MS/MS provided 
better confirmation of the identity of metabolites than UV spectra; (3) Ability to measure 
metabolites with poor UV spectral absorbance, and this was especially true for the 
dihydropyrimidines; (4) The increased specificity and sensitivity inherent in MS/MS, which allows 
overlapping or co-eluting metabolite peaks to be distinguished by their mass characteristics, meant 
that a more efficient reverse phase HPLC method could be developed. This method required only an 
18 min run time compared to 35 min using UV/PDA (for which metabolite peaks must be fully 
resolved to be quantifiable).  
Nucleotides have not been analysed at this stage because of limitations on time and access to 
equipment during the thesis research, and this should be a focus of future work (see Future Studies, 
Chapter 5). 
 
2.6.3 ADULT SALIVA 
In human adult saliva, nucleotide metabolite concentrations were found to be low (median ≤2 µM) 
except for uric acid. This agreed with the results of a previous small survey of 23 adults [117] in 
which saliva was reported to contain hypoxanthine, xanthine and inosine at low levels, and with 
uric acid concentrations similar to those in plasma. The concentrations of the metabolites reported 
here were similar to those previously reported, but the metabolites examined here provided an in-
depth profile of purines and pyrimidines, and show a large range of values. Interestingly, 
hypoxanthine, xanthine, inosine and uracil were elevated in several adult participants, which 
suggested that there was either; (a) genetic polymorphisms in the population that regulate salivary 
nucleotide metabolites or; (b) that these specific metabolites may be markers for oral health, dental 
hygiene, diet, or commensal bacteria. The latter hypothesis, while simpler, was excluded by the 
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results found for infant saliva discussed below. These studies suggested that there may be genetic 
differences within populations with regard to salivary metabolites; this has not previously been 
examined. For the purposes of this project, all non-Caucasian participants were deliberately 
excluded in order to reduce genetic variability. Thus, there is scope for further studies of other 
ethnic/racial groups.  
In plasma, nucleotide metabolites are normally present at less than 1 µM concentrations, with the 
exception of uric acid and uridine [4, 142-145, 162]. Importantly, measurement of hypoxanthine in 
plasma is only reliable when blood cells are separated from plasma within a very short time, as this 
metabolite (and ammonia) increases rapidly after blood sample collection due to the breakdown of 
blood cell ATP [163]. Concentrations of some purine and pyrimidine bases (but not nucleosides) 
can be higher in normal urine [146]. Nucleotides usually exist only intracellularly, and are 
indicators of cellular damage when they appear in extracellular fluids. 
 
2.6.4 INFANT SALIVA 
Most of the salivary metabolite concentrations in neonates were high and not simply in equilibrium 
with plasma. These data suggest that specific transport mechanisms may operate in neonates. 
Nucleosides and bases from neonates have been measured in umbilical cord blood [163, 164], 
plasma [163], and urine [165]. These nucleotide metabolites are also in low concentrations in 
neonatal cerebrospinal fluid [162]. Raised hypoxanthine concentrations in newborn umbilical cord 
blood and plasma have been reported as a biomarker for birth hypoxia [166-168]. 
 
Urate was found in high concentrations in neonatal saliva. This purine metabolite accumulates in 
saliva of humans and higher apes due to the absence of uricase. In other mammals the role of urate 
is as a minor intermediate metabolite, and therefore mammals have not evolved specific urate 
transporters, and this absence continues in humans/higher apes. Urate is thought to undergo non-
specific transport in mammalian cells via anion transporters and the fructose transporter SLC2A9 
[169, 170], which have comparable activities in neonates and adults. The raised urate levels 
observed in the saliva of newborns presumably originate from raised maternal urate concentrations, 
which peak during birth. Saliva is produced by the tubuloacinar cells of the salivary glands, while 
uric acid in saliva appears to be a dialysate of plasma. It was observed that there is significant 
variability in uric acid concentrations in infant saliva from birth up to 12 months of age. The lowest 
concentration was detected at 6 weeks of age where breast milk is likely to be the main source of 
uric acid. In contrast, the uric acid concentration at birth was higher than at 6 weeks of age 
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suggesting that this was of maternal origin. The highest level of uric acid, which approached adult 
levels was detected at 12 months of age when most infants depend on breast and/or formula feeding 
as well as from introduction of solids [171]. 
 
The highly selective and species-dependent presence of such metabolites in high levels in early life 
suggested an essential role at this stage where the immunity of the newborn is still developing. This 
observation of a gradual decrease in nucleotide metabolites in young children may be explained by 
the growth and development of infants during this period.  
 
2.6.5 TRANSITIONING FROM INFANT TO ADULT: THE LONGITUDINAL STUDY 
The investigation of nucleotide metabolite levels in the saliva of young children at various ages is of 
value in understanding the pattern of changes during growth. Therefore, having observed the 
significant differences between neonatal and adult saliva with respect to the pattern of purines and 
pyrimidines, a longitudinal study was undertaken to cover the first year of life of individual infants. 
The results showed that the median salivary concentrations of some nucleotide metabolites 
decreased rapidly particularly for pyrimidines such as uracil and uridine, while others declined more 
gradually over the first year of life. There were significant differences between all metabolites, with 
the lowest levels detected at 12 months of age, except where levels of some metabolites remained 
low throughout the study (orotic acid and adenine). However, a few infants showed elevated 
concentrations of the pyrimidine base orotic acid; this may have been secondary to the feeding of 
infant milk formula of bovine origin which contains high levels of orotic acid [172], in contrast to 
human milk, which contains high levels of the pyrimidine nucleoside uridine but not orotic acid.  
Individual variation in salivary patterns was found in infants, as in adults. This was particularly 
noticeable in the longitudinal study. These highly variable levels of metabolites found in neonates 
cannot be attributed to oral health or microbiota as these subjects were only hours old and would be 
unlikely to have pathologies such as gum disease. All infants sampled for saliva were in good 
health, as exclusion factors for saliva collection included no history of infection and they were not 
receiving antibiotics. In addition, while they were all delivered vaginally they were sampled at least 
6 hours after birth when it was judged that trauma from birth should have subsided. In fact, these 
differences in patterns of metabolites between infants persisted well beyond the neonatal period and 
were present in some infants at 6 weeks.  
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2.6.6 SALIVARY PATTERNS IN OTHER MAMMALS 
The third Specific Hypothesis (Section 2.2) was that purine and pyrimidine metabolites would be 
found also in other mammals. This was not a particularly bold proposal, but what surprising was 
that in non-human mammalian saliva the concentration of nucleotide metabolites showed 
significant inter-species variability. Generally, the (adult) animals studied showed elevated levels of 
various nucleosides and bases compared to human adults, except for sheep and cows, which usually 
had the lowest amounts of salivary metabolites. Uracil was the most prevalent of the nucleotide 
salivary metabolites, with the highest levels occurring in horse saliva (median 80.5 µM). This 
nucleobase is not salvaged by mammalian cells, but can be utilised by bacteria to form pyrimidine 
nucleotides [36].  
There was considerable individual variability within animal species. Similar to humans, there may 
be genetic variability in salivary metabolites among other mammals, but for the examples of 
domesticated animals used here, more variation would be expected among outbred animals (dogs, 
cats) or between breeds (horses), but not for inbred strains (sheep, cattle, goats). For example, levels 
of nucleotide metabolites in goats were elevated compared to sheep and cows. Elevated levels of 
deoxynucleosides were detected in all horse saliva and in some individual cats, but these were 
negligible in human saliva and in the other animals. The sample sizes for the domestic/farm animals 
here were low, so variability was not fully tested. It is not possible to comment on the camel results, 
as only one animal was tested. However, these animal studies were intended as a pilot to encourage 
future research. 
The highest levels of adenosine and adenine were present in canine saliva. Adenosine and adenine 
are products of the breakdown of adenine nucleotides. Free adenine is unusual; this is usually 
recycled to ATP within cells via adenine phosphoribosyltransferase. Adenosine is not usually found 
in free form in body fluids, as it is efficiently salvaged back to ATP via adenosine kinase, however 
adenosine is thought to function as an extracellular 'alarm signal' [173]. Interestingly, adenosine in 
the brain is also proposed to act as a homeostatic regulator of sleep and to be a mediator between 
the humoral and neural mechanisms of sleep-wake regulation [174, 175].  
With the exception of sheep and cattle, the high levels of salivary nucleosides and bases in the 
sampled non-human mammals more closely resembled those of human babies than human adults, 
with consideration given to intra-species variability. Presumably this may provide further insights 
into preferred metabolic pathways in differing species. The difference between the major milk 
pyrimidine noted above (uridine in humans vs orotic acid in cattle) is suggestive of preferential 
metabolic pathways in animal species, and this aspect in saliva warrants further investigation. 
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2.6.7 CONCLUSIONS AND FURTHER HYPOTHESES 
The present study provided some important biological data for salivary nucleotide metabolite levels 
in healthy neonates and adults (see Chapters 3 and 4 for investigation of proposed roles of 
nucleotide metabolites in neonatal saliva). The presence of these purine and pyrimidine metabolites 
was both species dependent and developmentally regulated (in humans). The absence of de novo 
synthesis intermediates, such as SAICAR or AICAR (as ribotides), and of catabolic intermediates 
such as the dihydropyrimidines, is evidence for the functional importance of the nucleosides and 
bases that were found in saliva. 
Saliva is a bodily fluid that can be obtained non-invasively, and it appears that some classes of 
metabolites might be actively secreted into saliva, e.g. hypoxanthine and xanthine appear in saliva 
at much higher concentrations than in plasma. On the other hand, some metabolites occur in low 
concentrations in saliva despite having high levels in plasma (e.g. creatinine), therefore there may 
be advantages in using saliva in metabolic studies.  
 
The biochemical investigations of nucleosides and bases in human saliva, presented in this chapter, 
led to the formulation of 3 further hypotheses: 
1. Based on the substantially raised xanthine and hypoxanthine concentrations in neonatal saliva, it 
was considered that these two salivary metabolites, which are both substrates for xanthine oxidase, 
may react with this enzyme in milk during breast-feeding, to produce hydrogen peroxide (see 
Chapter 3). This peroxide is considered to be an important molecule in triggering other reaction 
cascades of immune reactive oxygen species which could be crucial for infant innate immunity, 
such as the lactoperoxidase system [76, 176].  
2. The other elevated bases and nucleosides in neonatal saliva may have a role as nucleotide 
metabolites enhancing the selection for oral commensal microbiome during early stages of life and, 
accordingly, enhance innate immunity, (see Chapter 4 for further details). 
3. Furthermore, these nucleotide metabolites could be also utilised by the gut apical cells for their 
growth. Uauy et al (1994) reported that rapidly growing tissues such as intestinal epithelium cells 
lack significant capacity for de novo synthesis of nucleotides and require exogenous sources of 
purine and pyrimidine bases. The study suggested these metabolites are utilised by intestinal cells 
for proliferation with excess purines being converted to uric acid [17]. Furthermore, nucleoside 
supplementation in weanling rats showed acceleration of intestinal maturation compared with a 
control group on a nucleoside-free diet [177]. This thought-provoking hypothesis was not pursued 
for this project, but could be an interesting future study. 
75 
 
 
 
 
 
 
 
 
 
Chapter 3 
Human milk xanthine oxidase  
and neonatal salivary nucleotide metabolites:  
Their role in generating hydrogen peroxide in the neonatal mouth 
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3.1 INTRODUCTION 
As discussed in Section 1.2.8, xanthine oxidoreductase (XOR) is a complex molybdeno-
flavoprotein which catalyses the oxidation of the purine bases hypoxanthine to xanthine to uric acid. 
The enzyme exists in two protein forms of the same gene product, referred to as xanthine oxidase 
(XO) and xanthine dehydrogenase (XDH): XO reduces oxygen and water to hydrogen peroxide 
(H2O2) and superoxide anion, while XDH reduces NAD
+
 to NADH [43, 50, 55].  
XO has been the focus of considerable research into ischemia reperfusion injury [62, 63], however 
there is increasing evidence that XO has important physiological functions associated with its 
synthesis of ROS and RNS where the enzyme is viewed as an evolutionarily conserved component 
of the innate immune system [59]. XO activity has been found in the milk of all mammals studied 
so far [48], being particularly high in bovine milk in comparison to human milk [67]. Its role is 
considered primarily to produce peroxide, which then acts as an antibacterial agent in both the milk 
glands (to prevent mastitis) and in the milk itself to inhibit microbial growth [79]. Furthermore, 
peroxide free radicals can combine with thiocyanate (SCN
-
), which is abundant in adult and infant 
saliva catalysed by the enzyme lactoperoxidase (LPO), which is also present in milk and saliva, to 
produce a more potent anti-bacterial free radical hypothiocyanite (OSCN
-
): this is known as the 
'lactoperoxidase system' [76-78] (Fig. 3.1). 
 
Figure ‎3.1 The lactoperoxidase system. In the first step, milk xanthine oxidase (XO) generates 
hydrogen peroxide (H2O2) which is used by lactoperoxidase (LPO) to convert thiocyanate into 
antibacterial hypothiocyanite. Note that hypoxanthine and xanthine as well as thiocyanate are 
abundant in neonatal saliva. 
 
The current studies have revealed appreciable concentrations of xanthine and hypoxanthine in 
human neonatal saliva (see Chapter 2). This observation raised the possibility that these metabolites 
could play an important role in generating H2O2 in the upper gastrointestinal tract of the neonate 
during suckling by re-activating breast milk XO production of H2O2, especially within the first few 
weeks postpartum when milk XO activity is high.  
This chapter is focused on a study aimed at validating an assay of milk XO and investigating its 
kinetics in fresh human breast milk, to confirm its ability to produce H2O2 when mixed with 
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neonatal saliva thereby emulating the reaction in the infant’s mouth. In addition, H2O2 
concentrations in fresh breast milk were measured to determine the physiological range of peroxide, 
as a prelude to studying its effects on bacterial species (Chapter 4). 
 
3.2 SPECIFIC HYPOTHESIS AND RATIONALE 
Hypothesis: Xanthine and hypoxanthine in neonatal saliva react with breast milk xanthine oxidase 
(XO) in an infant’s mouth to boost hydrogen peroxide to biologically active levels.  
Rationale: The mechanism of H2O2 production by XO in milk has been described previously for 
bovine milk, as a means of reducing mammary infections. But this has never been linked to saliva 
interactions during suckling. This hypothesis would provide an explanation of secretion of 
hypoxanthine and xanthine in the neonatal saliva, and XO in breast milk. The role of XO in milk 
can thus been seen to extend beyond the breast.  
Infancy is a stage of life characterised by immaturity of the ‘specific’ immune system (i.e. antibody-
immune cell regulated). Reactive oxygen species such as peroxide are a well-known biological 
defence mechanism to inhibit and kill microbial pathogens. A similar mechanism may occur for 
both the breast and infant mouth and digestive tract as part of the neonatal innate immune system.  
 
3.3 SPECIFIC AIMS 
1. To establish an assay for XO and determine the activity in breast milk collected during the 
first week after delivery (i.e. postpartum). 
2. To estimate the endogenous concentration of H2O2 in fresh breast milk 
3. To determine the H2O2 generation during the interaction between neonatal saliva and breast 
milk. 
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3.4 MATERIALS AND METHODS 
3.4.1 CLINICAL SAMPLES 
Prior written ethical approval for the collection of breast milk and saliva samples was obtained from 
the Human Research Ethics Committees of Mater Health Services, and The University of 
Queensland (see Appendices 1&2). The participating breastfeeding mothers' ages and gestational 
period, and the postpartum ages of the milk samples are shown in Table 3.1. Participants were 
selected only from those identifying themselves as Caucasian in order to minimise potential race-
related genomic variability.  
Breast milk samples were collected from 24 mothers, 1 to 5 days postpartum, by a research nurse 
using sterile gloves and hand expression into 50 mL sterile containers (Sarstedt Ply Ltd, Mawson 
Lakes, SA, Australia). Milk samples were placed on ice without delay and then transferred to the 
laboratory where they were subdivided into portions for the immediate assay of endogenous H2O2, 
or for storage at -80
o
C for further analyses such as XO assays. Pre-term and term Aptamil Gold 
Plus
®
 (Nutricia Australia Pty Ltd, Macquarie Park, NSW, Australia) infant formula and pasteurised 
breast milk were obtained for XO activity assays from the Division of Neonatology, Mater 
Mothers’ Hospital. Commercial pasteurised bovine milk was purchased fresh from a local retail 
outlet. Neonatal saliva samples were collected from 60 infants who were aged 1-4 days (see Chapter 
2 for details).  
Table ‎3.1 Information about breast milk samples and donor mothers 
 Gestational age (weeks) Postpartum age (hours) Mother's Age (years) 
Mean 39.5 52.8 28.9 
SD 1.5 28.0 6.0 
Range 37.3 - 42.3 15 -117 20 - 39 
 
3.4.2 REAGENT PREPARATIONS 
H2O2 (Merck Pty Ltd, Kilsyth, VIC, Australia), 30% v/v, 9 M, was used as a calibration standard by 
dilution to approximately 9 mM in 100 mM Tris-HCl pH 7.5 ('Tris buffer'). Concentrations of H2O2 
were accurately determined spectrophotometrically in triplicate at 240 nm, assuming a molar 
absorptivity of 43.6 M
-1 
cm
-1
.  
Peroxidase reagent containing 100 µM of Ampliflu Red (Sigma-Aldrich Pty, Castle Hill, NSW, 
Australia) and 0.8 U/mL horseradish peroxidase (Sigma-Aldrich Pty, Castle Hill, NSW, Australia) 
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was supplemented with hypoxanthine to give the following series of reaction concentrations in Tris 
buffer: 0, 8, 12.5, 25, 50,100, 200, 300, 400 μM. Buffers and aqueous reagents for all experiments 
were prepared from MilliQ water. 
3.4.3 XANTHINE OXIDASE ASSAYS 
XO activity was measured by monitoring the rate of H2O2 production during the oxidation of 
hypoxanthine to uric acid. Note that one mole of hypoxanthine produces 2 moles of H2O2, via the 
sequential reaction with xanthine. In the presence of horseradish peroxidase, H2O2 converts 
Ampliflu Red (10-acetyl-3,7-dihydroxyphenoxazine) into resorufin, which is a red fluorescent 
product having excitation and emission peak wavelengths of 544 nm and 590 nm respectively (Fig. 
3.2). The assay used raw breast milk, stored at -80
 o
C, without pre-treatment. Breast milk samples 
were diluted 1:30 (v/v) in Tris buffer, then 50 μL of diluted milk was mixed with 50 μL of 
peroxidase reagent in a 96-well microtiter plate (Becton Dickinson, North Ryde, NSW, Australia) to 
give a total reaction volume of 100 µL. The microtiter plate was incubated at 37
o
C for 60 min in a 
temperature-controlled FLUOstar Omega fluorimeter (BMG Labtech, Cary, NC, USA). The 
fluorescence of the formed product, resorufin, was measured fluorimetrically every 30 s for 5 min, 
then every 5 min up to 60 min at 544 nm (excitation) and 590 nm (emission). Each experiment was 
performed in duplicate. 
For each breast milk sample, a corresponding assay substrate blank (i.e. excluding hypoxanthine) 
was subtracted from each data point. The XO kinetic parameters were estimated for 6 breast milk 
samples using hypoxanthine concentrations of 0, 8, 12.5, 25, 50, 100, 200, 300, 400 µM as the final 
reaction concentration. XO activity of the remaining milk samples (n=18) were assayed directly 
using only 400 µM hypoxanthine working solution as the reaction concentration. XO activity was 
also assessed in the infant Aptamil Gold Plus
®
, pasteurised breast milk, and pasteurised bovine milk 
as described above. 
The H2O2 produced from the XO reaction was calculated from a standard curve generated by adding 
50 µL of H2O2 (0, 0.03, 0.06, 0.13, 0.25, 0.50, 1, 2, 3, 4, 5, 6, 7 µM) to microtiter wells each 
containing 50 µL of peroxidase reagent to give a reaction volume of 100 µL. The reaction mixture 
was incubated at 37
o
C for 60 min and the resorufin florescence was measured as described above.  
The rate of H2O2 production by XO was then estimated using the slope of the initial linear region of 
the enzyme reaction. The final activity of XO (U/L breast milk) was calculated from the following 
equation:  
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In this study the breast milk dilution factor was 60, and a unit (U) of XO activity was defined as the 
production of l µmol of H2O2 per min, using hypoxanthine as the substrate. The parameters of the 
Michaelis-Menten kinetic model, Vmax and Km, for breast milk XO were estimated using nonlinear 
regression analysis. The lower limit for detection of activity under these conditions of assay was 0.1 
U/L. 
To confirm that the H2O2 was produced by the activity of breast milk XO and not another enzyme 
reaction, breast milk pooled from 10 samples was supplemented with oxypurinol (Sigma-Aldrich 
Pty, Castle Hill, NSW, Australia), a XO-specific inhibitor, to give reaction concentrations of (0, 
0.38, 0.75, 1.5, 3, 6, 12, 25 µM) then incubated as above with peroxidase reagent containing 400 
μM of hypoxanthine. 
 
 
Figure ‎3.2 Principle of coupled enzymatic assays of XO using horseradish peroxidase-Ampliflu 
Red reagent. Oxidation of hypoxanthine or xanthine by XO results in generation of H2O2, which is 
coupled to conversion of the Ampliflu Red reagent to fluorescent resorufin by horseradish 
peroxidase (HRP).  
 
3.4.4 MEASUREMENT OF ENDOGENOUS HYDROGEN PEROXIDE IN HUMAN MILK 
Freshly expressed breast milk samples were diluted 1:5 (v/v) in Tris buffer, then in duplicate, 100 
μL of diluted milk was added to 1.5 mL polypropylene Eppendorf tubes containing 100 μL of 
peroxidase reagent (100 µM Ampliflu Red and 0.8 U/mL horse radish peroxidase in Tris buffer). 
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The reaction mixture was incubated in a water bath at 37
o
C for 60 min, then 150 μL of the mixture 
was microcentrifuged through an ultrafiltration membrane (Grace Davison Discovery Sciences, 
Rowville, VIC, Australia), 0.45 µm pore size, at 4500 g for 3 min, 4
o
C, to remove turbidity. The 
clear filtrate was transferred to a 96-well microtiter plate and the fluorescence was measured as 
described above for the XO assay. A negative control contained Tris buffer in place of the breast 
milk, and the fluorescence value from this control was subtracted from the assay reaction.  
To examine whether peroxide in breast milk is generated as a result of xanthine and hypoxanthine 
co-secretion, 10 breast milk samples were treated with 10% (w/v) trichloroacetic acid (TCA) 
immediately after the milk was expressed, to effect denaturation of XO and other proteins, then the 
samples were ultrafiltered and assayed immediately for xanthine and hypoxanthine (see Chapter 2 
for LC-MS/MS method).  
3.4.5 GENERATION OF HYDROGEN PEROXIDE BY MIXING HUMAN MILK WITH NEONATAL SALIVA 
As a proof-of-principle experiment, the amount of peroxide produced by a mixture of breast milk 
and neonatal saliva was measured. A pooled breast milk sample was diluted 1:6 in Tris buffer, 
while the pooled neonatal saliva (which was found to contain 70 µM hypoxanthine and 30 µM 
xanthine by LC-MS analysis) was diluted 1:5 in Tris buffer to produce 14 µM hypoxanthine and 6 
µM xanthine as the reaction concentrations. In duplicate microtiter plate wells, an aliquot of 33 µL 
of diluted breast milk was mixed with 33 µL of diluted saliva and 34 µL of peroxidase reagent to 
give a reaction volume of 100 µL, which was incubated at 37
o
C for 60 min, with the fluorescence 
measured every 30 s for 5 min, then every 5 min up to 60 min, protected from light since peroxide 
is light-sensitive. Calculation of the H2O2 formed included correction for the dilutions above. 
To assess the effect of endogenous breast milk lactoperoxidase and catalase enzymes on H2O2 
consumption, 600 µL of diluted pooled breast milk (1:15) was prepared in two 5 mL glass test 
tubes. Then 10 µL of sodium azide solution (Sigma-Aldrich Pty, Australia), an inhibitor of 
haemoprotein enzymes (i.e. catalase and lactoperoxidase), was added to one of the tubes to give a 
reaction concentration of 400 µM. An equal volume of H2O2 was added to both tubes to give 60 µM 
reaction concentrations. Another control was prepared by mixing equal volumes of Tris buffer with 
60 µM H2O2. The reaction was incubated in a water bath at 37
o
C for 30 min. In a 96-well microtiter 
plate, 50 µL aliquots of the above tubes were added to 50 µL of peroxidase reagent at timed 
intervals (2, 5, 10, 15, and 30 min) to quantitate the concentration of peroxide. The fluorescence 
was measured as described above, and the result from a negative control containing peroxidase 
reagent and diluted breast milk was subtracted from the assay results.  
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3.5 RESULTS 
3.5.1 BREAST MILK XANTHINE OXIDASE KINETICS 
Aim 1: To establish an assay for XO and determine the activity in breast milk collected during the 
first week after delivery (i.e. postpartum). 
The fluorescence standard curve generated by the reaction of Ampliflu Red with horseradish 
peroxidase and varying H2O2 concentrations displayed acceptable linearity (r
2 
= 0.999) up to 7 µM, 
as shown in Figure 3.3. This standard curve was subsequently used for both measuring endogenous 
peroxide levels in milk and for assaying XO activity. 
XO activity was assayed as the rate of formation of H2O2, by comparison with the peroxide standard 
curve. The enzyme rate was determined from the initial linear portion of the slope. H2O2 production 
versus incubation time was plotted for each substrate concentration (Fig. 3.4). Breast milk XO 
activity as a function of hypoxanthine concentration (8–400 µM) was analysed in 6 breast milk 
samples. The mean ± SD Km and Vmax values, estimated from the raw data shown in Figure 3.5, 
were 12.8 ± 2.1 µM and 8.9 ± 6.2 µmol/min respectively (Table 3.2). A hypoxanthine concentration 
of 400 µM was used for further studies.  
Having validated a reliable and accurate assay method, XO activity was then determined in 24 
samples of breast milk taken over period of 1-5 days postnatally. The activity of XO in the 24 breast 
milk samples ranged from 1.8 to 18.0 U/L with a mean activity of 8.0 U/L (Fig. 3.6). XO activity 
was undetectable (LOD < 0.1 U/L) in formula milk, pasteurised bovine milk, and pasteurised 
human breast milk.  
XO activity versus the gestational age (in hours) and postpartum time of each milk sample were 
plotted to assess the correlation using linear regression analysis (Fig. 3.7). There was no correlation 
between XO activity and gestational age (r
2
<0.001). In comparison, XO vs postpartum time 
revealed a weak correlation (r
2
=0.2). 
The addition of oxypurinol to breast milk showed an XO inhibitory, dose-dependent response with 
significant inhibition of H2O2 generation (p< 0.001). Maximum inhibition was obtained at 12 µM 
oxypurinol, with an apparent Ki 0.6 µM oxypurinol (Fig. 3.8). 
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Figure ‎3.3 Standard curve for H2O2 concentration versus fluorescence. The fluorescent red dye 
produced by conversion of Ampliflu Red to resorufin, in the presence horseradish peroxidase in a 
total volume of 100 µL including the assay reagents. Means and error bars (SD) were plotted. SDs 
were small and are masked by the symbols. 
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Figure ‎3.4 Kinetics of H2O2 production by XO during conversion of hypoxanthine to uric acid. 
Diluted breast milk was incubated with peroxidase reagent containing varying concentrations of 
hypoxanthine. Rates were linear for at least 20 min. Each assay was conducted in duplicate. This 
graph represents one of 6 experiments with different breast milk samples. 
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Figure ‎3.5 Hyperbolic nonlinear regression curve showing XO velocity as a function of increasing 
hypoxanthine concentration. Each assay was conducted in duplicate. This graph represents one of 6 
experiments with different breast milk samples. 
 
 
 
 
Table ‎3.2 XO kinetic parameters of breast milk samples (n=6), using hypoxanthine as substrate. 
           Sample Vmax (µmole/min) Km (µM) 
1 14.2 10.8 
2 2.40 15.9 
3 2.20 13.2 
4 15.0 12.7 
5 14.0 13.9 
6 5.50 10.1 
Mean±SD 8.9±6.2 12.8±2.1 
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Figure ‎3.6 Distribution of XO activity in breast milk. Samples were collected 1-5 day postpartum 
(n=24) and the milk was considered as colostrum. Error bars show mean±SD. The mean activity ± 
SD of XO was 8.0 ± 5.3 U/L. 
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Figure ‎3.7 Scatterplots of XO activity versus the gestational and postpartum age in hour. No 
significant correlations were observed, although there appeared to be a weak positive correlation for 
postpartum age (r
2
=0.2).  
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Figure ‎3.8 Dose dependent inhibition of breast milk XO by oxypurinol. The pooled breast milk 
sample were spiked with 0-25 µM oxypurinol concentrations in triplicate, then incubated with the 
peroxidase reagent. The graph shows an inhibitory dose-dependent response, with maximum 
inhibition obtained with 12 µM oxypurinol, confirming that H2O2 was produced by XO activity. 
Error bars show mean±SD. 
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3.5.2 ENDOGENOUS HYDROGEN PEROXIDE IN BREAST MILK 
Aim 2: To estimate the endogenous concentration of hydrogen peroxide in fresh breast milk 
The mean ± SD endogenous H2O2 concentration was 27.3±12.2 µM (range: 11 to 51 µM), as shown 
in the vertical scatterplot in Figure 3.9. Samples treated with 10% TCA contained undetectable 
hypoxanthine and xanthine concentrations (LOQ= <0.2 and <0.7 µM respectively) using LC-
MS/MS. The XO activities of 21 of the 24 milk samples were plotted against the endogenous H2O2 
concentration for each sample to assess any correlation, using a linear regression analysis method 
(Fig. 3.10). The data showed no correlation between the two parameters (r
2
< 0.001).  
3.5.3 HYDROGEN PEROXIDE GENERATION  
Aim 3: To determine hydrogen peroxide generation during the interaction between neonatal saliva 
and breast milk. 
The addition of neonatal saliva containing the substrates hypoxanthine and xanthine to breast milk 
generated an additional 40 µM of H2O2 after about 60 min of incubation, demonstrating that the 
reaction between XO in breast milk and the salivary XO substrates occurred in vitro and resulted in 
further peroxide generation, thus boosting the endogenous levels (Fig. 3.11).  
The addition of exogenous H2O2 to breast milk resulted in a gradual consumption of peroxide with 
time. This H2O2 consumption was presumed to be caused by endogenous breast milk 
lactoperoxidase and catalase enzymes. This decrease caused by the enzymes was inhibited by 
sodium azide. A negative control showed stable peroxide concentrations during the experiment 
(Fig. 3.12). 
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Figure ‎3.9 Distribution of concentrations of H2O2 in fresh breast milk samples (n=22). Error bars 
show the mean±SD (27.3±12.2 µM). 
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Figure ‎3.10 Scatterplot of XO activity versus endogenous H2O2 concentration in 21 of 24 breast 
milk samples. There was negligible correlation between breast milk H2O2 and XO (r
2 
<0.001).
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Figure ‎3.11 Kinetics of H2O2 generation after mixing 33 µL of diluted breast milk, 33 µL of 1/3 
diluted neonatal saliva and 34 µL peroxidase assay working solution (green circles). The negative 
control was buffer and peroxidase reagents (blue squares). The original concentrations of 
hypoxanthine and xanthine in the neonatal saliva were 70 µM and 30 µM respectively. Calculation 
of the H2O2 formed included correction for the dilution of saliva and milk. 
 
 
0 5 10 15 20 25 30
0
10
20
30
40
50
H2O2+Breast milk
H2O2+Breast milk+ NaN3
H2O2+Buffer
Time (min)
H
2
O
2
(
m
o
le
/L
)
 
Figure ‎3.12 Assessment of H2O2 consumption by breast milk. Peroxide showed a gradual decrease 
in concentration due to endogenous breast milk lactoperoxidase and catalase (blue open circles). 
Addition of sodium azide (400 µM) to the breast milk inhibited H2O2 consumption (purple open 
diamonds). The negative control (green triangles) was H2O2 added to Tris buffer, which showed a 
stable concentration throughout the experiment, (n=3). 
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3.6 DISCUSSION 
XO is widely distributed in nature [43, 44]. In humans XO tissue distribution is less widespread, 
with the highest activity occurring in small intestine and liver [45], but only low levels of XO RNA 
transcripts occur in human heart, brain, lung and kidney [46]. However, the high activity of XO in 
the milk of mammals, where it is associated with milk fat globule membrane (MFGM) [24, 47, 
178], suggests that it has a special biological significance in this fluid [67]. This suggestion has 
been supported by the discovery that lactating female mice with xanthine oxidoreductase gene 
knockout exhibited mammary epithelium collapse and MFGM synthesis abnormalities, supporting 
the important role of XO in MFGM envelopment and secretion [179]. 
 
3.6.1 XO ACTIVITY AND KINETIC PARAMETERS 
The combination of peroxidase with Ampliflu™ Red assay reagent offers a sensitive probe for 
measuring oxidative enzymes that generate H2O2, such as XO [180]. In this chapter, the fluorimetric 
assay of human milk XO activity was validated and its enzymatic kinetics were determined in fresh 
human breast milk using the peroxidase-based assay system using hypoxanthine as a substrate. 
Determination of XO activity in 24 fresh breast milk produced a range of 1.8 to 18 U/L using 
hypoxanthine as a substrate, which was slightly higher than published values of 0.16 to 9.2 U/L 
[181] using radio-isotopic xanthine, and 0.01 to 8.3 U/L [123] using radio-isotopic hypoxanthine. 
This 10-fold range may be attributed to at least 3 factors; (1) the postpartum time or gestational age 
of the milk samples, i.e. were some 'colostrum' samples and other samples from a much later 
postpartum age? (2) loss of activity due to poor sample handling; (3) genetic differences in XO 
activity among the mothers.  
With regard to point (1) above, the milk samples were collected from the mothers 1 to 5 days 
postpartum, with colostrum considered as the major first fraction of the breast milk. The analysis of 
human milk in a previous study reported that XO activity greatly increased in the first 10 to 15 days 
after birth, but then fell to basal levels soon after [123], so the samples examined here fell into the 
period of increasing activity (i.e. 1-5 days). There was only a mild correlation between postpartum 
age and XO activity (and no correlation for gestational age) observed for the milk presented here, 
and this was considered evidence for a lack of a strong contribution to XO activity arising from 
either postpartum or gestational age of the samples.  
With regard to point (2) above, as explained in the Methods the milk samples were immediately put 
on ice after being expressed, then delivered directly to the laboratory, subdivided into portions and 
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frozen at -80
o
C until assay. It is unlikely therefore that there was a large range of activity loss due to 
sample handling. It should be remembered that milk XO is localised within the milk fat globule 
membrane (MFGM), so that the substrates (hypoxanthine and xanthine) must diffuse into the 
MFGM (no transporters are described) then the product (H2O2) must diffuse out. However, most 
publications of milk XO kinetics have studied the enzyme outside its physiological environment. In 
the results presented here, XO was assayed in situ, i.e. within the MFGM.  
With regard to point (3), although complete XO deficiency is considered rare [182], in vivo studies 
of caffeine metabolism (which utilises liver XO) have indicated a wide range of activity in humans 
[183], although there are confounding factors such as cigarette smoking, drug therapies or liver 
disease [184]. Thus, the range of milk XO activities presently observed may arise from genetic 
variation, with some minor contribution due to postpartum age.  
Kinetic studies of the in situ XO (i.e. still embedded into the milk fat globule membrane “MFGM”) 
found that the Km was 12.8 ± 2.1 µM, which is slightly higher than a published value for the 
purified enzyme (Km=8 µM) [185] but lower than that for purified enzyme (Km=18 µM) [178] using 
xanthine as the substrate.  
The dose-dependent inhibition of H2O2 formation in breast milk treated with oxypurinol, was 
consistent with the action of oxypurinol as a specific inhibitor of XO [186], and confirmed that XO 
was responsible for the H2O2 production observed for the peroxidase assay. Within cells most 
xanthine oxidoreductase is in the form of xanthine dehydrogenase (XDH), however extracellular 
xanthine oxidoreductase is thought to exist solely as XO, e.g. in plasma XDH is transformed to XO 
by serum proteases, in other tissues the transformation is thought to be the result of oxidation of 
critical amino acids in the enzyme. Milk contains high amounts of proteases [187, 188], and it has 
been suggested that these may be responsible for XO as the dominant form in milk [189].  
 
3.6.2 XO ACTIVITY IN INFANT FORMULA AND PASTEURISED MILK 
XO activity was undetectable in preterm and term infant formulas, indicating that the preparation, 
processing and manufacturing of milk formula (from bovine milk) leads to complete loss of the 
enzyme activity. Modern 'powdered milk' used in formula milk is spray-dried, which involves 
spraying the milk into a high temperature air stream; this appears to inactivate the XO component, 
which means that formula-fed babies do not experience oral hydrogen peroxide generation nor the 
lactoperoxidase system. It is not clear whether this is beneficial to the baby or not. This was the 
subject for further hypothesis development and for study in this thesis.  
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Similarly, XO activity was not detected in pasteurised breast milk. Pasteurised human milk was 
developed specifically to provide mothers who were unable to breast feed with milk for their 
newborn babies, which was considered more 'natural' and possibly less allergenic than bovine milk. 
However, the status of XO activity in this product was previously unknown. The findings presented 
here are consistent with those reporting significant activity loss after breast milk thermal 
pasteurisation for essential enzymes/proteins such as lysozyme [190, 191], lactoperoxidase, 
secretory IgA and lactoferrin [190]. It has been suggested that pasteurisation may not be ideal for 
human milk, and this practice remains a controversial issue in neonatal intensive care units 
worldwide [192]. Several studies have shown that human milk thermal pasteurisation induced a 
significant loss of bactericidal capacity against E. coli [193], and both E. coli and S. aureus [192]. It 
was also confirmed here that fresh commercially pasteurised bovine milk lacked XO activity. The 
arguments for and against regulatory pasteurisation of bovine milk have been ongoing and 
vociferous, and are beyond the scope of this project.  
 
3.6.3 ENDOGENOUS BREAST MILK HYDROGEN PEROXIDE 
The endogenous H2O2 concentration in 22 of the 24 fresh breast milk samples was 27.3 ± 12.2 µM, 
which was highly consistent with published data in which the mean concentration of H2O2 in a first 
week sample was 25 µM [194]. The presence of peroxide in bovine milk has been proposed to be 
caused by the co-secretion of XO substrates xanthine and hypoxanthine into the mammary gland 
lumen during continuous milk production [79, 189]. In bovine milk, H2O2 has been calculated to be 
produced at a rate of 260-360 µmol/h from secreted hypoxanthine, or 130-180 µmol/h from 
secreted xanthine [79], but there are no reports of endogenous H2O2 concentrations in bovine milk 
(or milk other than human). Presumably the same mechanism operates in all mammals including 
humans. To test for the presence of xanthine and hypoxanthine in fresh breast milk, 10 freshly 
expressed breast milk samples were immediately acid-denatured and subjected to LC-MS/MS 
analysis. However, these contained no detectable xanthine or hypoxanthine. The absence of these 
substrates in fresh breast milk may be due to their short half-lives in the mammary glands because 
of the high activity of XO.  
The continuous generation of H2O2 within the mammary gland lumen has been proposed to have a 
bactericidal activity which may protect the breast against mastitis which is frequently caused by     
S. aureus [140, 195] (see Chapter 4). The concentration of peroxide in breast milk has been reported 
to peak in the first few weeks after birth, then declines to about 9 µM by the fourth week of infant 
life. This decline in peroxide concentration with postnatal age [194] is consistent with the report 
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that XO decreases in a similar pattern [123]. However, the data presented here do not support any 
association between endogenous breast milk H2O2 and XO activity. 
In addition to direct inhibition of bacterial growth, the H2O2 generated in breast milk is also thought 
to serve as an electron acceptor for the lactoperoxidase reaction; lactoperoxidase is abundantly 
expressed in human milk [196] and converts thiocyanate (SCN
-
), as a physiological substrate in the 
presence of peroxide to the powerful bactericidal radical hypothiocyanite (OSCN
-
). This complex 
system may provide mammary glands with continuous passive protection against invading bacteria. 
Thus, as well as its classical role in purine catabolism, XO can also be considered a component of 
innate immunity in mammals [59, 71].  
Interestingly, it has been found that H2O2 and other ROS and RNS play important roles as small-
molecule second messengers, similar to nitric oxide. Pan et al (2011) [197] suggested that H2O2 at 
low levels, in particular around 20 µM, stimulates cell viability and facilitates adhesion, migration, 
and wound healing in cornea cells or other tissues. Furthermore, in activated T cells the superoxide 
anion or low micromolar concentrations of H2O2 increased the production of the T-cell growth 
factor interleukin- 2, an immunologically important T-cell protein [198]. Other studies found that 
H2O2 has a role in inducing the expression of the haem oxygenase (HO-1) gene [199], and 
activation of the transcription factor nuclear factor kB (NF-B) [200]. In coordination with the role 
of H2O2 in cell signalling, nitric oxide (NO) has been found to have a regulatory role in the control 
of smooth muscle relaxation [201] and in the inhibition of platelet adhesion [202]. This suggests 
that milk H2O2 detected in this study may not only contribute to the innate immunity of neonates, 
but also may provide the appropriate concentrations for rapid cell signalling and growth. 
 
3.6.4 GENERATION OF HYDROGEN PEROXIDE IN NEONATAL MOUTH 
In this chapter, it was demonstrated that mixing neonatal saliva (which contains high levels of 
xanthine and hypoxanthine, as per Chapter 2), with breast milk led to stimulation of H2O2 
production. To maintain the reaction within the physiological pH range, both XO assays and 
peroxide stimulation by saliva were experimentally conducted at pH 7.5, which was within the 
normal pH range of breast milk (pH 6.4-7.6) and paediatric saliva (pH 6.4-8.24) [149]. It can be 
speculated that a similar mechanism occurs during breast feeding, especially as the median levels of 
xanthine (19 µM) and hypoxanthine (27 µM) in neonatal saliva are higher than the hypoxanthine Km 
(~13 µM) of breast milk XO.  
95 
 
The saliva sample used for the mixing experiment contained 70 µM hypoxanthine and 30 µM 
xanthine, which were then diluted and added to an equal volume of milk. Given that 1 mole 
hypoxanthine produces 2 moles of peroxide and 1 mole of xanthine produces 1 mole of peroxide in 
two-fold diluted saliva, the theoretical formation of H2O2 should be 70 µM peroxide from 
hypoxanthine and 15 µM peroxide from xanthine, yielding a total peroxide concentration of 85 µM. 
However, the estimated H2O2 production was only 40 µM. The reduced amount of free peroxide 
generated in vitro may be the result of competing consumption of the H2O2 by catalase and/or 
lactoperoxidase, both of which are expressed abundantly in breast milk [203, 204]. Evidence for 
this was provided in the present study by inhibiting milk peroxide breakdown with azide which 
targets haem enzymes such as catalase and peroxidase. 
The major enzymatic H2O2 consumption in normal human tracheal secretions is due to 
lactoperoxidase [205]. However, as fresh breast milk was found to contain concentrations of 
approximately 30 µM of peroxide, the additional amount generated by mixing with saliva was well 
within the levels reported to inhibit S. aureus growth (see Chapter 4). Even though some studies 
have suggested that H2O2 is sourced to the lactoperoxidase system by oral bacteria and/or by 
salivary leucocytes, the mechanism of the XO-peroxide regeneration in the neonatal oral cavity that 
we have identified could also serve as a rapid source of peroxide for the lactoperoxidase system 
similar to the mechanism discussed for the mammary gland, as the lactoperoxidase enzyme is also 
expressed in infant saliva [204, 206, 207].  
The persistence of peroxide in the mixed breast milk/ neonatal saliva mixtures for upwards of 1 
hour suggested that the system might also play a role in bacterial inhibition during its passage 
through the neonatal gut. It has been shown in bovine calves that the lactoperoxidase system is 
effective in preventing ‘scour’ (diarrhoea) [208, 209]. Importantly, the lack of breast milk feeding 
combined with the absence of saliva production due to tube feeding of early preterm babies may 
contribute to the high rate of necrotising enterocolitis (NEC) experienced by babies in neonatal 
intensive care units. In addition, the inhibition of this system by pasteurisation of human milk and 
in pre-term milk formula milks may be detrimental to the health of newborns by changing the 
selective processes that act on oral (and hence gut) microbiota. This theme was examined in 
Chapter 4. 
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Chapter 4 ‎ 
An innate immunity mechanism:  
Regulation of the neonatal microbiome by breast milk and saliva 
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4.1 INTRODUCTION 
4.1.1 THE ROLE AND REGULATION OF COMMENSAL BACTERIA 
An important outcome of studying the human microbiome, which has been greatly facilitated in 
recent years with the advent of molecular genetic techniques that allow identification of non- 
cultivable species, is an increased understanding of the complexity of the microbiota: this has 
provided new insights into human biology, as well as demonstrating the role of commensal (versus 
pathogenic) bacteria in human health [210].  
  
The largest microbial community of the human microbiome is located in the gastrointestinal tract 
(GIT), especially the large intestine [211, 212]. The commensal microbiota has a number of crucial 
roles: it forms part of the intestinal barrier, which protects the host from invasive pathogens [213]; it 
modulates host immune responses and promotes health [214, 215]; it metabolises nutrients within 
the host GIT, contributing to the digestive process and providing essential nutrients such as 
vitamins, amino acid chelates, and short-chain fatty acids [216, 217]. Microbial imbalance in the 
GIT has been linked to diseases in both human adults and neonates, including colon cancer [218, 
219], inflammatory bowel disease [220, 221], and necrotising enterocolitis (NEC) [222, 223]. A 
healthy mucosal microbiota is thus crucial to the survival of the human host and it has been 
suggested as a target for therapeutic intervention to prevent diseases including allergic diseases and 
inflammatory bowel disease [224-226].  
 
Compared to adults, the infant GIT microbiota is more variable in its composition and less stable 
over time. During the first two years of life, the infant GIT microbiota develops to become more 
densely colonised, with a population of GIT microorganisms that are generally similar to those 
found in the adults [227]. Although it is widely accepted that the GIT microbiota is established after 
birth (colonisation occurring from the mouth downwards into the GIT), there is evidence that 
bacterial DNA is present within the human placenta and meconium [228, 229], suggesting that 
some bacteria may colonise neonates before delivery. In the first few hours of life, the mother’s 
vaginal and faecal microbiota are usually the most important source of neonatal oral and GIT 
bacterial colonisers [230, 231], however, it has been shown that the mode of delivery can influence 
the numbers of bacteria and the types of bacteria present within the GIT microbiota [111].  
 
During a Caesarean delivery the mouth of the neonate is not exposed to the mother’s vaginal and 
intestinal microbiota, and this results in less diversity within the neonates’ GIT microbiota when 
compared to neonates that are delivered per vagina. Importantly, a low intestinal microbiota 
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biodiversity in early infancy appears to exacerbate the development of allergic disease later in life 
[232, 233]. For Caesarean-delivered neonates, GIT colonization by the genera Bifidobacterium and 
Bacteroidetes is also delayed [234, 235]. Bifidobacterium has been reported as the most 
predominant genus in the infant GIT [236]. However, interestingly, the numbers of Bifidobacterium 
within the GIT of neonates are higher in breast-fed infants compared to formula-fed neonates [237], 
in which the human milk itself appears to be the source of this commensal flora [109].  
 
4.1.2 EFFECTS OF FORMULA VERSUS BREAST FEEDING ON NEONATAL GUT MICROBIOTA 
While formula feeding has been shown to induce the most rapid weight gain in infants (which has 
been linked to subsequent obesity), it has also been demonstrated that breast milk feeding is clearly 
more healthy for both term and premature infants with regard to resistance to infections [238, 239]. 
Breast milk has a lower protein and calorie content than formula milk, but it is rich in 
immunological factors including maternal immunoglobulins, enzymes and growth factors. There is 
accumulating evidence that in neonates the immune defence mechanisms that normally maintain 
healthy and balanced GIT microbial communities may be inadequate, or at least not functioning at 
levels seen in adults [240]. During the early postnatal period the neonatal GIT is thus susceptible to 
abnormal bacterial colonisation [241]. It has also been shown that formula-fed babies show an 
increased incidence of NEC, the most common and lethal GIT emergency in preterm infants in 
neonatal intensive care units [242]. In contrast, preterm babies who are fed breast milk are 
significantly less likely to develop NEC than formula-fed preterm babies [243, 244]. This evidence 
supports the concept that early infants rely on 'innate' immune mechanisms to regulate their GIT 
microbiota until the development of the more mature cellular and antibody-based immune system 
present in adults [245, 246].  
 
4.1.3 OXIDATIVE MECHANISMS FOR ORAL MICROBIAL REGULATION IN NEONATES 
Xanthine oxidase (XO) has been proposed to trigger several antibacterial metabolic systems in the 
presence of its substrates (hypoxanthine / xanthine), producing microbiocidal reactive oxygen 
species (ROS): superoxide and hydrogen peroxide (H2O2). The latter subsequently acts as a 
substrate for the lactoperoxidase system, which in the presence of thiocyanate (CNS
-
) can generate 
the antibacterial reactive nitrogen species (RNS), hypothiocyanite (OSCN
-
) [189]. In addition to 
lactoperoxidase system activation, XO has been shown to catalyse the anaerobic reduction of 
inorganic nitrite (NO2
-
) to nitric oxide [72, 73]. Superoxide generated by XO in the presence of 
molecular oxygen also reacts rapidly with nitric oxide to yield the RNS, peroxynitrite (ONOO
-
), 
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which is also a powerful antibacterial agent [24, 73, 247, 248]. As discussed in Chapter 3, XO is 
highly active in human breast milk where it may function to provide an XO-induced “cascade” of 
oxidative molecular species which may regulate neonatal oral microbiota during breast-feeding. 
But does the XO system remain active within the neonatal stomach environment? Stevens et al. 
(2000) have shown that during breast-feeding, XO (and other milk proteins and fats) can survive 
passage through the infant stomach. Superoxide and H2O2 generation is markedly stimulated above 
pH 7 in the presence of oxygen, but the neonatal stomach is not highly acidic (pH 4-6), with an 
oxygen tension less than 5%, and these conditions are sufficient for XO to generate NO and 
consequently ONOO
-
 [71]. As a result, XO is considered to be a component of the innate immune 
system in mammals [59].  
 
4.1.4 OXIDATIVE MECHANISMS FOR MAMMARY GLANDS INNATE IMMUNITY  
Fresh milk contains a surprisingly high amount of H2O2. In bovine milk XO activity is about 10-
fold higher than in human milk and it has been predicted that the H2O2 is accordingly higher [79]. 
In Chapter 3 it was shown that the mean H2O2 in human milk was approximately 30 µM, although 
this may theoretically be boosted by another 80-100 µM by the XO metabolism of the hypoxanthine 
and xanthine present in neonatal saliva during breastfeeding. However, the effectiveness of the 
micromolar concentration range of H2O2 on bacterial growth has never been directly assessed. 
It has been proposed that ROS, particularly H2O2, are active in protecting mammals against 
mastitis, which is an inflammation of breast tissue caused by several species of microorganisms [79, 
189]. In particular, it has been suggested that H2O2 generated by XO in mammary ducts may 
provide a defence mechanism against Staphylococcus aureus [137, 139, 140, 195]. Mastitis can 
occur at any stage of lactation but the rate of occurrence is highest in the first few weeks 
postpartum, with an incidence of 2-33% [136, 139]. 
Allied to this concept, the XO-catalysed superoxide generating system has also been proposed to 
have an antibacterial role in mammary glands. These XO-induced cascades are enhanced when 
additional xanthine & hypoxanthine are added to breast milk. It was discovered in Chapter 2 that 
elevated concentrations of xanthine and hypoxanthine, as well as several important nucleotide 
metabolites, are present in neonatal saliva, compared to adult. Furthermore, in Chapter 3 it was 
demonstrated that by adding neonatal saliva to breast milk, XO was activated to generate ROS 
which may fuel a unique innate antibacterial mechanism in the neonatal mouth and then the GIT at 
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a time when other immune mechanisms are not fully developed. These observations led to the 
formulation of Specific Hypothesis 1, below. 
 
4.1.5 GROWTH STIMULATION MECHANISMS FOR MICROBIAL REGULATION 
A further hypothesis developed for this project, was that the high levels of nucleotide metabolites 
present in neonatal saliva may act as positive growth factors to selectively stimulate some species of 
commensal bacteria (Specific Hypothesis 2, below).  
Central to this concept of stimulating specific bacteria by providing growth factors, is the division 
of microorganisms into those that can synthesise their own biochemical compounds needed for 
growth ('prototrophs'), and those that are unable to synthesise a particular organic compound 
required for growth ('auxotrophs'), as defined by the International Union of Pure and Applied 
Chemistry (IUPAC, Zurich Switzerland).  
Prototrophic bacteria can thus synthesise de novo their own nucleotides (which are essential for 
energy and DNA synthesis – see Chapter 1). In contrast, bacteria that are auxotrophic with respect 
to nucleotide metabolites are poor at de novo synthesis of nucleotides but can effectively utilise 
external sources of purines and pyrimidines to enhance their growth, by using nucleotide salvage 
pathways to convert bases or nucleosides derived from their host to their corresponding nucleotides 
[18]. However, by salvaging nucleotide metabolites provided by the host, auxotrophic bacteria are 
able to synthesise nucleotides by less energy-demanding and more efficient biochemical pathways, 
and this presumably may give them a growth advantage over other bacteria that do not use salvage 
pathways for nucleotide synthesis. This may provide a positive selection mechanism for oral and 
perhaps GIT microbiota. 
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4.2 SPECIFIC HYPOTHESES AND RATIONALE 
Hypothesis 1: That the H2O2 generated in a neonatal mouth, when breast milk XO mixes with its 
salivary substrates xanthine and hypoxanthine, inhibits potentially pathogenic bacteria within the 
mouth and the GIT. 
Hypothesis 2: It is well known that some bacteria rely on external sources of purines and 
pyrimidines for their metabolism (see Section 1.2.7). It is proposed that bases and nucleosides 
present in neonatal saliva stimulate and select for commensal microbiota. 
 
Hypothesis 3: That the oral microbiota of 4-8 week old infants varies depending on the mode of 
feeding (i.e. breast-fed versus formula-fed), at least in part as a result of these selective metabolites 
in Hypotheses 1 and 2. 
 
Rationale: The effect of breastfeeding versus formula feeding has been assessed for infant faecal 
bacteria but it has never been determined for oral bacteria. Also, the foundation of the above 
hypotheses rests on the supposition that there will be a difference between oral microbial 
populations due to breastfeeding (i.e. XO-positive milk) versus formula feeding (XO- negative 
milk). Thus, it is essential to determine whether there is a measurable in vivo effect. 
 
 
4.3 SPECIFIC AIMS 
In relation to the previous studies (see Chapters 2 and 3), the aims of this study were to: 
1. Investigate in vitro the effect of micromolar H2O2 on bacterial growth 
2. Investigate in vitro the effects of adding breast milk (containing XO) to simulated neonatal 
saliva (with xanthine and hypoxanthine, and other nucleosides and bases) on bacterial 
growth 
3. Compare and contrast the in vivo differences in oral microbiota within neonatal mouth from 
babies who have been breast-fed (i.e. exposed to the milk XO-generated superoxide system) 
to the oral microbiota of babies who were exclusively formula-fed, using PCR amplification 
of the bacterial 16S rRNA and deep sequencing  
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4.4 MATERIALS AND METHODS 
4.4.1 NUCLEOTIDE METABOLITE PREPARATIONS 
Stock solutions (10 mM) of the nucleotide metabolites, inosine, guanosine, adenosine, uridine and 
uracil, and of hypoxanthine and xanthine (XO substrates), for reference standards and cell culture 
studies (Sigma-Aldrich Pty. Ltd, Castle Hill, NSW, Australia), were prepared in sterile distilled 
water except xanthine which was first dissolved in 20 mM NaOH. From these stock solutions 1 mM 
standards were prepared in sterile distilled water. The UV absorbance maxima for each purine and 
pyrimidine was measured using a spectrophotometer (Cary 50 Bio-visible, Wilson Drive, USA) and 
accurate concentrations were calculated for each compound from the UV molar extinction 
coefficients. Solutions were then sterilised by filtration through sterile 0.2 µm filters (Acrodisc
®
 
Syringe Filters, PALL, Cheltenham, VIC, Australia) and stored in aliquots at -80
o
C. 
 
4.4.2 HYDROGEN PEROXIDE STANDARDIZATION 
Hydrogen peroxide (30% v/v, ~9 M) (Merck Pty Ltd, Kilsyth, VIC, Australia) was standardised by 
diluting to 9 mM in 100 mM Tris-HCl buffer, pH 7.5 then the peroxide concentration was 
calculated by its absorbance at 240 nm, against a Tris-HCl buffer blank, assuming a molar 
extinction of 43.6 mol
-1
L
-1
cm
-1
. 
 
4.4.3 PREPARATION OF BIOLOGICAL SAMPLES  
Breast milk: Ten breast milk samples (1 mL each) were pooled to produce a stock milk pool, 
which was then divided into 50 µL portions and stored at -80
o
C.  
'Supplemented saliva': Due to the difficulty in obtaining sufficient volumes from infants (mean 
volume of the samples was approx. 100 µL, see Chapter 2), simulated neonatal saliva was prepared 
for this study by supplementing heat-inactivated and sterilised adult saliva. 
'Supplemented saliva' was prepared by pooling 50 adult salivary samples to produce 70 mL of 
pooled saliva. This was mixed thoroughly then heat inactivated at 56
o
C in a water bath for 35 min, 
with gentle mixing every 5 min to ensure uniform heating. The aim of heat inactivation was to 
remove antibody activity that is present in adult saliva, but which is negligible in neonatal saliva 
[161]. The 'supplemented saliva' was then sterilised by vacuum filtration through a sterile 0.45 µm 
filter (Grace Discovery Sciences, Rowville, VIC, Australia) with a sterile filtration apparatus.  
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'Supplemented saliva' was divided into four experimental aliquots as following:  
A. The first saliva aliquot ('Control') contained no additional nucleotide metabolites. 
However, there were naturally low concentrations of purine and pyrimidine metabolites 
present in adult saliva; an assay of these metabolites by LC-MS/MS (see Chapter 2 for 
details) provided values that were close to the median concentrations shown in Table 
2.8. 
B. The second saliva aliquot ('Full supplement, except X and HX') was supplemented with 
the major purine and pyrimidine nucleotide metabolites to produce the median 
concentrations found in neonatal saliva; inosine, adenosine, guanosine, uracil, and 
uridine (11, 12, 7, 5.3, 12 µM respectively), but excluding xanthine and hypoxanthine. 
C. The third aliquot ('Full supplement') was supplemented to produce the median 
concentrations of the major purine and pyrimidine metabolites found in neonatal saliva 
as above, plus xanthine (20 µM) and hypoxanthine (27 µM). 
D. The fourth saliva aliquot ('Full supplement + oxypurinol') was supplemented with the 
same concentrations of the major purine and pyrimidine metabolites as in 'C', as well as 
100 µM oxypurinol, an inhibitor of XO. 
 
See Table 4.1 for a summary of the saliva supplements. Each of these 'simulated neonatal saliva' 
aliquots was divided into smaller volumes and stored at -80
o
C. These saliva samples were also 
analysed using HPLC-PDA (Agilent, USA) to confirm the presence of the purines and pyrimidines 
at the correct concentrations (see Chapter 2 for HPLC-PDA method). 
 
Table ‎4.1 Saliva experimental solutions. Four experimental saliva formulations were used to 
evaluate in vitro the bactericidal activity of breast milk and simulated neonatal saliva. All saliva 
samples were collected from adults, heat inactivated, sterilised by filtration, and supplemented with 
bases and nucleosides. 
Saliva Supplements 
Control No supplements: control saliva only  
Full supplement except X, HX Major purines and pyrimidines except XO substrates (xanthine and hypoxanthine) 
Full supplement  Major purines and pyrimidines present in neonatal saliva including XO substrates 
Full supplement + oxypurinol Major purines and pyrimidines present in neonatal saliva plus oxypurinol (100 µM) 
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4.4.4 BACTERIAL PREPARATIONS 
Bacterial strains were obtained from the culture collection at the Queensland University of 
Technology, Faculty of Health, Brisbane, QLD, Australia. These included Escherichia coli (ATCC 
2592), Staphylococcus aureus (ATCC 29213), Salmonella spp. (ATCC 1311), Lactobacillus 
plantarum (UQM 297). Bacteria were stored in liquid nitrogen then cultured by inoculating onto 
either nutrient agar, horse blood agar (HBA), or de Man, Rogosa and Sharpe (MRS) agar (Oxoid 
Pty Ltd, Adelaide, SA, Australia) and incubated aerobically at 37
o 
C either for 24 h or 48 h. Bacteria 
then were subcultured into 25 mL of either MRS broth for Lactobacillus species, or nutrient broth 
for the other species. The suspensions were vortexed for 15 s and incubated aerobically for 24 h at 
37
o
C in a shaking incubator. After overnight incubation, the broth incubations containing bacteria 
were transferred into sterile centrifuge tubes, and the cells were harvested by centrifugation at 4000 
x g for 15 min at 4
o
C. The supernatants were then discarded and the pellets were resuspended in 3 
mL nutrient or MRS broth containing an equal volume of 20% glycerol (w/v). Each suspension was 
then vortexed for 15 seconds and divided into 100 µL aliquots in sterile Cryovial tubes (Sarstedt 
Australia Pty Ltd, Mawson Lakes, SA, Australia) and stored at -80
o
C for future experiments.  
The number of colony forming units (CFU) per mL in a thawed aliquot of the stock for each 
bacterial species was determined. For each bacterial species the thawed stock was serially diluted 
ten-fold (10
-1
 to 10
-5
) in phosphate buffered saline (PBS) and then 3 x 10 µL drops from each 
dilution were inoculated onto nutrient agar or MRS agar plate as appropriate. The plates then were 
incubated at 37
o
C for either 24 h or 48 h. The number of CFUs in 3 x 10 µL drops was counted 
visually on one plate (the dilution with well-separated CFU in numbers that could easily be 
counted) and the number of CFUs per mL was calculated for each species. 
 
4.4.5 DETERMINATION OF PURINE AND PYRIMIDINE METABOLITES IN BACTERIAL MEDIA USING 
LC-MS 
To determine the concentrations of purine and pyrimidine metabolites in bacterial culture media, 
aliquots of sterile Nutrient and MRS broths were ultra-filtered by microfuging using 0.5 mL, 50 
kDa membrane cut-off filtration units (Amicon Ultra, Merck Pty. Ltd., Kilsyth, VIC, Australia) at 
9500 x g, for 10 min at 20°C, then 10 µL of each medium was subjected to LC-MS/MS analysis 
(see Chapter 2 for details). 
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4.4.6 IN VITRO ORAL MICROBIOTA STUDIES 
4.4.6.1 Hydrogen peroxide titration against bacteria 
Bacterial growth inhibition assays were conducted using flat bottom 96-microtiter plates (Thermo 
Scientific, Scoresby, VIC, Australia). Bacterial stock being tested (prepared as described above) 
was diluted in nutrient broth and then kept on ice. The number of cells was adjusted to a final 
concentration of 200 CFU/mL. Serial two-fold dilutions of H2O2 in 50 µL nutrient broth were 
prepared within the rows of the microtiter plate to give final H2O2 concentrations of 400, 200, 100, 
50, 25, 12, 6, 3, 1.5, 0.75, 0 µM (11 wells). 50 µL of the diluted stock bacteria was added to each of 
the wells of the broth-peroxide dilution series to give a total volume of 100 µL. The final well (12
th
) 
in each row was a negative control and contained H2O2 and nutrient broth only. Each bacterial 
species was tested in triplicate in three H2O2 dilution series. The microtiter plate was sealed with a 
sterile adhesive microtiter sealer (MP Biomedicals, Seven Hills, NSW, Australia) and incubated at 
37
o
C in a shaking incubator (John Morris Scientific Pty Ltd, Chatswood, NSW, Australia) for either 
24 h or 48 h. Bacterial growth was determined turbidometrically using a microtiter reader (xMark, 
Bio-Rad Laboratories Pty. Ltd., Gladesville, NSW, Australia) by measuring absorbance at 600 nm. 
4.4.6.2 Effects on bacterial growth of saliva and breast milk 
Stock bacterial species (S. aureus, E.coli, L. plantarum, Salmonella spp.) were serially diluted in 
PBS and adjusted to 200 CFU/mL for all experiments. Breast milk was diluted 1:6 in sterile 100 
mmol/L Tris-HCl buffer (pH 7.5). In a 96-microtiter plate, 50 µL of each simulated neonatal saliva 
formulation (see Table 4.1) was pipetted into triplicate wells. To ensure that the metabolic reactions 
started simultaneously, breast milk (25 µL) was inoculated with bacteria (25 µL) in separate plate 
wells. Using a multichannel pipette, this mixture then was added to saliva to give a final 
concentration of 200 CFU/mL bacteria in a total volume of 100 µL. The plates were also sealed 
with a sterile microtiter adhesive sealer and incubated overnight at 37
o
C in a mechanical agitator 
(200 rpm). After the incubation, viable colony counts were determined for each mixture in triplicate 
as described above. 
To evaluate the dose dependent effects of xanthine and hypoxanthine concentrations on bacterial 
growth, serial dilutions of xanthine and hypoxanthine were generated in simulated neonatal saliva 
supplements. Bacteria and breast milk were then mixed with the supplemented saliva in triplicate as 
detailed above. The final concentrations of xanthine and hypoxanthine were 0, 6, 25, 50 µM. 
Bacteria growth was assessed by viable cell counts as above. See Figure 4.1 for a schematic 
summary of the experiment. 
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4.4.7 IN VIVO ORAL MICROBIOTA STUDIES OF BREAST-FED VERSUS FORMULA-FED NEONATES  
4.4.7.1 Subjects and specimen collection  
This study was approved by the Human Research Ethics Committees’ (see Appendices). Parents of 
the eligible infants were interviewed after delivery by a Neonatal Research Nurse at the Mater 
Mothers’ Hospital, South Brisbane, QLD, Australia and they gave consent for their infants’ to be 
recruited for this study. Breast-fed infants on antibiotics or infants’ whose mothers were on 
antibiotics before or at the time of collection were excluded from the study. Samples of buccal cells 
including bacteria were collected from healthy, full-term, vaginally delivered, Caucasian infants 
aged 4-8 weeks who had not been fed for at least 30 min. Infants’ buccal swab specimens were 
collected at the participants’ homes from breast-fed (n=26) and formula-fed (n=12) infants. The 
buccal cavity of each infant was swabbed gently for approximately 5 min using sterile swabs 
(Copan flocked swabs, Italy); no infant experienced any obvious discomfort and sterile gloves were 
worn during the collection. Three swabs were collected from each infant and placed in sterile 1.5 
mL Eppendorf tubes and frozen on dry ice immediately. Samples were immediately delivered to the 
laboratory and stored at -80
o
C for further analysis. See Table 4.3 for details of the infants’ 
characteristics. 
4.4.7.2 DNA extraction and purification 
For total genomic DNA extraction, buccal swabs were mixed with 100 µL of 4 g/L lysozyme (20 
mM Tris-HCl, pH 8.0; 2 mM EDTA; 1.2% Triton) (Sigma-Aldrich, Castle Hill, NSW, Australia) 
and incubated in a heating block for 35 min at 37
o
C. Lysozyme hydrolyzes glycosidic bonds within 
peptidoglycan (the bacterial cell wall), increasing the bacterial DNA yield. After incubation, 100 µL 
of 100 µg/mL Proteinase K (QIAGEN Pty Ltd, Chadstone Centre, VIC, Australia) solution was 
added and this was further incubated for 30 min at 37
o
C. Finally, 400 µL of lysis buffer was added 
to the mixture, which then was incubated at 56°C for a further 10 mins. The total genomic DNA 
was subsequently purified using the QIAamp DNA Mini Kit (QIAGEN Pty Ltd, Chadstone Centre, 
VIC, Australia) following the manufacturer’s instructions for Spin-Column Protocol for "DNA 
Purification from Buccal Swabs". The genomic DNA was eluted in 100 µL of PCR grade 
DNAse/RNAse-free distilled water (GIBCO UltraPure
TM
, Invitrogen, Mulgrave, VIC, Australia). 
Concentrations and DNA quality were assessed using a NanoDrop ND-1000 spectrophotometer 
(Thermo Scientific, Scoresby, VIC, Australia) and agarose gel electrophoresis. A 2% w/v agarose 
gel was prepared using the following ingredients: 2 g agarose powder (BIORAD) and 100 mL of 
0.5x tris-borate EDTA (TBE) Buffer (Sigma-Aldrich, Castle Hill, NSW, Australia), the mixture was 
then heated using a microwave to dissolve the agarose. As the gel cooled, 2 μL of ethidium bromide 
(Sigma-Aldrich, Castle Hill, NSW, Australia) was added and gel was poured into a mould. After the 
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gel had set, DNA samples were mixed with gel loading buffer, and added to the gel. The gel was 
run for 60 min at 80 V, then photographed. The intensity of staining of the DNA amplicons then 
was compared to the DNA molecular weight marker VIII (Roche, Castle Hill, NSW, Australia). The 
genomic DNA concentration was standardised for all samples to approximately 10 ng/µL before 
PCR amplification. These DNA samples then were sent to the Australian Genome Research Facility 
(University of Queensland, Brisbane, QLD, Australia) for bacterial 16S ribosomal RNA (rRNA) 
gene 'deep sequencing'. 
4.4.7.3 PCR amplification of the bacterial 16S rRNA genes 
PCR was performed using a Forward 27F primer (AGAGTTTGATCMTGGCTCAG) and a Reverse 
519R primer (GWATTACCGCGGCKGCTG) [249], with fusion primer sequences for both the 
forward and reverse directions for each amplicon. Each primer sequence was begun with the 
appropriate adapter sequence for Lib-L or Lib-A libraries followed by the key sequence of TCAG. 
This was then followed by the unique “barcode” sequences for a GS FLX MID for the forward and 
the reverse directions; the barcode sequences were used subsequently to identify and distinguish 
each of the samples. Table 4.2 summaries the design structure of the fusion primers, and the 16S 
rRNA target sequence primers [Adapter]-[Key]-[MID barcode]-[Target primers]. 
 
Table ‎4.2 Fusion primers design (5' to 3') for 16S rRNA amplification. The fusion primer 
sequences contained [Adapter]-[Key]-[MID barcode]-[Target primers]. 
 Forward fusion primer sequence Reverse fusion primer sequence 
Adaptor  CCATCTCATCCCTGCGTGTCTCCGAC CCTATCCCCTGTGTGCCTTGGCAGTCTCAG 
Key TCAG TCAG 
MID Barcode sample specific --------------- 
Target primer* GWATTACCGCGGCKGCTG AGAGTTTGATCMTGGCTCAG 
*Base redundancies were included within the target primers (W= A+T, K= T+G, M= A+C). 
 
The PCR amplifications were conducted in 384 well plates using 8 µL total volume per reaction. 
Each PCR reaction contained: 2 µL pooled DNA templates, 4 µL master mix containing Ampli Taq 
Gold (AmpliTAQ GOLD 360, Applied Biosystems, USA), and 2.25 µM of primers. The PCR 
cycling parameters were: 95°C for 5 min; 35 cycles of 95°C for 30 sec, 60°C for 30 sec, and 72°C 
for 2 min; a final extension step at 72°C for 7 min; and then the reactions were held at 10°C. All 
amplicons were purified using a robotic liquid handler (Beckman Coulter 384 Biomek NX, CA, 
USA) and Agencourt AMPure (Beckman Coulter, CA, USA). 
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4.4.7.4 Sample QC post PCR purification 
The PCR amplicons were quantified using PicoGreen® (Invitrogen, Mulgrave, VIC, Australia) to 
determine the DNA concentration with a slight modification to the manufacturer's instructions. 
Briefly, the samples were diluted 1:100 using PCR grade water, then reduced equal volumes (4 µL) 
of standards, samples and PicoGreen were used for the measurements. All samples were processed 
in 384 well plates. Samples then were normalised to the same molarity then a qPCR reaction was 
performed to check each sample. The samples were re-normalised based on the qPCR copy number 
results. This double normalisation technique is effective at ensuring an even number of de-
multiplexed reads post sequencing on the GSFLX. 
4.4.7.5 16S rRNA gene sequencing ('deep sequencing') 
The pool of samples then was set up according to Roche’s standard Lib-L emPCR method for 
XLR70 chemistry on the GSFLX+ instrument, emPCR Method Manual – Lib-L MV GX FLX 
Titanium Series October 2009 (Rev. Jan 2010), Germany. Emulsions were setup at 2 x MV 
(medium volume), both at 0.35 cpb (copies per bead) to achieve recoveries of 18% and 20% (the 
recommended range is 5 to 20%). 
Two million of such beads were sequenced in a half picotitre plate in Roche-454 GS FLX amplicon 
sequencing platform instrument (Roche, Castle Hill, NSW, Australia) according to Roche’s 
standard XLR70 protocol for the GSFLX+ instrument. Subsequently, the quantified libraries were 
amplified in micro-reactors through emulsion PCR (emPCR) followed by Streptavidin bead 
enrichment and emulsion breaking. The beads attached to amplified DNA fragments were 
denatured with 1N NaOH solution and annealed to a specific sequencing primer. All these steps and 
subsequent sequencing steps on Roche-454 GS FLX amplicon sequencing platform instrument were 
performed according to Roche-454 GS FLX amplicon sequencing manual protocol updated in 
October 2009 and revised by January 2010. Standard bioinformatics quality control (QC) involved 
reviewing internal QC metrics and de-multiplexing the results as per the barcodes included in the 
pool. 
4.4.7.6 16S rRNA gene sequence analysis 
The composition and species diversity in high-throughput amplicon sequencing data was analysed 
using the Quantitative Insights Into Microbial Ecology (QIIME) software package version 1.7.0 
(http://qiime.org/) [250]. A total of 589,945 reads of 250-550 bp in length were obtained from the 
infants’ oral swab samples. The sequence dataset was depleted of short reads (< 250bp) and then the 
reads from the forward primer were selected and assigned to sample identities (for breast-fed and 
formula-fed infants) based on their unique barcode sequences. Sequence accuracy was maintained 
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by setting the default Phred quality score on Q25 or above. The resultant 522,275 high quality reads 
were used to computationally describe (or define) the bacterial community diversity and richness 
within each sample, and the relative abundances taxonomic levels from Phyla to each operational 
taxonomic unit (OTU) using QIIME version 1.7.0. The oral microbiota of breast-fed and formula-
fed infants were also compared. 
 
The sequences were clustered into OTUs (6,101 in total) based on their similarity of sequences 
(97% identity cutoff) using the UCLUST clustering algorithm. For each OTU a representative 
sequence was selected (the most consistent sequence match for each OTU) for further analysis of 
bacterial community diversity and abundance. These representative OTU sequences were aligned 
and chimera checking was conducted against the 'greengenes' 16S rRNA reference core set as the 
template sequences using QIIME based Python Nearest Alignment Space Termination Tool 
(PyNAST) alignment. All unaligned and potential chimeric sequences were detected and removed 
from the aligned sequence dataset. For taxonomy based analysis, the Ribosomal Database Project 
(RDP) classifier [251] was used, with a confidence threshold of 85%. QIIME-based composition 
analysis was used to quantify the total number of reads per each OTU and their relative abundance 
at different taxonomic levels. 
4.4.7.7 Statistical analysis  
Mean values were compared between two different groups using an unpaired, two-tailed t-test, and 
between more than two groups using one-way analysis of variance (ANOVA). Comparison of oral 
abundance of bacterial phyla in breast-fed versus formula-fed infants was performed using the 
Mann-Whitney test. A p-value of 0.05 was set as the level of significance. All analyses of 
bactericidal experiments were analysed using GraphPad Prism 5.  
 
The study procedure is presented schematically in Figure 4.1. 
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Figure ‎4.1 Schematic diagram summarises the overall bacterial experimental plan. The study 
investigated: (1) the in vitro bactericidal effect of breast milk and saliva; and (2) the in vivo oral 
biodiversity in breast-fed versus formula-fed infants. Bactericidal effects were studied in two 
experiments: (1a) the evaluation of the bactericidal effect of increasing hydrogen H2O2 
concentrations and (1b) evaluation of the bacterial growth in four different simulated neonatal 
saliva aliquots, which were  added to human breast milk. Abbreviations: Cont, control;                  
FS (X&HX-), full supplement except xanthine and hypoxanthine; FS, full supplement; 
FS+oxypurinol, full supplement plus oxypurinol (XO inhibitor). 
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4.5 RESULTS 
4.5.1 SUPPLEMENTED SALIVA PREPARATION 
The purine and pyrimidine contents of the four ‘supplemented saliva’ formulations (Section 4.4.3) 
were assayed by HPLC-PDA, and the results are shown in Figure 4.2. The HPLC analysis of the 
'Control' simulated neonatal saliva (i.e. pooled and filtered, heat-inactivated adult saliva with no 
additional metabolites) found the concentrations of nucleosides and bases were below the limit of 
detection (Fig. 4.2 A). Analysis of the 'Full supplement except X, HX' simulated neonatal saliva 
confirmed the absence of hypoxanthine and xanthine (Fig. 4.2 B) and presence of the added 
nucleosides and bases at correct concentrations. Analysis of the 'Full supplement' simulated 
neonatal saliva (with all bases and nucleosides) showed the presence of uracil, hypoxanthine, 
xanthine, uridine, inosine, guanosine, and adenosine (Fig. 4.2 C) at correct concentrations. HPLC 
analysis of the fourth saliva formulation confirmed the full supplement with an additional peak for 
oxypurinol (not shown). The chromatograms also showed uric acid to be present in the pooled adult 
saliva; this end-product of purine catabolism is present also in similar concentrations in neonatal 
saliva (Section 2.5.4).  
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Figure ‎4.2 Chromatograms showing UV-absorbing peaks at 268 nm present in “supplemented 
simulated neonatal saliva” preparations. An aliquot of each formulation (20 µL) was ultra-filtered to 
remove protein and then injected into HPLC-PDA (see Chapter 2 for method details). 268 nm was 
used for monitoring as this is a mean value for purine and pyrimidine peak absorption.                 
(A) ‘Control’: no additional bases or nucleosides, (B) 'Full supplement except X, HX’: 
supplemented with bases and nucleosides except xanthine and hypoxanthine, (C) 'Full supplement’: 
supplemented with major bases and nucleosides including xanthine and hypoxanthine. 
Chromatograms also show the endogenous uric acid saliva peak. 
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4.5.2 DETERMINATION OF PURINE AND PYRIMIDINE METABOLITES IN BACTERIAL GROWTH MEDIA 
The concentrations of nucleotide metabolites in Nutrient and MRS broth were determined using 
LC-MS/MS are presented in Table 4.3 (see Chapter 2 for details). The concentrations ranged from 
as low as 1 µM for adenine in Nutrient Broth to 369 µM for adenosine in MRS. The method also 
detected high concentrations of creatinine: 1646 µM in Nutrient broth and 164 µM in MRS. All 
nucleotide metabolites were also detected in both media, some at high micromolar concentrations. 
Analysis of these commonly-used bacterial growth media has not been previously reported. 
 
 
Table  4.3 Concentration of nucleotide metabolites in Nutrient and MRS broth (µM) as determined 
by LC-MS 
Nucleotide metabolites Nutrient Broth MRS 
Thymine 3 6 
Creatinine 1646 164 
Uracil 14 48 
Hypoxanthine 121 31 
Xanthine 36 54 
Adenine 1 5 
Adenosine 19 369 
Deoxyuridine 4 1 
Inosine 148 12 
Guanosine 65 70 
Thymidine 9 3 
Uridine 87 183 
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4.5.3 IN VITRO ORAL MICROBIOTA STUDIES 
4.5.3.1 Hydrogen peroxide titration against bacteria 
Aim 1: Investigate in vitro the effect of micromolar H2O2 on bacterial growth 
Increasing concentrations of H2O2 had an inhibitory effect on bacterial viability in Nutrient Broth, 
with remarkable differences observed between bacterial species. Viability was assessed by 
measurement of the turbidity. For example, high concentrations of H2O2 (≥200 µM) markedly 
reduced the viability of all bacteria tested (S. aureus, L. plantarum, Salmonella spp, and E.coli) (Fig 
4.3). Of these four bacterial species, S.aureus, a Gram positive bacterium, was the most sensitive to 
H2O2, where >25 µM was able to inhibit the growth. By contrast, the Gram negative bacterial 
species (Salmonella spp., and E.coli) were only inhibited by higher concentrations of H2O2: 
Salmonella spp.>50 µM H2O2, and E.coli >200 µM H2O2. The Gram positive rod, L. plantarum was 
inhibited by >100 µM H2O2. 
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Figure ‎4.3 Effect of increasing H2O2 (0-400 µM) concentration on bacterial growth. Hydrogen peroxide was added to Nutrient Broth inoculated with 
bacteria and incubated for 24 h at 37
o
C, except for L. plantarum which was incubated for 48 h. The concentration of cells was determined by 
measuring turbidity at OD600. A) S. aureus, B) Salmonella spp., C) L. plantarum, and D) E.coli. Values represent the mean±SD of triplicate 
experiments. 
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4.5.3.2 Bacterial growth with saliva and breast milk 
Aim 2: Investigate in vitro the effects of adding breast milk (containing XO) to simulated neonatal 
saliva (with xanthine and hypoxanthine, and other nucleosides and bases) on bacterial growth 
The bactericidal activity of breast milk XO was evaluated by adding breast milk to the four different 
preparations of simulated neonatal saliva (Table 4.1) and these were then inoculated with bacteria. 
The growth of S. aureus did not benefit from the supplementation with nucleosides and bases (Full 
supplement except X, HX) when compared to the control (p=0.13). But the growth of S. aureus was 
significantly inhibited in the presence of xanthine and hypoxanthine (Full supplement), which cause 
XO in the breast milk to produce H2O2 (p=0.016). The inactivation of XO by oxypurinol (Full 
supplement+oxypurinol) resulted in a significant increase in S. aureus growth (p=0.001) (Figure 4.4 
A). These results are consistent with those observed when S. aureus was grown in the presence of 
H2O2 (Fig. 4.3A).  
Similarly, the growth of Salmonella spp. was not affected by supplementation of simulated saliva 
with nucleosides and bases in the media (Full supplement except X, HX) (p=0.62) (Fig. 4.4B). 
However, the growth of Salmonella spp. was significantly inhibited by the activity of breast milk 
XO in the presence of xanthine and hypoxanthine (Full supplement) (p=0.007) (Fig 4.4B), and the 
growth was significantly restored by the inactivation of XO by oxypurinol (p=0.013) (Fig 4.4 B). 
This apparent sensitivity to H2O2 was in contrast to the direct H2O2 titration experiment, which 
showed that >50 µM H2O2 was needed to inhibit the growth of Salmonella spp (Fig. 4.3 B). 
L. plantarum growth was noticeably stimulated in the presence of bases and nucleosides (Full 
supplement except X,HX) compared to the control (p=0.09) (Fig 4.4C). The growth of L. plantarum 
was noticeably inhibited by XO in the presence of its substrates (Full supplement) (p=0.08) (Fig 
4.4C). However, the exclusion of xanthine and hypoxanthine (p=0.1) and inhibition of XO by 
oxypurinol (p=0.1) restored the bacterial growth. However, L. plantarum response to the above 
systems was not statistically significant. In comparison no significant or noticeable effect, either 
stimulation or inhibition, was observed when E.coli was introduced to these four different 
metabolism experiments (Fig 4.4 D). 
To further define the effect of the metabolism of substrates (in neonatal saliva) by XO (within 
breast milk) on bacterial growth, simulated neonatal saliva was supplemented with serial dilutions 
of hypoxanthine and xanthine prior to the incubation with breast milk and bacteria. Enhanced 
growth inhibition was observed with increased XO substrate concentrations as illustrated in Figure 
4.5. Xanthine and hypoxanthine inhibited, in a dose-dependent manner, the growth of S. aureus 
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(p=0.001), Salmonella spp. (p=0.003) and L. plantarum (p=0.001), where the increase in the XO 
substrates concentration was assumed to result in an increase of H2O2 generation. However, 
compared to the above species, E.coli was not affected by increasing H2O2 and the activity of the 
XO metabolic reaction system (p=0.3) (Figure 4.5 D), which was also consistent with the results of 
the previous experiment (Figure 4.4 D). 
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Figure ‎4.4 The effect of breast milk plus simulated neonatal saliva (with and without supplements) 
on bacterial viability. Bacteria were incubated with breast milk and 3 “supplemented saliva 
aliquots” and a control (Table 4.1). The mixtures were incubated for 24 h at 37oC. Bacterial survival 
was assayed by agar plating and viable cells were measured as Log CFU/mL. A) S. aureus, B) 
Salmonella spp., C) L. plantarum, and D) E. coli. Values represent the mean±SD, from triplicate 
experiments. Symbols: ns, not significant (p>0.05); * p<0.05; ** p<0.01. 
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Figure ‎4.5 Bactericidal effects of H2O2 generated by breast milk (XO) and increasing 
concentrations of salivary xanthine and hypoxanthine (0-50 µM). Bacteria were incubated with 
breast milk and simulated neonatal saliva for 24 h at 37
o
C. The viable cells were assayed by the 
CFU grown on agar plates. Figures display the concentration-dependent effect of xanthine and 
hypoxanthine versus log CFU/mL:  A) S. aureus, B) Salmonella spp., C) L. plantarum, and           
D) E.coli. Values represent the mean±SD, of triplicate experiments. 
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4.5.4 IN VIVO ORAL MICROBIOTA STUDIES OF BREAST-FED VERSUS FORMULA-FED NEONATES  
Aim 3: Compare and contrast the in vivo differences in oral microbiota within neonatal mouth from 
babies who have been breast-fed (i.e. exposed to the milk XO-generated superoxide system) to the 
oral microbiota of babies who were exclusively formula-fed, using PCR amplification of the 
bacterial 16S rRNA and deep sequencing. 
 
4.5.4.1 Participants for in vivo studies of oral bacteria 
In this study, 38 neonates were enrolled (26 breast-fed and 12 formula-fed) with parents’ informed 
consent. For each infant recruited to this study, the data that was collected and included were the 
gestational age at delivery, the birth weight, and the age at the time of collection of the neonate’s 
saliva clinical specimen. These results are summarised in Table 4.4. There were no differences in 
the gestational age (p=0.3), the birth weight (p=0.2), or age (p=0.2) of breast-fed babies compared 
to formula- fed babies.  
 
 
Table ‎4.4 Infants’ mean gestation and weight at delivery and the infants’ mean age at the time of 
collection of the oral bacteria samples by buccal swabs 
 
 Breast-fed Formula fed 
p value 
 Male Female Total Male Female Total 
 12 14 26 5 7 12  
Gestational age (w)1 
   
  
       
   Mean±SD                                   40±0.5 40±1 40±1 40±2 39±2 40±2 0.3 
   Range 
 
 
39-41 38-42  
 
38-41 37-41   
Birth weight (g) 
   
  
       
   Mean±SD 3488±316 3584±570 3539±464 3916±599 3664±227 3779±432 0.2 
   Range 3054-4110 2700-4492  3182-4720 3490-4092   
Age (w)1        
   Mean±SD 6±1 6±2 6±2 7±1 6±2 6±1 0.2 
   Range 
 
 
4-8 4-8  6-8 4-8   
1
w= weeks 
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4.5.4.2 Breast-fed and formula-fed associated oral taxa detected using 16S rRNA 'next-
generation deep sequencing' 
The microbiota within neonatal saliva of breast-fed (n=26) and formula-fed (n=12) infants (age: 4 
to 8 weeks) was examined using the Roche-454 GS FLX amplicon-sequencing platform. 
Sequencing of 38 samples yielded 522,275 curated high quality reads following extraction of 11.5% 
low quality sequences, which were removed from the original dataset. The maximum and minimum 
number of sequences for each sample were 18,903 and 8,132 respectively. A refraction method was 
applied to normalise the sequence counts, to obtain the similar proportion of OTUs for each sample 
with respect to its read count. This allowed a comparison of sample diversity at an equal sequencing 
depth. Bacterial loads in the collected samples were not compared, as there was no effective control 
for differences in the sampled volumes; instead, each sample DNA concentration was initially 
standardised to 10±0.9 ng/μL. The raw data of 16S rRNA are shown in Appendix 26.The curated 
sequence dataset were published in Figshare repository (Appendix 27). 
4.5.4.3 Phylum level comparison of breast-fed and formula-fed oral bacterial communities 
The OTU analyses of oral swabs from 26 breast-fed and 12 formula-fed infants clustered within 5 
bacterial phyla: Actinobacteria, Bacteroidetes, Firmicutes, Fusobacteria, and Proteobacteria. 
Phylum-level distribution patterns demonstrated that the microbiota within neonatal saliva of 
breast-fed babies was distinct from formula-fed babies.  
From the breast-fed neonatal buccal swab specimens, the percent abundances of the most prevalent 
phyla identified were: Firmicutes, Actinobacteria, and Proteobacteria. In contrast, for the formula-
fed infants the most prevalent phyla detected within the buccal swab specimens were: Firmicutes, 
Bacteroidetes, and Actinobacteria (Figure 4.6A).  
Firmicutes represented the predominant phylum in the two experimental cohorts, accounting for 
(mean ± SD) 96.3%±0.04 in breast-fed infants, compared to 95.3%±0.05 in formula-fed infants (p= 
0.5). Actinobacteria represented 2.1%±0.03 in breast-fed infants, compared to 1.6%±0.03 in 
formula-fed (p=0.8). Proteobacteria were significantly higher in breast-fed infants (0.23%±0.01) 
compared to in formula-fed infants (0.01%±0.001) (p=0.04). Finally, Bacteroidetes were 
significantly lower in breast-fed infants (0.11%±0.01) compared to in formula-fed infants 
(1.8%±0.02) (p=0.01). 
Since the phylum Firmicutes was the predominant phylum within buccal swabs of both the breast-
fed and formula-fed infants, the relative distributions of the remaining bacterial phyla were re-
graphed after excluding the Firmicutes (Figure 4.6B). 
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Figure  4.6 Bar graph showing the relative distributions of the major oral phyla operational 
taxonomic units (OTUs). (A) Breast-fed versus formula-fed and (B) Breast-fed vs formula-fed 
excluding the Firmicutes. Taxa were detected by 16S rRNA analysis using Roche-454 GS FLX 
deep sequencing. Each column within the bar graph represents the precentage of the bacterial 
16SrRNA gene detected within a clinical specimen.  
A 
B 
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4.5.4.4 Family level comparison of breast-fed and formula-fed oral bacterial communities 
The bacterial families within buccal swabs of breast-fed and formula-fed infants were analysed. 
Distributions of the family of the major three bacterial phyla (i.e. Firmicutes, Actinobacteria, 
Bacteroidetes) found in this study are shown as pie graphs in Figure 4.7. The Firmicutes phylum 
was the predominate OTU identified in buccal swabs of both the breast-fed and formula-fed infants; 
however, the most abundant families within this phylum varied depending on the cohort. In the 
breast-fed neonates, the Gemellaceae and the Lactobacillaceae accounted for 5% and 2% of the 
bacteria identified within neonatal buccal swabs compared to 3% and 0% respectively within buccal 
swabs of formula-fed infants. The Streptococcaceae was the most abundant family detected within 
the Firmicutes phylum, accounting for 83% of bacterial oral isolates in breast-fed infants and 93% 
of isolates in formula-fed infants.  
The abundance of the Actinobacteria phylum OTUs showed marked variations between the two 
experimental cohorts. Within the Actinobacteria the bacterial family Micrococcaceae accounted for 
the majority of bacteria, 57% of isolates within buccal swabs of breast-fed infants compared to 93% 
of isolates for formula-fed infants. However, the greatest differences in the microbiota noted 
between these two groups of infants were high abundances the Actinomycetaceae family (19% of all 
isolates) and Coriobacteriaceae family (22%) in the buccal swabs of breast-fed infants, compared 
to only 2% and 3% of isolates respectively in formula-fed infants. In addition, 1% of the bacterial 
isolates in buccal swabs of breast-fed infants were of the Bifidobacteriaceae family but these 
bacteria were not detected within the saliva of formula-fed infants.  
Whilst Prevotellaceae was the major family of the Bacteroidetes phylum detected in both cohorts, 
the abundance of this family also varied dramatically. Prevotellaceae accounted for 65% of the 
family isolates within buccal swabs of breast-fed infants, compared to 91% of isolates for formula 
fed-infants. Similarly, marked variations were noticed in the abundance of Porphyromonadaceae 
and Flavobacteriaceae families in the buccal swab specimens from breast-fed infants, 33% and 2% 
respectively, compared to only 9% and 0% respectively in specimens from formula-fed infants. 
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Figure  4.7 Relative abundances of the most common Firmicutes, Actinobacteria, and Bacteroidetes 
families in buccal swabs of breast-fed vs formula-fed infants. The pie charts represent the mean 
values. 
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4.6 DISCUSSION  
Human neonates and older infants are more vulnerable to infectious microorganisms than older 
children and adults. Increasing evidence suggests that neonatal immune responses may not be fully 
developed, thereby predisposing a susceptibility to microbial imbalances [252]. Although XO is 
well known to have antibacterial properties as a result of ROS generation [47], this enzyme’s ability 
to kill bacteria nonetheless depends on the presence of appropriate substrates. Superoxide radicals 
such as peroxide are a well-known defence mechanism to inhibit and kill microbial pathogens. A 
similar mechanism may occur for both the breast and neonatal mouth and digestive tract as part of 
their innate immunity. Additionally, peroxide may encourage or at least provide a growth advantage 
to commensal microbiota. The present study was initiated after elevated concentrations of the XO 
substrates xanthine and hypoxanthine were detected in neonatal saliva (Chapter 2). It was 
hypothesised that the concentrations of these substrates when reacted with XO may produce H2O2 at 
physiologically active levels, i.e. which could affect bacterial growth (Chapter 3). Breast milk XO 
and its substrates in neonatal saliva thus constituted a H2O2-generating system, and this was 
investigated in this chapter for its ability to inhibit bacterial growth. 
 
4.6.1 HYDROGEN PEROXIDE TITRATION AGAINST BACTERIA 
The direct effect of H2O2 at micromolar concentrations on bacterial growth was tested by titrating 
bacterial growth against H2O2, but importantly this was performed at micromolar concentrations 
that would be normally considered pharmacologically ineffective. Initial investigation of the 
antibacterial activity of H2O2 was conducted using a simple and rapid method: serial dilutions of 
H2O2 against four species of bacteria, with a spectrophotometric-based assay for turbidity. This 
showed significant variation in susceptibility of bacteria to micromolar H2O2, with S. aureus being 
the most sensitive to H2O2 at a ‘physiological’ concentration, i.e. a concentration that was predicted 
from mixing breast milk XO with neonatal saliva. In contrast, Salmonella spp., E.coli, and L. 
plantarum were inhibited only at higher concentrations of H2O2.  
However, the initial experiments were conducted using “Oxoid Nutrient Broth” growth media, 
which did not mimic the physiological conditions of a breast-feeding infant's mouth. For example, 
the lactoperoxidase system was not present in this experiment. In addition, the Nutrient Broth media 
was shown to contain high concentrations of purine and pyrimidine metabolites which support 
bacterial growth, consequently this may have confounded the effects of the inhibition studies. 
However, these experiments demonstrated for the first time that micromolar concentrations of 
H2O2, which had previously been considered too low to be bactericidal actually, had strong 
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inhibitory effects on bacterial growth and that the response to H2O2 was species-specific for the 4 
different bacterial strains tested. These experiments demonstrated clearly that H2O2 concentrations 
as low as 30 µM could inhibit the growth of S. aureus, and support a role for peroxide as a cellular 
messenger similar to nitric oxide [86].  
 
4.6.2 BACTERIAL GROWTH WITH SALIVA AND BREAST MILK 
It was then shown that the addition of supplemented simulated neonatal saliva to breast milk also 
exhibited bactericidal effects. In order to mimic the physiological conditions within neonatal saliva, 
‘simulated’ neonatal saliva was used, i.e. adult saliva that was heat-inactivated and supplemented 
with various components. This made it possible to 'dissect' the physiological activities of neonatal 
saliva. This was added to breast milk and bacteria, so that the culture assays were performed 
without the addition of bacterial growth enhancing media such as Nutrient Broth. This physiological 
approach also contained other antibacterial systems such as the lactoperoxidase-system and was 
therefore a more complex system compared to the direct H2O2 titration experiments that were 
initially conducted to demonstrate antibacterial activity. 
Using the physiological simulated saliva it was demonstrated that nucleotide precursor 
supplementation (nucleosides, bases, but not xanthine, hypoxanthine) of saliva had no effect on S. 
aureus, Salmonella spp. and E.coli compared to the negative control, suggesting these species did 
not benefit from nucleosides and bases as growth factors, i.e. these species were exhibiting 
prototrophic behaviour. By contrast, the combination of breast milk and fully supplemented saliva 
(containing xanthine/hypoxanthine) exhibited a bactericidal effect on S. aureus and Salmonella 
spp., which was prevented/reversed by oxypurinol, an XO inhibitor. This demonstrated that the XO-
saliva system produced sufﬁcient amounts of H2O2 to inhibit the growth of bacteria. In particular, S. 
aureus grown within the physiological saliva/breast milk system was shown to have inhibition 
kinetics similar to those observed with the H2O2 titration experiments.  
In early studies of the XO antibacterial effect, Green et al [253] and Lipmann et al., [254] 
demonstrated the inhibition of growth of S. aureus by purified bovine milk XO. They attributed 
these findings to the cytotoxic effect of XO-generated hydrogen peroxide. In addition, Stevens et al. 
[71] demonstrated that E. coli and Salmonella spp. were inhibited by this system, after adding 100 
µM hypoxanthine to breast milk.  
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Although these some studies have proposed that bacterial growth inhibition was caused by H2O2, 
others have suggested that XO-derived H2O2 exerts its antibacterial effects by activating the 
lactoperoxidase system [255].  
Whilst S. aureus asymptomatically colonises the surface of the skin, it is also a major opportunistic 
human pathogen [256], and the most common causative pathogen of mastitis [195]. S. aureus 
causes serious infections in neonatal units, being responsible for cellulitis, abscesses, bacteraemia, 
and sepsis infections in neonates [257-259]. These infections may also be difficult to treat as many 
S.aureus strains have acquired multiple antibiotic resistant genes, so that greater than 60% of S. 
aureus isolates are now resistant to methicillin [87].  
Lactobacillus species are major commensals within the GIT [260] and within the female lower 
genital tract (LGT). These bacteria are transferred to babies by vertical transmission at the time of 
birth [261]. In this current study there was a noticeable, but not significant, stimulation of 
Lactobacillus growth in the presence of nucleotide metabolites in simulated saliva in comparison to 
the other tested bacteria, indicating that this commensal bacterium was auxotrophic in its growth 
habit. This increase in L. plantarum growth was reversed when xanthine and hypoxanthine were 
added to the supplemented saliva aliquots, and growth was restored when oxypurinol, the potent 
inhibitor of XO, was added to this mixture, however this was not significant (p=0.09).  
The increase in the growth of L. plantarum in the presence of nucleotide metabolites in saliva is 
suggestive of an important role in the selection and the maintenance of commensal bacterial 
microbiota. Lactobacillus species are important commensal flora; in particular L. gasseri OLL2716 
strain as probiotic bacteria, showed a significant suppression of the growth of H. pylori [262].The 
continuous secretion of these metabolites in neonatal saliva especially in the first few weeks 
postpartum (see Chapter 2, Longitudinal study) may select for commensal bacterial microbiota by 
enhancing the growth and consequently lead to establishment of important bacteria within normal 
flora communities in the early stages of life. Development of this bacterial community is crucial for 
the establishment of a suitable innate immunity [263, 264]. L. plantarum showed intolerance to 
H2O2 generated by the xanthine/hypoxanthine-XO system (p =0.001). This was in contrast with 
direct H2O2 titration of Lactobaccilus growth, raising the possibility that the milk lactoperoxidase 
system contributed to the inhibition of this species.  
For these bacterial growth experiments with supplemented saliva and breast milk, it was reasonable 
to assume that salivary peroxidase was inactivated by the heating process used to inactivate 
antibodies. However, the breast milk lactoperoxidase was highly active: this was confirmed by 
assays (not shown here). But in the adult mouth H2O2 produced by bacterial metabolism is 
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presumed to serve as a substrate for the salivary peroxidase system. In neonates these peroxidative 
bacteria may not be established and therefore the presence of the milk XO-saliva 
hypoxanthine/xanthine system may be of critical importance within the early neonatal period. 
Peroxidase has been shown to be important in the defence of the lung against bacterial infection 
[265]. Further studies of lactoperoxidase in terms of its protective effects for the mouth and upper 
GIT are needed, especially at the physiological concentrations present in human milk and neonatal 
saliva. 
The use of a peroxide defence against bacteria exists in other natural mechanisms. Recently, 
reactive oxygen species (ROS) generation as a defence system has been described in honey. Honey 
contains the enzyme glucose oxidase, which at some dilutions, reacts with its excess substrate, 
glucose, to generate H2O2. This reaction has substantial inhibitory effects against several bacterial 
species [266-268]. However, the concentrations of H2O2 produced from this system in honey are 
much greater (as high as 3,000 µM) [269] than those generated by the milk XO system (i.e. 
approximately 30-100 µM in human milk, and estimated up to 300 µM in bovine milk [79]). These 
findings indicated that honey may be used externally to treat a wide range of wounds including 
abscesses, surgical wounds, traumatic wounds, burns, and ulcers of varied aetiologies using a range 
of dilutions; this provides further evidence for the natural occurrence of ROS generation 
contributing to non-specific host defence systems. 
The XO-peroxide system may contribute to neonatal GIT innate immunity by playing an important 
role in prevention of opportunistic infections. In particular, XO can generate ROS as well as RNS 
under conditions present within the neonatal GIT (of low oxygen tension and neutral stomach pH), 
which is optimal for the XO metabolic reaction. Absence of this system may increase the risk of 
opportunistic GIT infections such as NEC. This disease has a high risk in preterm babies, who rely 
on formula feeding (and who also invariably have their saliva suctioned) [270, 271]. It has been 
shown in this project that the activity of XO is absent from formula feed preparations as well as 
pasteurized breast milk (see Chapter 3). Lactoperoxidase is also absent from formula and 
pasteurised milks (results not shown). Therefore, in the absence of milk XO and lactoperoxidase, 
this antimicrobial defence mechanism in the neonatal mouth, and then the GIT, may partially 
explain the greater susceptibility of bottle-fed infants to infection.  
 
4.6.3 IN VIVO ORAL MICROBIOTA STUDIES OF BREAST-FED VERSUS FORMULA-FED NEONATES  
Upon delivery, the neonate is exposed to a wide variety of microbes, many of which are provided 
by the mother during and after birth. Importantly, there is increasing evidence that an imbalance in 
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the microbial communities has an impact on human health [272, 273]. Therefore, in the current 
study, 16S rRNA gene deep sequencing, a culture-independent method, has been utilised to screen 
the oral microbiota composition of healthy breast-fed and formula-fed infants. This study was 
conducted to address the questions of how oral bacterial communities are structured by the mode of 
feeding, and the differences existing between the oral bacteria in breast-fed compared to formula-
fed infants. 
The microbiota within the infant GIT has been studied previously and remarkable variations were 
demonstrated according to the feeding style [227, 274-276]. For example, it has been found that at 
approximately 6 days after birth, the number of CFU/mL of Lactobacilli in the faeces of breast-fed 
infants was 1000 times higher than that of Enterobacteriae, but 10 times less in the faeces of bottle-
fed infants [277]. At the time of writing, the study presented here is the first to investigate the 
effects of breast-feeding versus formula-feeding on the selection of microbiota within the neonatal 
mouth.  
The study samples were only collected from vaginally delivered babies to minimize the effect of 
delivery mode on oral bacterial communities. This is important because the delivery mode has been 
shown to shape the oral bacteria in human infants [111]. In previous studies [278], 64-82% of 
reported cases of methicillin-resistant S. aureus (MRSA) infections in newborns occurred in 
Caesarean-delivered infants, suggesting that the delivery mode has an influence on bacterial 
communities. 
Interestingly, the breast-fed and formula-fed groups had distinct microbiota distribution patterns. In 
addition, there was marked inter-individual variation within each group, in the taxon-level 
community compositions along with some variation at the phylum level. Experimental variability 
could have been further assessed by repeat analyses of all samples, repeat analysis of samples from 
each individual, or from obtaining a larger sample size, to improve evaluation of the inter- and 
intra- individual differences. However, despite the limitations provided by ethical restrictions, 
limited access to the sequencing facility (i.e. AGRF), and the inevitable restricted funding for a PhD 
thesis project, the results were consistent with other studies in which large inter-individual 
variations were reported in the healthy oral cavity [107] and intestinal tract [211, 275, 279, 280]. 
This suggests that various bacterial species might respond to differences in, for example, host 
metabolism that result in differences in the oral environmental niche of individuals. This may serve 
as a hallmark of microbiota stability, as well as potentially being a biomarker for human health – 
fruitful areas for further research.  
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This study established that formula-fed infants had a higher prevalence of Bacteroidetes within their 
saliva. This is consistent with a study of infant gut microbiota, which reported increased 
Bacteroidetes associated with formula feeding [227]. Apart from Bacteroidetes, the 
Bifidobacteriaceae family was detected in the mouths of breast-fed infants but was absent within 
the mouths of formula-fed infants. Bifidobacterium spp. are among the first anaerobic bacteria to 
reach high concentrations within the GIT of most neonates within the first few weeks of life. The 
prevalence of this bacterial species has been shown to be enhanced by breast feeding [237]. 
Since saliva and breast milk contain growth-enhancing and antibacterial factors such as amino 
acids, organic acids, proteins, enzymes, and immunoglobulins, the variations reported here in infant 
oral microbiota cannot be attributed solely to the XO-system. However, from the in vitro 
experimental data shown above, it is apparent that XO-system has an effect on bacterial selection 
and growth. It is also important to mention here that nucleotide metabolites are present in bacterial 
growth media as demonstrated in this study (Table 4.3), some of these metabolites were detected at 
physiological concentrations, similar to the concentrations detected within neonatal saliva; this 
confirms their importance in enhancing bacterial growth, and thereby modulating oral microbiota.  
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Chapter 5 
Conclusions and future directions 
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5.1 CONCLUSIONS 
Purines and pyrimidines in adult and neonatal saliva: It is clear from the studies presented here 
that nucleotide metabolites are excreted actively by the salivary glands and that saliva is not just a 
plasma filtrate. The significance of this has not appeared in the literature, namely that saliva may 
provide a unique fluid to aid in the diagnosis of metabolic disorders. Furthermore, it has been 
shown for the first time that higher concentrations of these metabolites exist in neonatal saliva 
compared to adult saliva, and that the transition occurs during the first 6 months of life. It is 
reasonable to conclude that the raised concentrations of nucleotide metabolites in neonatal saliva 
(compared to adult saliva) must play a physiological role rather than being simply the result of 'birth 
stress'. This was demonstrated by the highly selective nature of the nucleosides and bases found in 
saliva (i.e. non-functional metabolites were not found in saliva), and the fact the effect persisted 
beyond the neonatal period. This led to the conclusion that raised nucleotide metabolites in neonatal 
saliva have a role in regulating microbiota and consequently the enhancement of neonatal innate 
immunity.  
Breast milk XO and generation of peroxide: In particular, high levels of hypoxanthine and 
xanthine were found in the neonatal mouth. From these elevated levels of XO substrates, it was 
hypothesised that there must be some link to XO in milk. From the evidence presented, it can be 
seen that xanthine and hypoxanthine in the neonatal mouth react with milk XO to generate reactive 
oxygen species (ROS). These highly reactive radicals are well known to have antibacterial 
properties. It was thus considered that this mechanism was likely have a role in neonatal innate 
immunity. 
Bacterial studies: The bacterial studies were divided into 2 aspects: in vitro inhibition and 
stimulation of 4 test species of bacteria by peroxide and nucleotide metabolites, and an in vivo study 
of the effect of breast milk on selection of oral bacteria. The conclusions reached from the in vitro 
experiments were that an ‘ROS cascade’ produced by XO and its substrates can inhibit pathogenic 
bacteria at physiological concentrations, suggesting that the XO system may have an important role 
in neonatal innate immunity as well as preventing mastitis in the mother. This was the first time that 
the milk XO-peroxide system was considered as working beyond the breast. In addition, it was 
shown that other nucleosides and bases in neonatal saliva could serve as growth factors for some 
commensal bacteria and consequently may help to regulate the commensal bacterial community in 
the early stages of life. These nucleosides and bases may also have a role in feeding developing gut 
cells in the newborn, although this was not examined here. The in vivo study was important, as it 
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was the first to show that there was an effect of breastfeeding on oral bacteria. Interestingly, if no 
effect had been demonstrated then the other hypotheses would have been more difficult to justify. 
Overall conclusions: The results presented here demonstrated the following: nucleosides and bases 
are higher in neonatal saliva than adult saliva; xanthine and hypoxanthine in saliva react with breast 
milk XO to generate H2O2, which can inhibit the growth of specific bacteria. The same mechanism 
may also occur in the mammary gland, supported by the presence of H2O2 in fresh breast milk. The 
nucleoside and bases in neonatal saliva may provide a good source for commensal flora to enhance 
the microbiota communities in the neonates’ mouth and gastrointestinal tract. Overall, the 
experiments provided evidence for the important role of regulation of the neonatal microbiome by 
breast milk and saliva. 
 
5.2 FUTURE STUDIES 
1. Measurement of nucleotides (i.e. in addition to nucleosides and bases presented here) might be 
important future approaches. Due the difficulty in measuring nucleotides at low concentrations, 
as previously reported for adults, a HPLC method compatible with mass spectrometry was not 
available, and there was insufficient time to establish such a method for nucleotides – this work 
is continuing. 
2. It was noted that some adults tend to have higher concentrations of nucleotide metabolites such 
as xanthine, hypoxanthine and inosine, which might be explained by the genetic variation (e.g. 
SNPs), which includes racial/ethnic groups. Therefore, investigation of the transport mechanisms 
of these metabolites into saliva for both neonates and adults and monitoring the plasma level in 
neonates after birth would be an important focus of the future studies. 
3. It has been also demonstrated in this thesis that mixing breast milk XO with neonatal saliva 
elicits ROS generation, and this system could be of importance at early stages of life. Besides the 
importance of ROS as bactericidal factors, the XO system serves as donor of H2O2 for the 
lactoperoxidase system to generate other antibacterial metabolites (e.g. hypothiocyanite). There 
is accumulating evidence that in adults the salivary lactoperoxidase system may obtain H2O2 
from the metabolism of oral microbiota, however when the microbiota are not established in the 
neonatal mouth another source of H2O2, namely the milk XO system, might be critical. Thus, 
further investigation of these antibacterial systems using physiological conditions, rather than 
growth media, may improve our understanding of the innate immunity of neonates and early 
infants. 
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4. Future studies might also include the ability of XO to directly generate RNS. XO can convert 
NO2 to NO, the latter can react with O2
.-
 to produce NOO
-
 a powerful antibacterial agent. The 
importance of the XO system as demonstrated here is to donate O2
.-
 to the above mechanism to 
generate bactericidal RNS, particularly in the neonatal stomach where conditions are appropriate 
for this mechanism. 
5. There is some evidence that ROS such as H2O2 play an important role in cell signalling and 
regulation of cell proliferation and apoptosis. Importantly, it has been demonstrated in this thesis 
that H2O2 is present in breast milk as well as regenerated in vitro by adding neonatal saliva to 
breast milk at physiological concentration. Thus, this might be essential for gut cell signalling 
and growth, during the rapid cell growth in neonates. This topic is important to investigate in the 
future. Neonatal gut cell growth may also benefit from salivary nucleosides/bases.  
6. Some the in vitro experiments of bacterial growth reported in this thesis will benefit from being 
repeated and extended, e.g. stimulation studies with supplemented saliva:  
a) One control experiment to perform would be to incubate bacteria with supplemented saliva 
alone (i.e. no milk) – this is what happens a lot of the time in the baby's mouth. This would 
show whether the purine and pyrimidine supplementation actually assisted growth of some 
bacteria. This has never been done correctly because previous researchers have used growth 
media that are not physiological. Indeed, 'supplemented saliva' may be an excellent 
physiological medium for growing some commensal bacterial species. 
b) In retrospect, the generation times (24 h) used were probably too short for Lactobacillus, so 
growth stimulation was not fully measured.  
7. Only 4 species of bacteria were examined: other species are awaiting study. 
8. The presence of nucleotide metabolites could be helpful markers for the diagnosis of some 
metabolic disorders. 
  
135 
 
5.3 SUMMARY OF RESEARCH RATIONALE, OUTCOMES AND BENEFITS  
1. By studying one of the earliest postnatal mechanisms of regulating oral and gut microbiota, this 
research may improve the oral and gut health of newborns through to adults, by providing an 
improved understanding of natural anti-bacterial and pro-biotic mechanisms. 
2. Specifically, this research could assist in understanding the pathogenesis of necrotising 
enterocolitis (NEC) that can affect premature and some full-term babies. It may also assist in 
providing new methods of prevention of NEC, e.g., through new milk formulations and feeding 
mechanisms that more closely imitate the natural regulation of microbiota.  
3. It may contribute to the prevention of middle ear infections, which are more common in non-
breast-fed infants and after weaning.  
4. The study may also initiate new lines of inquiry into how best to establish or conserve normal 
oral and gut flora in young children with severe illness or requiring major surgery (e.g. for 
abdominal, chest or cardiac malformations).  
5. It is likely that this project will provide yet more evidence to support breast feeding compared to 
milk formula feeding. 
6. Lastly, these considerations may also apply to some nursing mothers, e.g. with metabolic 
disorders. For example, although small in number, there has never been a survey of oral/gastric 
infections among babies of mothers with xanthinuria (inherited xanthine oxidase deficiency), or 
for nursing mothers on allopurinol. For example, there are presently 2 identified xanthinuric 
women of child-bearing age in the Brisbane area, and many more world-wide. 
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Al-Shehri S, Shaw PN, Cowley D, Liley H, Henman M, Tomarchio A,  Charles B, Duley JA (2011) Nucleotide 
precursors in neonatal and adult saliva.  J. Inherit. Metab. Dis. 34:S73. Poster was also presented at SSIEM, 2011, 
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NUCLEOTIDE PRECURSORS IN NEONATAL AND ADULT SALIVA 
Al-Shehri S
1*
, Shaw PN
1
, Cowley D
2
, Liley H
2
, Henman M
2
, Tomarchio A
2
,  Charles B
1
, Duley JA
1,2 
1 
School of Pharmacy, The University of Queensland, Brisbane 4072, Australia; 
2
Mater Medical Research Institute, 
Brisbane 4101, Australia. 
Background: Human saliva has been extensively described for its composition of major proteins, electrolytes, cortisol, 
melatonin and some metabolites such as amino acids. Little is known, however, about nucleotide precursors in human 
saliva. Nucleotides are essential for synthesis of DNA/RNA, supplying energy, regulating G-protein signalling, and 
biosynthesis.  
Methods: Saliva samples were collected from full-term neonates, aged 1-3 days, using cotton swabs. Unstimulated 
fasting (morning) saliva samples were collected directly from adults. The samples were extracted and ultrafiltered, then 
nucleotide precursors were analysed by reversed-phase HPLC with UV-detection and mass spectrometry (with stable-
isotope internal standards). 
Results: Concentrations of salivary nucleobases and nucleosides as µM±SEM for Neonates\Adults respectively were: 
Pseudouridine 2±0.4\0.27±0.07, Uracil 15±4\4.4±1.5, Thymine 0.2±0.1\0.35±0.16, Dihydrouracil 8±1\1.1±0.21, 
Dihydrothymine 2±02\0.43±0.1, Uridine 19±4\1.7±0.7, Urate 157±23\203±24, Hypoxanthine 41±9\3.8±1.5, Xanthine 
29±7\4.9±2.3, Adenosine 13±3\0.04±0.02, Inosine 22±7\0.43±0.13, Guanosine 11±3\0.22±0.05, Succinyladenosine 
6±2\0.63±0.25. Deoxynucleosides and dihydroxy-adenine were negligible.  
Discussion: Salivary concentrations of purine nucleotide precursors such as hypoxanthine, xanthine, adenosine, inosine 
and guanosine are surprisingly high in neonates and much higher than in plasma. Transition to lower adult levels 
appears to occur during the first year. These precursors in saliva may be useful biomarkers for diagnosis of inborn 
errors of nucleotide metabolism and the investigation of some pharmacogenetic disorders. 
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Appendix 11 A poster presented at SSIEM, 2011, Geneva. 
 
 
182 
 
Appendix 12 An abstract and a poster presented at ASBMB ComBio2012 
 
Longitudinal‎study‎of‎nucleotide‎metabolites‎in‎infants’‎saliva‎compared‎to‎adults‎and‎mammals‎ 
Al-Shehri S
1*
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2
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2
, Charles B
1
, Shaw PN
1
, Liley H
2
, Duley JA
1,2 
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School of Pharmacy, The University of Queensland, Brisbane 4072, Australia; 
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Mater Medical Research Institute & 
Health Services, Brisbane 4101, Australia 
Background: Human saliva has been extensively described for its composition of major proteins, electrolytes, cortisol, 
melatonin and some metabolites such as amino acids. Little is known, however, about nucleotide precursors in human 
saliva. Nucleotides are essential for synthesis of DNA/RNA, supplying energy, regulating G-protein signalling, and 
biosyntheses. 
Methods: Saliva swabs were collected from full-term neonates, aged 1-4 days, 6-weeks, 6-months and 12- months. 
Unstimulated fasting (morning) saliva samples were collected directly from adults. Samples were extracted and 
ultrafiltered, then nucleotide metabolites were analysed by RP HPLC with UV-photodiode array and ESI-QTrap mass 
spectrometry. 
Results: Median concentrations (µM) of salivary nucleobases and nucleosides in infants for neonates/6-weeks/6-
months/12-months respectively were: uracil 5.3/0.80/1.4/0.70, hypoxanthine 27/7.0/1.1/0.80, xanthine 19/7.0/2.0/2.0, 
adenosine 12/7.0/0.90/0.80, inosine 11/5.0/0.30/0.40, guanosine 7.0/6.0/0.50/0.40, uridine 12/0.80/0.30/0.90. 
Deoxynucleosides, dihydropyrimidines and dihydroxyadenine concentrations were essentially negligible. The 
concentrations in human adults/cows/horses/dogs respectively were: uracil 0.80/3.8/81/12, hypoxanthine 
2.0/0.20/7.0/0.20, xanthine 2.0/0.40/34/1.2, adenosine 0.10/0.20/0.10/19, inosine 0.20/0.50/9.4/3.4, guanosine 
0.10/0.30/10/30, uridine 0.40/0.40/27/4.0. Salivary deoxyuridine (13µM), deoxyinosine (10µM), deoxyguanosine 
(7µM), and thymidine (18µM) were unusually high in horses. Saliva from cats, goats, sheep and camel were also 
assayed. 
Discussion: Salivary concentrations of purine nucleotide precursors such as hypoxanthine, xanthine, adenosine, inosine 
and guanosine were surprisingly high in neonates and higher than in plasma. Transition from human neonate to adult 
levels occurred during the first year. These precursors in saliva may be useful biomarkers for diagnosis of inborn errors 
of nucleotide metabolism and the investigation of some pharmacogenetic disorders. 
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Appendix 13 A poster presented at ASBMB ComBio, 2012, Adelaide. 
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Al-Shehri S, Liley HG, Knox CL, Henman M, Cowley DM, Charles BG, Duley JA. Human milk xanthine oxidase and 
neonatal salivary nucleotide precursors generate hydrogen peroxide; a novel pathway with potential role in regulating 
oral micro flora. J Paediatrics Child Health 2013;49 (S2), (Suppl 2), p.121 
 
Human milk xanthine oxidase and neonatal salivary nucleotide precursors generate hydrogen peroxide; a novel 
pathway with potential role in regulating oral microflora. 
Al-Shehri SS
1
, Liley HG
2
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3
, Henman M
2
, Cowley DM
2
, Charles BG
1
, Duley JA
1,2
 
1
School of Pharmacy, University of Queensland, Brisbane, Australia,
2
Mater Medical Research Institute and Mater 
Health Services, Brisbane, Australia,
3
 Institute of Health and Biomedical Innovation, Queensland University of 
Technology, Brisbane, Australia 
Email: helen.liley@mater.org.au 
Background: Xanthine oxidase (XO) is a molybdeno-flavoprotein occurring with high activity in the milk fat globule 
membrane and is involved in the final stage of degradation of purine nucleotides. It catalyzes the sequential oxidation of 
hypoxanthine to xanthine and uric acid, accompanied by production of hydrogen peroxide and superoxide anion. 
Human saliva has been extensively described for its composition of proteins, electrolytes, cortisol, melatonin and some 
metabolites such as amino acids, but little is known about nucleotide metabolites. 
Method: Saliva was collected with swabs from 60 babies at full-term 1-4 days, 6-weeks, 6-months and 12-months. 
Unstimulated fasting (morning) saliva samples were collected directly from 77 adults. Breast milk was collected from 
24 new mothers. Saliva was extracted from swabs and ultra-filtered. Nucleotide metabolites were analyzed by RP-
HPLC with UV-photodiode array and ESI-MS/MS mass spectrometry. XO activity was measured as peroxide 
production from hypoxanthine. Bacterial inhibition over time was assessed using CFU/mL or OD. 
Results: Median concentrations (μmol/L) of salivary nucleobases and nucleosides for neonates/6-weeks/6-months/12-
months/adult respectively were: uracil 5.3/0.8/1.4/0.7/0.8, hypoxanthine 27/7.0/1.1/0.8/2.0, xanthine 19/7.0/2.0/2.0/2.0, 
adenosine 12/7.0/0.9/0.8/0.1, inosine 11/5.0/0.3/0.4/0.2, guanosine 7.0/6.0/0.5/0.4/0.1, uridine 12/0.8/0.3/0.9/0.4. 
Deoxynucleosides and dihydropyrimidines concentrations were essentially negligible. XO activity (Vmax:mean±SD) in 
breast milk was 8.9±6.2 μmol/min/L and endogenous peroxide was 27±12 μmol/L; mixing breast milk with neonate 
saliva generated ~40 μmol/L peroxide, which inhibited Staphylococcus aureus. 
Conclusions: Salivary metabolites, particularly xanthine/hypoxanthine, are high in neonates, transitioning to low adult 
levels between 6-weeks to 6-months (P<0.001, Mann-Whitney). Peroxide occurs in breast milk and is boosted during 
suckling as an antibacterial system. 
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Appendix 16 Raw data set of adult salivary nucleotide precursors concentrations (µM). 
Subject Creatinine Pseudouracil Uracil Hypoxanthine Xanthine Adenine Adenosine Inosine Guanosine Dihydrothymine Dihydrouracil Uridine Thymine Orotate Urate 
1 <5 <0.2 <1.5 0.9 0.8 0.1 <0.03 0.3 0.3 <1.5 <3 <0.02 <1.5 <0.5 224.0 
2 <5 <0.2 1.6 2.5 1.1 0.8 <0.03 0.3 0.1 <1.5 2.5 0.4 <1.5 <0.5 153.0 
3 <5 0.2 <1.5 3.1 2.6 0.4 0.0 0.4 0.3 <1.5 <3 0.8 <1.5 0.5 271.0 
4 <5 <0.2 4.5 0.7 <0.7 0.1 <0.03 0.1 0.1 <1.5 <3 0.5 <1.5 <0.5 146.0 
5 <5 0.6 20.0 10.0 12.3 1.3 0.2 1.0 0.4 <1.5 <3 2.9 7.2 1.0 211.0 
6 <5 <0.2 <1.5 0.3 <0.7 0.1 <0.03 <0.06 0.1 <1.5 <3 <0.02 <1.5 <0.5 131.0 
7 5.6 1.0 10.9 22.0 32.7 1.3 <0.03 1.9 0.7 <1.5 <3 2.4 8.4 <0.5 396.0 
8 <5 <0.2 <1.5 1.1 0.8 0.2 <0.03 0.2 0.2 <1.5 <3 0.4 <1.5 <0.5 135.0 
9 6.9 <0.2 8.5 3.4 4.5 1.0 <0.03 <0.06 0.1 <1.5 <3 0.0 <1.5 2.2 162.0 
10 8.6 0.4 7.4 2.3 5.6 0.9 0.2 0.6 0.1 <1.5 <3 1.5 2.3 <0.5 294.0 
11 <5 0.4 5.3 3.5 6.3 1.1 0.1 0.6 0.1 <1.5 <3 <0.02 2.0 0.5 91.0 
12 <5 <0.2 <1.5 1.3 <0.7 0.1 <0.03 0.2 0.2 <1.5 <3 <0.02 <1.5 <0.5 201.0 
13 <5 0.2 <1.5 1.3 1.1 0.2 <0.03 0.3 0.3 <1.5 <3 <0.02 <1.5 <0.5 105.0 
14 8.4 0.2 <1.5 0.6 0.7 0.2 0.1 0.1 0.2 <1.5 <3 0.1 <1.5 0.5 318.0 
15 <5 0.3 <1.5 5.2 2.4 1.0 0.1 0.2 0.2 <1.5 <3 0.1 <1.5 0.8 184.0 
16 11.5 0.6 8.0 10.3 15.8 1.5 <0.03 0.4 0.2 <1.5 <3 <0.02 1.9 0.9 248.0 
17 8.8 0.2 1.5 3.4 3.7 0.5 <0.03 0.3 0.2 <1.5 <3 <0.02 <1.5 <0.5 214.0 
18 6.9 <0.2 <1.5 1.2 <0.7 0.1 <0.03 0.1 0.1 <1.5 <3 <0.02 <1.5 <0.5 212.0 
19 <5 <0.2 <1.5 0.6 <0.7 0.2 <0.03 <0.06 <0.03 <1.5 <3 <0.02 <1.5 <0.5 162.0 
20 6.5 0.4 2.1 3.0 9.6 0.9 <0.03 0.3 0.2 <1.5 <3 8.4 1.7 0.8 287.0 
21 5.9 0.2 <1.5 1.8 2.0 0.6 0.1 0.2 0.2 <1.5 <3 <0.02 <1.5 <0.5 109.0 
22 6.1 0.2 <1.5 1.0 1.7 0.9 0.7 0.3 0.2 <1.5 <3 <0.02 <1.5 0.8 142.0 
23 5.8 0.2 <1.5 0.7 1.1 0.2 <0.03 0.1 0.1 <1.5 <3 0.1 <1.5 <0.5 178.0 
24 7.7 <0.2 <1.5 10.4 13.0 3.1 0.5 0.9 0.5 <1.5 <3 0.2 <1.5 0.5 177.0 
25 <5 0.2 <1.5 1.2 1.7 0.8 <0.03 <0.06 0.1 <1.5 <3 0.4 <1.5 <0.5 98.7 
26 <5 <0.2 <1.5 0.4 <0.7 0.2 <0.03 <0.06 <0.03 <1.5 <3 0.4 <1.5 <0.5 78.8 
27 9.8 0.2 <1.5 1.9 1.6 0.7 <0.03 <0.06 <0.03 <1.5 <3 0.4 <1.5 <0.5 162.0 
28 5.2 <0.2 <1.5 <0.2 <0.7 <0.1 <0.03 <0.06 <0.03 <1.5 <3 <0.02 <1.5 <0.5 92.7 
29 <5 <0.2 <1.5 2.5 2.0 1.3 0.1 0.2 0.1 <1.5 <3 0.0 <1.5 0.5 74.7 
30 <5 0.2 <1.5 5.4 1.4 0.8 0.4 1.0 0.3 <1.5 <3 0.0 <1.5 <0.5 95.8 
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Appendix 16 (continued) 
Subject Creatinine Pseudouracil Uracil Hypoxanthine Xanthine Adenine Adenosine Inosine Guanosine Dihydrothymine Dihydrouracil Uridine Thymine Orotate Urate 
31 8.5 0.2 <1.5 2.2 2.2 0.4 <0.03 0.1 0.1 <1.5 <3 <0.02 <1.5 <0.5 170.0 
32 7.6 <0.2 <1.5 0.9 <0.7 0.6 <0.03 <0.06 0.0 <1.5 <3 0.1 <1.5 0.6 39.0 
33 5.1 <0.2 <1.5 0.6 0.7 0.8 0.2 <0.06 0.1 <1.5 <3 0.1 <1.5 0.5 195.0 
34 7.1 <0.2 <1.5 0.8 2.8 0.5 0.1 0.1 0.2 <1.5 <3 0.5 <1.5 0.5 105.0 
35 6.6 0.3 3.3 6.9 7.8 2.3 <0.03 0.2 0.1 <1.5 <3 0.6 <1.5 1.6 197.0 
36 <5 <0.2 <1.5 0.6 <0.7 0.6 0.1 0.1 0.0 <1.5 <3 0.1 <1.5 <0.5 89.5 
37 <5 0.4 <1.5 3.9 3.6 0.6 0.2 0.3 0.2 <1.5 <3 0.9 <1.5 0.7 246.0 
38 <5 0.2 <1.5 0.7 <0.7 0.5 <0.03 0.2 <0.03 <1.5 <3 0.2 <1.5 0.9 112.0 
39 <5 0.3 <1.5 2.8 1.0 0.7 0.3 51.0 0.3 <1.5 <3 0.1 <1.5 0.9 89.5 
40 <5 0.2 <1.5 3.6 0.9 0.8 0.1 0.1 0.1 <1.5 <3 0.7 <1.5 0.9 242.0 
41 <5 <0.2 7.7 3.2 2.1 2.2 0.4 0.4 0.2 <1.5 <3 0.4 <1.5 1.2 107.0 
42 <5 <0.2 9.2 5.4 6.2 3.7 0.3 0.2 0.2 <1.5 <3 0.3 <1.5 2.7 176.0 
43 <5 0.2 <1.5 2.0 1.5 1.6 0.4 0.3 0.2 <1.5 <3 0.8 <1.5 1.0 240.0 
44 <  <0.2 <1.5 0.3 1.2 1.2 0.4 0.2 0.3 <1.5 3.4 0.2 <1.5 0.8 84.1 
45 <5 0.2 1.6 2.3 1.1 2.1 0.3 0.3 0.2 <1.5 <3 0.9 <1.5 1.0 59.7 
46 <5 0.2 <1.5 2.1 0.9 1.2 0.1 0.2 0.1 <1.5 <3 0.2 <1.5 0.7 222.0 
47 <5 0.3 <1.5 1.7 1.3 0.8 0.3 0.4 0.4 <1.5 <3 0.4 <1.5 1.1 140.0 
48 5.8 0.4 18.3 1.9 16.5 0.8 <0.03 <0.06 <0.03 <1.5 <3 <0.02 <1.5 <0.5 102.0 
49 <5 0.3 <1.5 0.7 1.1 1.0 0.1 0.1 0.1 <1.5 <3 0.2 <1.5 1.8 131.0 
50 <5 0.3 1.6 5.2 4.8 1.4 0.4 0.5 0.3 <1.5 <3 0.6 <1.5 0.7 176.0 
51 6.6 <0.2 1.7 2.4 2.0 0.4 0.5 0.7 0.3 <1.5 <3 0.0 1.8 1.4 101.0 
52 8.2 <0.2 3.0 2.1 0.9 1.0 0.2 0.1 0.2 <1.5 <3 0.4 <1.5 1.1 212.0 
53 <5 <0.2 <1.5 1.0 <0.7 0.5 0.1 0.1 0.1 <1.5 <3 0.2 <1.5 1.0 168.0 
54 <5 0.5 <1.5 6.8 3.5 1.2 0.3 0.8 0.2 <1.5 <3 0.4 <1.5 1.4 284.0 
55 <5 <0.2 <1.5 1.5 <0.7 0.5 0.3 0.4 0.2 <1.5 <3 0.2 <1.5 0.9 178.0 
56 <5 <0.2 <1.5 1.9 0.7 0.5 0.3 0.3 0.2 <1.5 <3 0.6 <1.5 1.1 108.0 
57 <5 0.3 <1.5 2.2 1.4 1.0 0.3 0.5 0.3 <1.5 <3 0.9 <1.5 1.2 161.0 
58 <5 0.2 <1.5 1.8 <0.7 0.7 0.7 0.7 0.2 <1.5 <3 0.4 <1.5 0.9 210.0 
59 <5 0.3 <1.5 0.6 0.7 0.2 0.3 0.3 0.2 <1.5 <3 0.4 <1.5 0.7 205.0 
60 <5 0.4 <1.5 1.2 <0.7 0.7 0.2 0.3 0.2 1.8 3.4 0.6 <1.5 1.5 521.0 
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Appendix 16 (continued) 
Subject Creatinine Pseudouracil Uracil Hypoxanthine Xanthine Adenine Adenosine Inosine Guanosine Dihydrothymine Dihydrouracil Uridine Thymine Orotate Urate 
61 <5 <0.2 3.9 3.5 3.7 3.5 1.2 0.6 0.4 <1.5 <3 0.2 <1.5 2.1 146.0 
62 <5 0.4 <1.5 <0.2 <0.7 0.3 <0.03 <0.06 <0.03 <1.5 <3 0.3 <1.5 <0.5 235.0 
63 <5 0.4 13.9 2.2 9.0 0.9 <0.03 <0.06 <0.03 <1.5 <3 <0.02 <1.5 0.8 72.8 
64 <5 <0.2 5.0 0.6 2.1 0.3 <0.03 <0.06 <0.03 <1.5 <3 0.2 <1.5 <0.5 205.0 
65 5.7 <0.2 9.6 2.4 5.2 0.6 0.1 0.1 0.1 <1.5 <3 0.1 <1.5 0.5 130.0 
66 <5 <0.2 9.0 1.5 2.8 0.6 <0.03 <0.06 <0.03 <1.5 <3 0.3 <1.5 0.5 131.0 
67 <5 <0.2 9.4 2.1 7.1 1.0 <0.03 <0.06 <0.03 <1.5 <3 0.0 <1.5 1.6 360.0 
68 5.8 0.2 5.7 1.1 5.3 0.1 <0.03 <0.06 <0.03 <1.5 <3 0.3 <1.5 <0.5 268.0 
69 <5 0.2 10.9 4.2 6.3 1.0 <0.03 <0.06 <0.03 <1.5 <3 0.1 <1.5 2.9 217.0 
70 <5 0.2 5.3 5.2 5.3 0.4 0.1 0.3 0.1 <1.5 <3 0.1 <1.5 0.5 123.0 
71 <5 <0.2 9.7 2.6 5.3 0.7 <0.03 <0.06 <0.03 <1.5 <3 <0.02 <1.5 3.1 128.0 
72 5.3 <0.2 20.9 3.3 9.9 1.0 <0.03 <0.06 <0.03 <1.5 <3 <0.02 <1.5 4.4 179.0 
73 <5 <0.2 <1.5 1.4 0.7 0.2 0.1 0.1 0.0 <1.5 <3 0.1 <1.5 1.9 189.0 
74 6.1 <0.2 <1.5 3.3 8.2 0.6 <0.03 <0.06 <0.03 <1.5 <3 <0.02 <1.5 1.1 252.0 
75 5.3 0.4 8.2 4.8 14.2 1.1 0.2 0.5 0.4 <1.5 <3 <0.02 2.9 0.5 611.0 
76 <5 0.3 4.6 3.9 <0.7 0.4 0.0 0.1 0.0 <1.5 <3 <0.02 <1.5 <0.5 235.0 
77 7.3 0.2 21.1 0.8 6.5 0.7 <0.03 <0.06 <0.03 <1.5 <3 <0.02 <1.5 <0.5 206.0 
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Appendix 17 Raw data set of neonatal salivary nucleotide precursors concentrations (µM). 
Subject Creatinine Pseudouracil Uracil Hypoxanthine Xanthine Adenine Adenosine Inosine Guanosine Dihydrothymine Dihydrouracil Uridine Thymine Orotate Urate 
1 6.8 0.5 3.0 14.0 4.4 <0.1 5.4 4.8 2.1 1.8 <3 6.5 <1.5 <0.5 78.0 
2 21.0 1.6 <1.5 16.0 7.1 3.1 12.3 14.0 8.7 2.2 3.9 11.2 <1.5 <0.5 182.7 
3 29.0 3.0 31.0 61.0 41.6 <0.1 6.5 15.1 8.4 3.9 18.5 25.1 <1.5 <0.5 359.8 
4 25.0 1.4 5.7 27.0 14.4 0.8 7.9 8.0 4.1 2.5 7.1 11.0 <1.5 <0.5 124.0 
5 22.0 4.9 37.0 95.0 85.4 9.6 26.0 41.0 24.6 3.0 9.8 45.3 <1.5 <0.5 61.6 
6 24.0 2.0 <1.5 4.1 4.5 1.4 11.5 21.2 14.6 1.9 4.7 13.1 <1.5 1.9 156.0 
7 29.0 2.6 37.0 59.0 37.8 <0.1 7.0 8.5 4.9 3.7 13.5 16.2 <1.5 <0.5 291.0 
8 32.0 2.2 16.0 31.0 8.4 0.1 7.8 7.3 6.2 2.9 10.6 16.3 <1.5 <0.5 163.2 
9 26.0 4.6 53.0 88.0 68.4 0.4 14.0 20.2 14.2 <1.5 7.6 8.9 <1.5 <0.5 439.0 
10 6.2 0.6 2.2 8.6 5.9 1.1 4.5 1.4 1.7 1.6 <3 3.7 <1.5 <0.5 159.0 
11 36.0 4.1 17.0 86.0 47.6 2.8 27.2 66.5 22.3 2.1 12.4 32.3 <1.5 0.7 97.3 
12 37.0 6.0 31.0 59.0 92.2 0.8 12.5 19.6 9.7 1.8 25.3 16.4 <1.5 <0.5 267.8 
13 19.0 2.5 3.3 15.0 32.1 0.9 10.3 16.3 8.6 1.9 6.9 19.6 <1.5 <0.5 101.4 
14 15.0 1.2 4.0 10.0 14.7 <0.1 5.5 1.8 1.8 1.5 <3 6.0 <1.5 <0.5 129.0 
15 17.0 2.5 5.4 34.0 32.9 1.3 8.3 18.2 8.6 2.1 7.5 9.4 <1.5 <0.5 105.8 
16 20.0 1.6 3.6 11.0 10.8 3.6 10.3 6.2 4.0 <1.5 3.5 8.9 <1.5 <0.5 123.0 
17 29.0 5.4 7.6 80.0 60.8 5.2 43.9 85.3 34.6 3.1 7.3 43.2 <1.5 0.9 156.0 
18 12.0 2.3 40.0 65.0 46.1 0.1 7.0 11.8 5.3 1.6 15.4 15.6 <1.5 <0.5 80.8 
19 29.0 2.5 31.0 56.0 34.8 5.6 12.2 10.3 9.0 <1.5 5.1 11.8 <1.5 26.4 58.5 
20 27.0 4.0 28.0 47.0 46.1 0.3 29.3 10.7 7.8 <1.5 9.0 23.2 <1.5 <0.5 273.0 
21 6.8 1.0 3.4 10.0 6.0 0.1 6.0 1.8 2.0 <1.5 <3 5.1 <1.5 0.9 45.6 
22 8.8 1.5 5.7 23.0 17.3 14.4 6.9 4.1 3.4 1.5 <3 4.1 <1.5 <0.5 260.0 
23 32.0 1.9 <1.5 10.0 17.0 1.8 11.5 7.6 6.6 2.3 5.3 8.3 <1.5 <0.5 134.0 
24 24.0 6.6 95.0 113.0 85.3 1.5 11.3 43.1 28.8 2.0 18.1 42.6 <1.5 0.6 180.8 
25 23.0 1.7 18.0 35.0 22.1 0.3 7.0 9.0 5.2 1.9 7.1 12.3 <1.5 <0.5 240.0 
26 6.9 0.5 6.5 4.7 2.1 0.1 3.0 1.5 1.8 1.5 <3 3.4 <1.5 1.0 34.8 
27 <5 0.5 7.0 5.7 2.5 0.7 9.0 5.4 3.6 <1.5 <3 4.3 <1.5 3.5 25.6 
28 18.0 1.5 19.0 28.0 11.5 0.3 11.5 5.9 4.2 2.1 6.8 9.6 <1.5 <0.5 163.8 
29 16.0 2.3 3.0 28.0 12.4 3.2 13.1 11.0 8.9 1.8 7.7 7.3 <1.5 0.9 66.3 
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Appendix 17 (continued)  
Subject Creatinine Pseudouracil Uracil Hypoxanthine Xanthine Adenine Adenosine Inosine Guanosine Dihydrothymine Dihydrouracil Uridine Thymine Orotate Urate 
30 20.0 1.0 4.3 10.0 7.5 0.1 4.0 1.2 2.0 2.4 <3 4.7 <1.5 <0.5 124.0 
31 42.0 9.0 5.5 84.0 69.0 9.7 36.8 42.8 18.2 2.6 <3 54.0 1.5 2.2 73.1 
32 26.0 3.5 <1.5 48.0 33.0 2.2 14.4 29.3 14.0 1.7 8.0 14.4 <1.5 0.6 95.6 
33 50.0 3.6 <1.5 49.0 23.0 2.7 23.9 39.5 16.9 2.6 7.4 17.9 <1.5 0.8 92.2 
34 43.0 4.0 4.6 56.0 42.0 4.4 76.4 45.0 25.4 <1.5 9.8 34.7 <1.5 0.9 147.0 
35 25.0 4.2 85.0 105.0 81.0 0.4 31.5 29.0 20.5 2.6 18.6 39.8 <1.5 0.6 119.0 
36 16.0 2.5 17.0 20.0 36.0 3.2 10.1 11.1 8.6 1.5 5.6 16.5 <1.5 0.6 132.0 
37 17.0 1.6 <1.5 17.0 8.7 1.8 11.9 14.1 5.0 <1.5 2.8 10.1 <1.5 0.8 109.0 
38 58.0 7.4 <1.5 83.0 49.0 9.3 25.5 22.1 9.6 <1.5 3.0 23.9 <1.5 1.0 400.0 
39 13.0 1.1 <1.5 12.0 7.5 1.4 16.6 3.2 3.7 <1.5 <3 6.2 <1.5 <0.5 178.0 
40 49.0 3.9 56.0 55.0 56.0 0.3 12.4 11.3 7.4 3.4 12.8 13.8 <1.5 0.6 253.4 
41 17.0 1.5 <1.5 23.0 14.0 1.7 31.5 16.6 7.0 <1.5 2.6 11.3 <1.5 <0.5 84.0 
42 18.0 0.9 5.0 5.9 9.8 0.1 16.8 5.5 4.1 1.7 2.7 11.6 <1.5 <0.5 173.0 
43 15.0 1.0 1.7 23.0 12.0 1.7 20.4 13.3 8.3 <1.5 3.4 7.2 <1.5 <0.5 94.8 
44 20.0 1.4 <1.5 14.0 11.0 2.9 21.1 4.7 3.9 <1.5 <3 6.1 <1.5 <0.5 193.0 
45 30.0 4.2 5.1 54.0 39.0 2.0 67.3 34.5 19.9 3.1 11.1 31.9 <1.5 0.5 198.9 
46 5.9 1.0 <1.5 6.2 3.8 0.5 8.9 10.0 6.5 <1.5 <3 8.3 <1.5 3.2 112.0 
47 26.0 1.1 4.7 11.0 6.3 0.1 22.7 4.8 3.7 <1.5 <3 11.6 <1.5 <0.5 242.0 
48 18.0 2.1 12.0 27.0 20.0 <0.1 6.7 2.7 2.0 <1.5 4.9 9.0 <1.5 0.9 231.0 
49 13.0 1.2 1.5 6.0 3.7 0.2 10.3 4.8 4.6 <1.5 <3 6.6 <1.5 <0.5 117.0 
50 28.0 4.0 14.0 69.0 31.0 2.2 31.5 98.5 31.5 1.4 9.8 36.5 <1.5 0.6 77.8 
51 19.0 1.6 12.0 26.0 24.0 0.9 0.6 10.6 4.6 2.5 3.5 13.5 <1.5 <0.5 185.0 
52 36.0 1.9 <1.5 21.0 4.3 4.3 44.5 14.1 10.8 1.6 <3 11.4 <1.5 23.5 109.0 
53 7.6 0.7 3.2 7.4 3.8 0.1 10.0 1.7 1.7 <1.5 <3 4.4 <1.5 <0.5 108.0 
54 3.4 0.6 <1.5 4.3 2.1 0.1 9.2 0.8 0.9 <1.5 <3 2.9 <1.5 <0.5 73.1 
55 8.1 0.6 <1.5 11.0 1.2 1.0 11.1 5.6 3.3 <1.5 <3 3.9 <1.5 <0.5 136.0 
56 29.0 5.6 5.5 69.0 37.0 6.5 40.5 64.7 20.1 1.7 7.4 19.8 <1.5 1.2 82.9 
57 22.0 1.2 3.1 14.0 13.0 0.3 5.9 6.8 4.4 1.3 <3 16.8 <1.5 <0.5 153.0 
58 33.0 3.5 25.1 51.0 45.0 0.4 16.4 13.8 5.9 <1.5 9.2 20.8 <1.5 <0.5 309.0 
59 39.0 4.3 12.0 62.0 57.0 9.5 24.7 29.8 10.8 <1.5 10.2 18.1 <1.5 1.9 281.0 
60   11.0 68.0 73.0 89.0 0.1 18.6 28.6 11.8 2.1 10.1 32.5 <1.5 1.4 509.0 
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Appendix 18 Raw data set of cow salivary nucleotide precursors concentrations (µM). 
Subject 1 2 3 4 5 6 7 8 
Creatinine 38.1 27.2 20.6 50.5 26.3 34.8 52.5 25.8 
Pseudouridine <0.2 0.2 0.2 0.5 0.4 <0.2 <0.2 0.3 
Uracil 1.6 5.7 4.1 5.8 5.6 1.6 2.8 3.4 
Hypoxanthine 0.2 <0.2 0.3 0.2 0.4 <0.2 <0.2 <0.2 
Xanthine <0.7 0.7 <0.7 <0.7 0.9 <0.7 <0.7 0.2 
Adenine <0.1 0.2 0.1 0.1 0.6 <0.1 0.1 0.1 
Adenosine 0.1 0.7 0.2 0.4 1.3 <0.03 0.1 0.1 
Deoxyadenosine 0.1 0.1 0.1 0.2 0.3 <0.02 0.0 <0.02 
Deoxyuridine <0.5 <0.5 <0.5 <0.5 0.6 <0.5 <0.5 <0.5 
Inosine 0.2 0.9 0.4 1.3 3.0 <0.06 0.2 0.7 
Guanosine 0.1 1.1 0.2 1.3 3.9 0.0 0.2 0.4 
Deoxyinosine 0.4 0.5 <0.4 0.6 1.9 <0.4 <0.4 <0.4 
Deoxyguanosine 0.6 0.5 0.1 0.8 2.0 <0.05 0.3 0.2 
Thymidine 0.7 0.9 0.3 0.8 1.7 <0.3 0.5 0.3 
Dihydrouracil <3 4.9 6.5 <3 <3 <3 4.1 <3 
Uridine 0.2 1.5 0.5 2.3 4.0 0.1 0.3 0.4 
Orotate <0.5 <0.5 <0.5 <0.5 <0.5 <0.5 <0.5 <0.5 
Urate 27.3 34.6 48.0 40.6 30.0 34.7 43.9 26.3 
Thymine <1.5 <1.5 <1.5 <1.5 <1.5 <1.5 <1.5 <1.5 
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Appendix 19 Raw data set of sheep salivary nucleotide precursors concentrations (µM). 
Subject 1 2 3 4 5 
Creatinine 7.5 9.8 11.7 7.4 10.7 
Pseudouridine 0.4 0.2 0.2 0.2 0.2 
Uracil 8.3 9.0 3.4 3.8 9.7 
Hypoxanthine 1.1 1.3 1.1 0.9 0.7 
Xanthine 2.3 1.7 0.9 7.8 0.9 
Adenine 0.1 1.2 1.6 0.3 1.2 
Adenosine 2.1 2.2 11.1 7.8 9.0 
Deoxyadenosine 0.1 0.1 0.2 0.2 0.2 
Deoxyuridine <0.5 <0.5 <0.5 <0.5 <0.5 
Inosine 1.1 1.0 2.0 1.0 1.1 
Guanosine 1.9 2.5 6.5 2.8 4.9 
Deoxyinosine <0.4 <0.4 <0.4 <0.4 <0.4 
Deoxyguanosine <0.5 <0.5 <0.5 <0.5 <0.5 
Thymidine 0.3 <0.3 0.5 0.6 0.4 
Dihydrouracil 6.3 <3 3.3 10.9 6.8 
Uridine 1.5 2.2 3.7 1.9 2.9 
Orotate <0.5 <0.5 <0.5 <0.5 <0.5 
Urate 40.2 43.0 40.2 44.3 42.3 
Thymine <1.5 <1.5 <1.5 <1.5 <1.5 
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Appendix 20 Raw data set of goat salivary nucleotide precursors concentrations (µM). 
Subject 1 2 3 4 
Creatinine 22.3 23.4 30.8 25.4 
Pseudouridine 1.6 1.5 1.6 1.7 
Uracil 40.0 29.5 61.4 50.3 
Hypoxanthine 12.8 14.6 29.8 32.4 
Xanthine 25.4 14.3 31.2 29.1 
Adenine 1.1 4.2 4.1 2.4 
Adenosine 1.4 4.0 3.0 2.3 
Deoxyadenosine 0.1 0.3 0.2 0.1 
Deoxyuridine <0.5 0.5 0.8 0.7 
Inosine 5.4 27.1 6.0 4.8 
Guanosine 2.7 29.5 6.6 3.8 
Deoxyinosine 0.6 0.7 0.9 0.7 
Deoxyguanosine 0.3 0.5 0.8 0.3 
Thymidine 1.8 2.9 5.1 1.9 
Dihydrouracil 15.5 <3 <3 15.2 
Uridine 7.2 48.5 13.0 5.6 
Orotate 0.9 0.1 <0.5 <0.5 
Urate 57.0 47.8 102.6 59.9 
Thymine 3.6 2.2 10.4 4.6 
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Appendix 21 Raw data set of horse salivary nucleotide precursors concentrations (µM). 
Subject 1 2 3 4 5 
Creatinine 20.1 29.8 28.9 19.7 30.8 
Pseudouridine 1.2 4.4 2.3 2.1 4.9 
Uracil 28.2 91.3 72.3 80.5 130.0 
Hypoxanthine 0.6 1.4 6.9 19.2 17.8 
Xanthine 2.4 18.9 34.0 50.8 48.9 
Adenine 0.2 2.5 0.1 0.3 0.1 
Adenosine 0.1 0.1 0.1 0.2 0.2 
Deoxyadenosine 0.1 0.0 0.0 0.1 0.0 
Deoxyuridine 6.2 17.9 13.2 11.3 24.5 
Inosine 5.4 22.1 6.9 9.4 26.6 
Guanosine 6.2 21.4 6.6 10.2 39.9 
Deoxyinosine 5.7 16.7 9.9 9.0 18.8 
Deoxyguanosine 2.8 11.6 4.3 7.4 15.2 
Thymidine 7.6 20.2 17.8 11.6 25.5 
Dihydrouracil <3 <3 <3 <3 <3 
Uridine 20.1 61.6 29.6 22.3 94.4 
Orotate 0.4 1.4 1.2 <0.5 1.3 
Urate 71.4 286.0 193.0 116.0 394.0 
Thymine 11.6 21.8 33.1 26.0 47.6 
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Appendix 22 Raw data set of one camel salivary nucleotide precursors concentrations (µM). 
Subject 1 
Creatinine 24.4 
Pseudouridine 1.3 
Uracil 24.2 
Hypoxanthine 14.6 
Xanthine 9.3 
Adenine 2.5 
Adenosine 1.4 
Deoxyadenosine 0.5 
Deoxyuridine 4.8 
Inosine 10.0 
Guanosine 10.2 
Deoxyinosine 2.9 
Deoxyguanosine 2.6 
Thymidine 5.5 
Dihydrouracil <3 
Uridine 17.6 
Orotate <0.5 
Urate 47.1 
Thymine 8.9 
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Appendix 23 Raw data set of dog salivary nucleotide precursors concentrations (µM). 
Subject 1 2 3 4 5 6 7 
Creatinine 6.3 5.3 <5 14.6 12.7 10.5 23.6 
Pseudouridine 0.7 0.4 <0.2 0.8 1.1 0.4 0.4 
Uracil 33.3 3.2 <1.5 12.7 36.6 12.0 1.6 
Hypoxanthine 0.5 0.3 <0.2 <0.2 <0.2 0.2 0.3 
Xanthine 4.2 0.9 <0.7 1.1 1.4 1.6 1.2 
Adenine 9.5 1.2 0.1 5.7 14.6 19.3 5.6 
Adenosine 35.8 19.0 0.8 28.9 9.7 19.9 4.6 
Deoxyadenosine 18.2 3.6 0.0 1.9 9.0 4.8 0.3 
Deoxyuridine 3.8 <0.5 <0.5 0.5 1.7 0.6 <0.5 
Inosine 8.3 3.1 0.4 11.0 3.4 5.8 0.7 
Guanosine 3.5 3.5 0.5 6.0 3.3 2.2 0.5 
Deoxyinosine 4.8 <0.4 <0.4 1.9 4.1 1.0 <0.4 
Deoxyguanosine 5.9 3.5 0.1 1.1 5.7 2.3 0.2 
Thymidine 13.7 1.7 <0.3 1.6 8.1 3.4 0.4 
Dihydrouracil 3.1 <3 6.3 <3 6.2 <3 4.4 
Uridine 9.3 3.4 0.4 7.6 3.9 5.0 1.1 
Orotate <0.5 <0.5 <0.5 <0.5 <0.5 <0.5 <0.5 
Urate 62.3 50.0 34.0 45.0 36.0 58.2 42.6 
Thymine 2.1 <1.5 <1.5 <1.5 8.4 <1.5 <1.5 
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Appendix 24 Raw data set of cat salivary nucleotide precursors concentrations (µM). 
Subject 1 2 3 4 5 
Creatinine 27.7 28.4 29.0 20.2 27.0 
Pseudouridine 0.8 2.2 1.5 0.4 1.2 
Uracil 25.1 189.6 82.6 24.9 32.9 
Hypoxanthine 11.6 68.2 2.2 0.5 13.4 
Xanthine 11.4 115.0 7.8 2.1 17.9 
Adenine 5.3 38.0 1.8 0.2 0.4 
Adenosine 2.0 10.2 3.2 0.7 1.9 
Deoxyadenosine 1.0 2.7 2.5 0.4 2.7 
Deoxyuridine 1.6 2.9 24.8 4.5 14.8 
Inosine 9.1 18.6 10.3 1.8 30.5 
Guanosine 5.4 15.4 12.2 2.6 33.0 
Deoxyinosine 2.1 3.8 27.2 5.2 21.3 
Deoxyguanosine 1.5 3.6 20.6 3.4 16.4 
Thymidine 4.6 8.5 47.5 12.7 29.0 
Dihydrouracil <3 <3 <3 <3 <3 
Uridine 5.5 14.1 13.1 3.3 40.1 
Orotate 1.3 <0.5 2.8 <0.5 0.6 
Urate 48.5 68.0 46.9 37.3 31.2 
Thymine 15.5 75.4 38.2 16.2 11.5 
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Appendix 25 Gel electrophoresis of bacterial 16S rRNA gene amplicons 
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Appendix 26 Summary of the de novo assembly statistics of 16S rRNA deep sequencing 
Sample 
Number of 
Sequences 
Total Number of 
Bases 
Average Sequence 
Length 
%GC 
1_BF01 19318 9860320 510 52.55 
2_BF02 16462 8359642 507 52.35 
3_BF03 12782 6512350 509 52.75 
4_BF04 17402 8892343 510 52.54 
5_BF05 12069 6168019 511 52.02 
6_BF06 15098 7697329 509 52.44 
7_BF07 12823 6515245 508 52.54 
8_BF08 15376 7795346 506 52.36 
9_BF9 14341 7277190 507 52.27 
10_BF10 13141 6685145 508 52.16 
11_BF11 14726 7489693 508 52.82 
12_BF12 15997 8190104 511 52.48 
13_BF13 14612 7470382 511 52.45 
14_BF14 12835 6578916 512 52.77 
15_BF15 13624 6965154 511 52.61 
16_BF16 12170 6230373 511 52.5 
17_BF17 14329 7326207 511 52.38 
18_BF18 12382 6325951 510 52.46 
19_BF19 13003 6645984 511 52.37 
20_BF20 11444 5867277 512 52.69 
21_BF21 10224 5238193 512 51.26 
22_BF22 14973 7583317 506 52.57 
23_BF23 8282 4129303 510 52.42 
24_BF24 11690 5972391 510 52.56 
25_BF25 12405 6311171 508 52.52 
26_BF26 12787 6519538 509 52.1 
27_FF01 13150 6707120 510 52.35 
28_FF02 13416 6810800 507 52.32 
29_FF03 11574 5903588 510 52.49 
30_FF04 11057 5644652 510 52.29 
31_FF05 11409 5802858 508 52.37 
32_FF06 13552 6883423 507 52.45 
33_FF07 9561 4887924 511 52.46 
34_FF08 17875 9092127 508 52.49 
35_FF09 14296 7282066 509 52.38 
36_FF10 12675 6457842 509 52.8 
37_BF11 9688 4953122 511 52.49 
38_FF12 8304 4241905 510 52.42 
Total 
Demultiplexed 
589945 300767108 509 52.43 
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Appendix 27 16S rRNA sequence dataset 
16S rRNA curated sequence data are available in a FASTA format at: 
 http://dx.doi.org/10.6084/m9.figshare.894974 
 and  
http://dx.doi.org/10.6084/m9.figshare.894968 
 
 
 
 
